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Background: Chronic haemodialysis treatment of 3–4 hours’ duration two or three 
times a week is the most common renal replacement therapy for adult patients 
diagnosed with stage 5 end-stage kidney failure. During the procedure 200-250 
ml/minute of the patient‘s blood volume is extracorporeal and patency of the circuit 
is maintained by an anticoagulant, for example, unfractionated heparin (UFH). 
Incorrect dosage or time of administration of UFH can have serious adverse 
effects if not fatal consequences for patients. It is important to perform base-line 
clotting studies before the initial administration and subsequent doses of UFH. 
There is a paucity of published information on renal unit practitioners’ knowledge, 
attitude and practice (KAP) concerning the administration of UFH globally and no 
published South African studies were located. 
Aim: To describe renal unit practitioners’ self-reported KAP regarding use and 
effects of UFH in purposively selected adult chronic haemodialysis centres in the 
Cape Town Metropole. Secondly, to determine whether there is an association 
between KAP regarding the use and effects of unfractionated heparin and 
selected variables (category of renal unit practitioner, years of experience, 
duration of orientation to the adult chronic haemodialysis unit and in-service 
education on the pharmacology of UFH). 
Methods: A cross-sectional descriptive survey by self-administered questionnaire 
was undertaken. Non-probability convenience sampling was used and the data 
were analysed using descriptive and inferential statistics. 
Setting: The study was conducted in the dialysis units of two tertiary government 
hospitals and in five dialysis units of one private dialysis provider. 
Study population: Registered and enrolled nurses and (nephrology) clinical 





Results: Of the 77 respondents (51 Registered Nurses, 21 Nephrology Clinical 
Technologists, 5 Enrolled Nurses), 58 (75.3%) were female. The mean age of 
74/77 (96.1%) respondents was 41.1 years (range 23–64 years). The difference in 
age between RNs (mean age 44.9) and CTs (mean age 31.4) reached statistical 
significance (p<0.001) and between ENs (mean age 44.4) and CTs (p=0.002). 
Most respondents (41/77, 53.2%) had 0–5 years of experience. The odds of 
Enrolled Nurses having poorer knowledge of UFH than Registered Nurses were 
18.7 times higher at a 95% CI (1.9-187.4) and this difference reached statistical 
significance (p=0.013). The odds of delivering poor practice having ≤ five years of 
experience and no in-service education were 4.6 times higher at a 95% CI (1.4–
15.6) than for respondents who had ≥ six years of experience (the difference 
reaching statistical significance p=0.014) and 4.3 times higher (CI 1.1–16.5) than 
for respondents who did receive in-service education (the difference reaching 
statistical significance p=0.032) respectively. Study findings have implications for 
safety. 
Conclusion: The results of this study suggest that professional category 
influences knowledge and use of UFH and that there is a direct relationship 
between years of experience and quality of haemodialysis practice and between 
having in-service education (on the pharmacology of UFH) and quality of 
haemodialysis practice. 
Key words: adverse effects, attitude, chronic kidney disease, end-stage kidney 
failure, haemodialysis, knowledge, pharmacology, practice, renal unit practitioner 






CONCEPTUAL DEFINITIONS  
Activated partial thromboplastin time: Test used to determine how long it takes 
whole blood to clot, used for heparin monitoring (Medline Plus, 2011). 
Administration: Giving out or applying something (Soanes & Hawker 2008:12). 
That is, the method or route of giving medication. 
Anticoagulant: Is an agent that stops blood from clotting (Dorland, 2007:103). 
Adverse event: A negative situation arising from medical care that results in 
patient injury from unsafe care rendered, whether intentional or unintentional 
(World Health Organization, 2005). 
Bioavailability: The rate at which, after administration, a drug or other substance 
becomes available at the targeted tissue (Dorland, 2007:219). 
Chronic kidney disease/ end-stage kidney failure (synonym): Failed natural 
kidney functioning. Kidneys are unable to filter toxins and maintain fluid balance. 
Chronic haemodialysis unit: Treatment centre where patients with end-stage 
kidney failure receive chronic haemodialysis. 
Clinical Technologist: A person who has studied for a 3 year Diploma or a 4 year 
Bachelors Degree in Nephrology Clinical Technology and is registered to practice 
with the Health Professions Council of South Africa. 
Dialyser: An artificial kidney, hollow in shape, made up of thousands of fibres with 
a semi-permeable membrane that allows blood to pass through, and surrounded 
by dialysate to assist in the blood purification process. 
Dialysis centre or unit/ haemodialysis centre or unit (synonym): Terminology 
used interchangeably for ease of use. 
Enrolled Nurse (synonym Staff Nurse): A person educated to practice basic 





professional nurse (South African Nursing Council (SANC) Nursing Act, No.33 of 
2005, 2005:chap2). 
European Best Practice Guidelines (EBPG)/European Renal Best Practice 
(ERBP): In 2008, some board members of the European Renal Association-
European Dialysis and Transplant Association Council changed the name of the 
initiative from EBPG to ERBP (European Renal Association-European Dialysis 
and Transplant Association (ERA-EDTA), n.d.). 
Estimated glomerular filtration rate: Test to measure the level of kidney function 
and determine the stage of kidney disease (Kidney Disease Outcome Quality 
Initiative, 2006). 
Glycosaminoglycans: High molecular weight polysaccharides composed of 
repeating disaccharide units in heparin (Dorland, 2007:805). 
Heparin-induced thrombocytopenia: Platelets are broken down due to an 
allergic reaction to the drug heparin (Dorland, 2007:1947). 
Knowledge: Information and skills gained through experience or education 
(Soanes & Hawker, 2008:562). 
Medical litigation: A legal case against health care personnel for negligence, that 
resulted in harm to or the death of a patient. 
Monitoring: Observe the progress to determine the outcome of treatment 
(Soanes & Hawker, 2008:657). 
Nurse/renal unit practitioner: terminology used interchangeably to include all 
categories of respondents in this study, Clinical Technologists, Enrolled Nurses 
and Registered Nurses. 
Oversulfated chondroitin sulfate (OSCS): Not found in biological sources, 
comes about in a sulphuric process from biological molecule and copies heparin 





Registered Nurse (synonym Professional Nurse): Is a person who is qualified 
and competent to independently practice comprehensive nursing in the manner 
and to the level prescribed and who is capable of assuming responsibility and 
accountability for such practice (SANC Nursing Act, No.33 of 2005, 2005:chap2). 
Renal unit practitioner: A specific category of staff: Registered Nurses, Enrolled 
Nurses and Clinical Technologists working in a haemodialysis centre. 
Researcher’s experience: The researcher’s 23 years of Nephrology Nursing 
experience resulted in her achieving a wealth of knowledge, attitude and practice. 







AHRQ: Agency for Healthcare Research and Quality 
aPTT: activated Partial Thromboplastin Time 
CDC: Centre for Disease Control 
CI: Confidence interval 
CKD: Chronic kidney disease 
CT: Clinical Technologist 
CVI: Content validity index 
EBPG: European Best Practice Guideline 
EN: Enrolled Nurse 
ERBP: European Renal Best Practice 
ESKF: End-stage kidney failure 
HIT: Heparin-induced thrombocytopaenia 
IHI: Institute for Healthcare Improvement 
ISMP: Institute for Safe Medication Practices 
IU: International Units 
JCAHO: Joint Commission on Accreditation of Healthcare Organisations 
KAP: Knowledge, attitude and practice 
KDOQI: Kidney Disease Outcome Quality Initiative 
NPSA: National Patient Safety Agency 
OSCS: Oversulfated chondroitin sulphate 





RN: Registered Nurse 
SARS: South African Renal Society 
STROBE: Strengthening the Reporting of Observational Studies in Epidemiology  
UFH: Unfractionated heparin 
US: United States 
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CHAPTER 1: INTRODUCTION 
1.1 Introduction 
This study examines renal unit practitioners’ knowledge, attitude and practice 
(KAP) relative to the use and effects of unfractionated heparin (UFH) in the adult 
chronic haemodialysis population in purposively selected haemodialysis centres in 
the Cape Town Metropole. Even though UFH is beneficial to prevent clotting in the 
haemodialysis blood circuit, decades later there are still warnings of it being a 
high-alert medication (Institute for Safe Medication Practices [ISMP], 2006). For 
this reason, if safety precautions such as ensuring the right dose of UFH at the 
right time of administration and close monitoring are absent, serious adverse 
consequences can result. The National Patient Safety Agency (NPSA, 2006) in 
the United Kingdom, reported that anticoagulants are often the cause of 
preventable harm to patients, which can result in admission to hospital. The 
Institute for Healthcare Improvement (2008) reported that the Joint Commission on 
Accreditation of Healthcare Organisations (JCAHO) supported the initiation of the 
adoption of safety measures for anticoagulants. Hence, the JCAHO in the United 
States of America developed a project, ‘Anticoagulation Therapy as a National 
Patient Safety Goal’, which they implemented in January 2009 (JCAHO, 2009). 
With the knowledge and skills involved in nursing advancing steadily, the 
development of high nursing standards using research and application of 
evidence-based practice in clinical nursing practice assists in improving patient 
safety and the quality of patient care delivered. This study will inform the Renal 
Unit Management teams and renal staff on the current KAP of renal unit 
practitioners concerning UFH, including whether any shortcomings exist. 
1.2 Background to the study 
Chronic kidney disease (CKD) describes deteriorating kidney function (Kidney 





stages, depending on the estimated glomerular filtration rate (Hurst & Thomas, 
2008:127) since this measures the normal functions of the kidneys (Hurst et al., 
2008:127). The 2006 KDOQI guidelines affirm that stage one is to alert the renal 
unit practitioner that the person is at risk of potential decreased kidney functioning 
and at the extreme end, stage five indicates serious kidney failure, where the 
person requires supportive renal replacement therapy to survive. Chronic 
haemodialysis treatment is the most common renal replacement therapy for 
patients diagnosed with stage five adult end-stage kidney failure (ESKF). Patients 
with ESKF depend on safe, quality chronic haemodialysis treatment as a lifetime 
supportive therapy to survive until receiving a kidney transplant or death occurs. 
The main purpose of chronic haemodialysis therapy is to restore the body's 
homeostasis. Patients on chronic haemodialysis have treatment for 3-4 hours’ 
duration, two or three times a week, as prescribed by the Nephrologists. During 
the haemodialysis procedure 200-250 ml/minute of the patient‘s blood volume is 
extracorporeal. This predisposes a high risk to the patients' blood circulation, as 
the patient's blood is extracorporeal in the blood circuit of the haemodialysis 
machine and can therefore clot. The administration of an anticoagulant, such as 
UFH, is essential (South African Renal Society [SARS] 2006) and can assist in 
reducing the risk of the patient's blood clotting in the extracorporeal blood circuit 
(Roy & Kalra, 2012:107). However, even though the use of UFH is to prevent the 
danger of clotting, the patient is at risk of bleeding if the individualised dose of 
UFH administered is not appropriate. 
Research by Winkler, Sheppard and Fantz (2007:499), reports that the efficacy of 
heparin will be determined by its bioavailability through its route of administration. 
Although an approximate 35% of UFH is filtered by normal kidneys for patients 
who are on chronic haemodialysis the excess heparin cannot be excreted, which 
means that heparin is not dialysable (Pittard, 2001:75). This is one reason why it is 
important for renal unit practitioners to be knowledgeable of the pharmacological 
aspects of UFH to minimise harm to patients (Schull, 2006:xv). The Institute for 





widely used, there continues to be errors and lack of tight control of the treatment 
of patients receiving anticoagulants. 
1.3 Orientation to the field of study  
"Heparin is frequently unmonitored, untested, and unsupervised in many dialysis 
facilities” (Pittard, 2001:75). The National Patient Safety Agency (NPSA) reported 
of 480 cases of patient harm from the use of anticoagulation therapy in the United 
Kingdom until the end of 2002 (NPSA, 2006). In addition, the National Patient 
Safety Agency (NPSA, 2006) reported that 28 reports of deaths were associated 
with the use of UFH. However, the NPSA report failed to mention whether any of 
the deaths related to patients on chronic haemodialysis. Essentially, UFH errors 
accounted for 2.1% of total records submitted to the Med Marx national error 
database, of which 4.5–5.5% were harmful (Niccolai et al., 2004:146S). 
Furthermore, in 2010 a study (Grissinger et al., 2010:195) focusing on patient 
safety and quality assurance retrieved electronic data regarding UFH from three 
large patient safety-reporting systems in the United States of America. The results 
were that patient harm from UFH accounted for 1.4% to 4.9% of the reports 
submitted, and most of the harm (56%) occurred in the administration phase 
(Grissinger et al., 2010:195). 
Policy guidelines for monitoring baseline-clotting studies before the administration 
of the initial and subsequent doses of UFH were only available in one of the seven 
Cape Town Metropole dialysis centres under study. The other six dialysis centres 
had a patient prescription chart that the Nephrologist used to prescribe the 
patient’s dose of UFH. 
Additionally, five of the seven-dialysis centres had a protocol on how to administer 
UFH. Published statistical data from the Cape Town Metropole are not available 
on either adverse events or deaths of adult patients on chronic haemodialysis 
related to UFH. A valid explanation for the lack of evidence is that perhaps none 
occurred or were documented. On the other hand, the South African Renal 





morbidity and mortality of the renal population in South Africa relating from 
anticoagulation therapy. 
Anticoagulation therapy usage during haemodialysis is mandatory to prevent 
clotting in the extracorporeal circuit (South African Renal Society [SARS] 2006). In 
the dialysis centres under study, UFH is the anticoagulant of choice and in 
international published literature as well; this is supposedly due to proven efficacy, 
simplicity to administer and cost-effectiveness (Latham, 2006:548). In the SARS 
(2006) and other published guidelines the focus is on the dosage of UFH and not 
on the required KAP needed by renal unit practitioners. 
The findings from this study will indicate trends in the KAP of this population of 
health care professionals. Secondly, it will assist in refining policy guidelines for 
practice relative to the use and effects of UFH and in designing in-service training 
programmes. 
1.4 Problem statement 
Renal unit practitioners have used UFH since the inception of chronic 
haemodialysis therapy in the 1930s. However, the published literature confirms 
that there is still confusion, controversy and concern about the preparation, 
administration, monitoring and safety aspects of UFH (Ouseph & Ward, 2000:181; 
Pittard, 2001:75; Baglin et al., 2006:21; Brunet et al., 2008:794). Under-or over-
coagulation seriously compromises patient safety, yet globally knowledge and 
safety practices of renal unit practitioners who administer this medication to 
patients receiving chronic haemodialysis remain insufficiently documented. 
1.5 Research questions 
The research questions of this study were as follows: 
1.5.1 What is the knowledge, attitude and practice (KAP) of renal unit 
practitioners relative to the use and effects of UFH in selected adult chronic 





1.5.2 Is there an association between selected variables (category of renal unit 
practitioner, years of experience, duration of orientation to the adult chronic 
haemodialysis unit and in-service education on the pharmacology of UFH) 
and KAP of renal unit practitioners concerning the use and effects of UFH? 
1.6 Aim of the study  
The primary purpose of the study was to describe renal unit practitioners’ KAP 
regarding the use and effects of UFH in selected adult chronic haemodialysis 
centres in the Cape Town Metropole. 
The secondary purpose was to determine whether there is an association between 
selected variables (category of renal unit practitioner, years of experience, 
duration of orientation to the adult chronic haemodialysis unit and in-service 
education on the pharmacology of UFH) and the KAP of renal unit practitioners 
concerning the use and effects of UFH. 
1.7 Specific objectives 
1.7.1 The primary objectives of this study were to describe respondents’ self-
reported: 
1.7.1.1 knowledge of UFH using a structured 6-item closed-ended and 7-item 
open-ended questionnaire (Appendix 1, Section C); 
1.7.1.2 attitude regarding the use and effects of UFH using a structured 4-item 
closed-ended questionnaire (Appendix 1, Section D, Q23 - 26); 
1.7.1.3 practice regarding UFH using a structured 5-item closed-ended and 4-
item open-ended questionnaire (Appendix 1, Section E, Q27 - 35). 
1.7.2 A secondary objective was to describe respondents’ demographic and 
professional profiles and to determine differences between the groups 





1.7.3 Sub-objectives of the study were to determine whether there is an 
association between selected variables1 and: 
1.7.3.1 knowledge concerning the use and effects of UFH (Appendix 1, 
Section C, Q10 - 22); 
1.7.3.2 attitude concerning the use and effects of UFH (Appendix 1, Section D, 
Q23 - 26); and 
1.7.3.3 practice concerning the use and effects of UFH (Appendix 1, Section E, 
Q27 - 35). 
1.8 The null hypotheses 
1.8.1 Professional category of renal unit practitioner does not influence KAP 
regarding the use and effects of UFH. 
1.8.2 Years of experience do not influence renal unit practitioners’ KAP regarding 
the use and effects of UFH. 
1.8.3 Duration of orientation to the chronic haemodialysis unit does not influence 
renal unit practitioners’ KAP regarding the use and effects of UFH. 
1.8.4 In-service education on the pharmacology of UFH does not influence renal 
unit practitioners’ KAP regarding its use and effects. 
1.9 Relevance of the study 
The significance of a study relates to the possibility of it contributing to the body of 
scientific knowledge (LoBiondo-Wood & Haber 2006:51). 
The researcher has 23 years of experience in Nephrology Nursing. During this 
period, she has noticed the uncertainty and confusion amongst renal unit 
practitioners concerning many aspects of the use and effects of UFH in chronic 
haemodialysis units.  Concerns about the prescription, dosing, administration and 
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monitoring the effects of unfractionated heparin also appear in the published 
literature (Ouseph & Ward, 2000:181; Pittard, 2001:75; Baglin et al., 2006:21; 
Brunet et al., 2008:794). Suranyi and Chow (2010:386) have appealed to dialysis 
clinicians to regularly review and update their knowledge regarding UFH. Shen 
and Winkelmayer (2012:483) suggest that “large scale studies (eg, cluster 
randomised trials) be conducted on contemporary cohorts” to confirm the safe 
therapeutic range for different anticoagulants against their risks and benefits.  
Studies about renal unit practitioners’ KAP, specifically regarding the use and 
effects of UFH, were not located in the available published literature. The data 
obtained from this study will add to the limited body of knowledge currently 
available by confirming what is known and adding new knowledge that can be 
explored in further research. Locally, the study findings will be useful for providing 
relevant content designing in-service training programmes for renal unit 
practitioners to promote patient safety and improve the quality of renal care 
delivered. This study attempts to fill this theoretical gap. 
1.10 Format of the dissertation 
The study consists of five chapters, as outlined below. 
Chapter 1 presents the introduction, background, orientation, problem statement, 
aims and objections, hypothesis, relevance of the study and format of the 
dissertation. 
Chapter 2 covers the literature review regarding the pharmacology, dosage and 
monitoring relating to UFH, KAP in general and relating to medication, and the 
theoretical framework of the study. 
Chapter 3 describes the chosen research methodology. 
Chapter 4 discusses the results of the study. 
Chapter 5 discusses the findings in relation to the published literature, strengths 






This chapter discussed the need to study renal unit practitioners’ KAP relative to 
the use of a high-alert medication such as UFH in the context of a paucity of 
published studies in this field. 
This study has attempted to contribute new knowledge about trends in renal unit 
practitioners’ practice concerning the use and effects of UFH for the promotion of 
patient safety and informing the staff in-service education programme. 
In the next chapter, the published literature that was reviewed to inform the need 
for such a study on the KAP of renal unit practitioners relative to the use and 





CHAPTER 2: LITERATURE REVIEW 
2.1 Introduction 
A literature search was conducted to gather information on available current and 
past studies on the KAP of renal unit practitioners regarding the use and effects of 
UFH and to identify gaps in the published literature, relating to the research topic. 
The search strategy is described below. 
Search strategy 
Only the literature published in English was included in the review. Keywords 
(Table 2.1) were used to locate relevant publications via the available electronic 
databases of the University of Cape Town (UCT)’s Health Science library and 
Google and Google Scholar search engine to inform the purpose of the study. In 
addition, applicable Nephrology textbooks were consulted. Additional journal 
articles were sourced from the references in journal articles that were reviewed 
and used in the study. The UCT Harvard method of referencing was used for in-
text citation and in the reference reporting section. 
Limited published studies on UFH were sourced from South Africa. The 
contribution that the two South African published studies that were located would 
make to inform the study research question, aims and objectives was considered 
minimal and these were not included. This led to an exploration of International 
online articles relating to UFH, KAP studies and general medication studies on 
administration, monitoring, adverse effects/events and medication calculation. For 
this study, peer and non- peer reviewed e-journal articles from nursing and other 
medical disciplines were evaluated. Published articles on anticoagulation therapy 
that focused on low molecular weight heparin and other alternative forms were 
excluded. However, articles accepted for review were those relating to both UFH 
and low molecular weight heparin, with the concentration focused on the UFH 
section. Although all anticoagulants are used to minimize blood clotting, the 
administration, dosage, monitoring and adverse effects are different. Secondly this 





but a focus of UFH which is most commonly prescribed anticoagulant for patients 
on haemodialysis. UFH is the anticoagulant of choice and in international 
published literature as well; this is supposedly due to proven efficacy, simplicity to 
administer and cost-effectiveness (Latham, 2006:548).  
E-journal articles on Benner’s theory model, including critiques of her model, 
worldwide renal guidelines and safety agencies’ concerned with UFH and 
anticoagulation therapy were downloaded for evaluation.  
Excluded from review were published literature on paediatric renal patients, 
peritoneal dialysis patients and kidney transplant patients related to the current 
study theme (UFH).  
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Total  183 90 
Publications between the years 1993 and 2013 were reviewed but due to the 
paucity of published KAP studies, cited references provided additional sources of 





date from the 1980’s and others that informed the methodology section were 
included. 
Available local and international renal guidelines do not include nor suggest 
methods to improve or standardise the KAP of renal unit practitioners regarding 
the high-alert medication UFH. The guidelines appear to focus on other aspects, 
such as UFH dosage and frequency. Shen and Winkelmayer (2012:473) report 
that in the United States of America there is no standard heparin dose for 
administration in haemodialysis patients and little is known about the safety 
aspects of UFH in haemodialysis. 
However, international health organisations (NPSA, 2006; ISMP, 2006; Institute 
for Healthcare Improvement (IHI), 2008; Agency for Healthcare Research and 
Quality (AHRQ) n.d.) are appealing for safer practice relating to UFH. The appeals 
are specifically to the personnel administering and monitoring the use and effects 
of UFH, to minimise the unnecessary complications experienced by patients 
receiving it. Niccolai et al. (2004:146S) emphasise the need to solve problems 
relating to UFH monitoring. This sentence added to the relevance section of the 
study. 
There is an appeal (Suranyi & Chow, 2010:386) for dialysis clinicians to regularly 
review and update their knowledge regarding UFH. Nurses (renal unit 
practitioners) are the front-line administrators of drugs to patients (Feldman, 
2006:ix). They should be aware of adverse drug events and how they can prevent 
patients from experiencing the negative consequences of drug administration or 
from the prescribed drug dose (Feldman, 2006:ix; Ndosi & Newell, 2008:572). 
Essentially, nurses (renal unit practitioners) should have an adequate knowledge 
of medications and an easily accessible source of current drug information to 
identify adverse drug events (Wimberley & Wiggins, 2004:47; Feldman, 2006:ix). 
A review of the published literature does provide a strong basis for research 
and/or evidence-based practice projects (LoBiondo-Wood & Haber, 2010:16), 





essence, using a systematic approach in the search for published peer-reviewed 
journal articles, textbook information, computer-accessed material and audiovisual 
material pertinent to the study (KAP of renal unit practitioners regarding UFH) 
assisted in evaluating studies on the subject matter and their outcomes, and the 
gaps became evident (LoBiondo-Wood & Haber, 2010:57). 
A review of nephrology nursing and medical literature relating to UFH was 
undertaken. This included KAP studies to support the discussion in chapter one: to 
be alert to and provide evidence of the potency of UFH used routinely in adult 
chronic haemodialysis patients. As well as a discussion of the overview of the 
literature, a review of methods for KAP surveys, maintenance of quality assurance 
of the study, adoption of Benner’s theoretical framework, general medication 
studies, medication adverse effects studies, medication KAP studies and the 
pharmacological aspects, dosage and administration of UFH were all reviewed to 
inform the study. 
2.2 Literature review to determine methodology 
A descriptive KAP survey by self-administered questionnaire was purposively 
selected, because it was important to collect information that accurately described 
(World Health Organization (WHO), 2008; Bowling, 2009:214; Neuman, 2011:38; 
Unite for Sight, 2000-2011) the renal unit practitioners’ unprejudiced perspectives 
regarding UFH. Renal unit practitioners administer UFH daily to their chronic 
haemodialysis patients. There is a possibility that each renal unit practitioners’ 
patient allocation is a minimum of 4–5 patients per session (a dialysis session is 
normally 4 hours). This depends on the dialysis unit protocol and number of 
patient sessions (a day can have one, two or three shifts), implying that they will 
be administering UFH to 8–12 patients per day. 
Using a self-administered questionnaire to collect their responses ensured no 
influence by factors such as interviewer bias and them having their identity known 
(Bowling, 2009:285). To design the questions for the questionnaire, a search was 





KAP studies reveal natural, non-manipulated information about what the personnel 
know about a certain phenomenon, person or thing. Gathering this collected data 
will allow the identification of the knowledge gaps of renal unit practitioners, their 
needs [attitude], and the problems [clinical practice] they experience, as well as 
barriers encountered (WHO, 2008). 
Analysing the data collected will assist in the design of effective solutions for 
improving quality of delivered (renal) care and (renal) patient safety (WHO, 2008) 
regarding UFH. Whether it is trial and error or evidence-based, the WHO (2008) 
affirms that it is important to maintain patient safety and improve patient outcomes, 
and this directly improves safe nursing practice (Melnyk & Fineout-Overholt, 
2005:5). 
A survey is a non-experimental approach to collecting information on people's 
actions, knowledge, intentions, opinions, attitudes and values (Polit & Hungler, 
1993:148; Neuman 2011:49). Literature states that there is a hierarchical system 
for weighing evidence. Supposedly, a survey is non-experimental and produces 
level IV evidence (LoBindo-Wood & Harper, 2010:196). This is confirmed by 
Melnyk and Fineout-Overholt (2005:10) as being classified as level IV evidence 
because it comes from case-control and cohort studies (Table 2.2), which in 
essence are non-experimental design methods (Melnyk & Fineout-Overholt, 
2005:256). Level IV evidence is not as strong as that produced from systematic 
reviews or meta-analyses of randomised controlled studies (Melnyk & Fineout-
Overholt, 2005:10). Nevertheless, the "information yielded by these studies 
[surveys] is critical to developing evidence based in [nursing] practice and may 
represent the best evidence available to answer research or clinical questions" 
(LoBindo-Wood & Harper, 2010:196). 
The data in Table 2.2 represent the hierarchy of an evidence rating system 





Table 2.2: Hierarchy of evidence rating 
Level Hierarchy of evidence Strength of evidence 
I Evidence from a systematic review or meta-analysis of all relevant 
randomised controlled trials (RCTs), or evidence-based clinical practice 












II Evidence obtained from at least one well-designed RCT 
III Evidence obtained from well-designed controlled trials without 
randomization 
IV Evidence from well-designed case-control and cohort studies 
V Evidence from systematic reviews of descriptive and qualitative studies 
VI Evidence from a single descriptive or qualitative study 
VII Evidence from the opinion of authorities and/or reports of expert 
committees 
Adapted from Melnyk & Fineout-Overholt (2005:10) 
Polit and Hungler (1993:27) proposed that persons completing a study 
questionnaire are called respondents instead of participants, therefore for this 
reason the renal unit practitioners completing this study questionnaire are called 
respondents (Polit & Hungler, 1993:27) and not participants. It is worth noting that 
data gathering is deemed the most challenging part of a study, as without high-
quality data collecting methods, the accuracy and reliability of the research 
outcomes will not be credible (Polit & Hungler, 1993:200). For this study a self-
administered questionnaire was employed and chosen for the following reasons 
(Polit & Hungler, 1993:205): 
 It allows the respondents’ anonymity and, privacy to participate in the 
study. 
 Absence of the researcher ensures no bias in responses. 
 Less cost, less time, including less energy to administer. 
As much as there are benefits to conducting a survey using a self-administered 
questionnaire, the researcher is aware of limitations such as the following: 
 Poor response rate because not all renal unit practitioners involved in 
administering UFH will participate,  
 Some staff will be on annual leave or sick leave, and  





Since it is not feasible to study all renal unit practitioners in South Africa, this study 
employed a purposive sampling method to include respondents working in the 
Cape Town Metropole haemodialysis centres and who daily administer UFH to 
patients receiving haemodialysis (Polit & Hungler, 1993:179). The selection of 
respondents in purposive sampling can affect the sample size. According to Polit 
and Hungler (1993:184) and Strydom (2011:234), the sample size has to be large 
enough to represent accurately the size of the entire study population, therefore 
limiting bias, preventing inaccurate findings, and sampling errors. 
Determining the power analysis ensures an appropriate selection for the sample 
size of the population under study and whether there are significant, differences 
present (Burns & Grove 2001:497). Undertaking this will prevent type II errors from 
occurring and non-rejection of the null hypothesis, even though differences do 
exist between groups (Burns & Grove 2001:485). Equally important is that the 
study needs to have scientific rigour, which refers to “the ideas, rules, techniques 
and approaches” (Neuman, 2011:17) to ensure that the findings are credible. To 
ensure accuracy, data tools needed validation. Therefore, as a measure of the 
validity of the tool, the chosen device needs to measure what it intends to, without 
it being “erratic, inaccurate and inconsistent” (Polit & Hungler, 1993:249; Leedy & 
Ormrod, 2005:28; Babbie, 2007:146). 
Two aspects to determine the validity of the tool to be used are content and face 
validity. Content validity looks at the sampling adequacy of the content area (KAP 
questions) being measured. How valid is the representation of the specific content 
of study for UFH. Content validity is based on judgement. Although it is reported 
that there is no objective method to evaluate whether there is sufficient coverage 
of the research topic (Polit & Hungler, 1993:250), Lynn (1986:382-385) provides 
guidelines to establish the index of content validity of a questionnaire. Face validity 
on the other hand is the unscientific, unassuming explanation of validity and 
describes the visual aspects of looking at an instrument to validate that it appears 
to measures what it supposed to be measuring and adds value for validity testing 
of an instrument (Delport & Roestenburg, 2011:174). Furthermore, it is stated that 





measuring the same aspects because they do not (Delport & Roestenburg, 
2011:174). 
Upon completing the validity testing of the instrument, the reliability test is 
performed using a pilot study to establish whether results are consistent when 
measured by different persons and often, and at different times (Delport & 
Roestenburg, 2011:177). 
2.3 Quality assurance of the KAP cross-sectional study  
Globally there is a concern about the poor quality of reporting of study results, so a 
number of guidelines and checklists have been published to ensure improvement. 
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) 
is one such checklist, and the STROBE initiative group concurs that “poor 
reporting hampers the assessment of the strength and weakness of a study and 
the generalisability of the results” (Vandenbroucke et al., 2007:805). The cross-
sectional study design (Vandenbroucke et al., 2007:805) was one of three 
methods included in the STROBE checklist, and provided guidance on how to 
improve the standard of quality reporting of the observational study. Because the 
present study utilises a descriptive cross-sectional design approach, the STROBE 
checklist was appropriate as a quality control measurement instrument. Use of the 
STROBE checklist ensured transparency in reporting the action plan, how the 
study was performed and the relevant findings (Vandenbroucke et al., 2007:805). 
Since no published KAP study by nurses and/or renal unit practitioners’ for UFH 
administration was located, the next section discusses the conceptual framework 
for this study, medication KAP surveys in general, and pharmacological aspects of 
UFH. 
2.4 Conceptual framework 
A conceptual model serves the purpose of “broadly explaining phenomena of 
interest, expressing assumptions, and reflecting a philosophical stance" (Burns & 





from novice to expert as diagrammatically displayed (Figure 2.1), was appropriate 
for this study for expressing assumptions and to guide the interpretation of renal 
unit practitioners’ self-reported KAP regarding UFH (Benner, 1984:v). 
Figure 2.1 shows the repetitive cycle of the five stages from novice to expert, 
which changes in a new field of work. 
 
Figure 2.1: Diagrammatic representation of the cycle of the five stages from novice to expert, adapted from 
Benner (1994). 
Benner’s model was originally conceptualised by Professors Dreyfus and Dreyfus 
in 1980, however, she adapted it for use in nursing practice with their approval. 
Shapiro (1998:18) articulated that Benner’s model guided the professional 
development of nurses (renal unit practitioners), enabling them to move up the 
clinical ladder to attain expertise and reap the financial and professional rewards. 
Thomes (2003:334) confirms that by reviewing each of the stages of Benner’s 
model from novice to expert, the nurse (renal unit practitioner) can communicate 
how the progression of skill acquisition is attained, with the novice finally becoming 
expert. 
The following aspects relating to Benner’s model are discussed: 
 History of the development of Benner’s model; 
 The various stages of Benner’s model; 
 Rationale for the application of Benner’s model to nephrology nursing; and 
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 Limitations of Benner’s model. 
2.4.1 History of the development of Benner’s model 
After observing the “imperfections” and “contingencies” (Benner, 1984:xvii) which 
nurses dealt with daily in their clinical nursing practice, Benner developed her 
competency model. She consulted with Professors H. L. Dreyfus and S. E. 
Dreyfus regarding adopting their ‘Five-Stage Model of the Mental Activities 
Involved in Directed Skill Acquisition’ to apply in clinical nursing practice (Benner, 
1984:xxvi).  
Aydelotte (cited in the foreword, Benner, 1984:v) commended the Benner model 
for aptly distinguishing differences between experts’ and beginners’ behaviour in 
different specific patient situations. Benner had interviewed nurses to gain a 
deeper understanding of their level of competence (Benner, 1984:xvii). She found 
that self-perception plays a role in expert nurses’ awareness in nursing judgement. 
Benner did not want skills acquisition to be depicted as advocating trial and error 
learning, being disorganised, fostering a poor doctor/nurse relationship and 
bestowing the ‘expert halo-effect’ status. According to Standing (2004 cited by 
Lewis-Beck et al., 2004:452), the ‘expert halo-effect’ status bestows indelible 
credibility on a person’s physical or personality traits, ranking the person’s abilities 
high above that of others. 
She reports that “experience based skills acquisition” is safer and quicker when it 
“rests upon a sound educational base”. Benner clearly affirms that her 
competencies are “not an end but a beginning”, and that there is no need for 
nurses to rush through the competencies, but rather “to encourage nurses to 
collect their own exemplars and to pursue their line of inquiry and research 
questions raised by their own clinical knowledge” (Benner, 1984:xvii-xxii). 
2.4.2 Stages of Benner’s conceptual model 
Following the tenets of the Dreyfus model, Benner described the different 





2.4.2.1 Novice practitioner 
In this stage, Benner’s analogy of a novice is that it can relate to new nursing 
students or nurses entering a new discipline of nursing. The presumption is that 
although a nurse may be an expert in another area of nursing, they will be 
considered as a neophyte in the new discipline, because the nurse lacks sound 
expertise (Benner, 1984:22). A novice nurse operates according to the textbook. 
Similarly, this is how a new renal unit practitioner behaves when he or she 
commences working in the haemodialysis unit (Ulrich, 2011:9). 
A novice nurse practical and theoretical knowledge, attitude and skills are lacking 
and thinking is tunnel vision. The new practitioner often feels insecure about 
capabilities, and follows verbal or written instructions without interrogation. 
Practice is context-free for ease of understanding and interpretation until 
competency is achieved (Benner, 1984:20-22). Hardt (2001:40), in reference to 
Benner’s (1984) model, proposed that a nurse would progress from novice to an 
advanced beginner over an 18-month period. 
2.4.2.2 Advanced beginner practitioner 
In this stage, Benner’s model proposes that some experience has been gained by 
the nurse. The nurse’s knowledge, attitude and clinical practice have improved to 
the extent that he/she can assume responsibility for some aspects of patient care. 
The nurse practitioner’s focus is on getting work done adequately (Benner, 
2004:198). However, the nurse still needs guidance from an expert to prioritise 
nursing care, thereby reducing general anxiety and fears and ensuring no harm 
comes to the nurse or patient. 
In clinical practice when different patient situations arise, the nurse gains 
experiential learning (Benner, 1984:22-24) on how to manage the patient situation 
on hand and in the future. This experiential learning can only be gained in clinical 
practice when different patient situations arise (Benner, 1984:22-24). 
2.4.2.3 Competent practitioner 
Benner’s model cites two years of experience for the competent practitioner. In her 





competent person can be a nurse who has spent two or three years in a similar 
clinical practice area and has the ability to set her own long-term goals. However, 
a practitioner can progress to a competent level after one to two years of practice, 
depending upon the specialty area, but some complex patient assignments will 
occur after a certain time has elapsed (Benner, 2004:193). 
With the years of experience gained, the nurse evolves from a stimulus-response 
person to being consciously involved in the analytical clinical decision-making 
process regarding patient care (Benner, 1984:25-26). The nurse feels that he/she 
is a master of their clinical specialty and can coordinate complicated patient care 
(Benner, 1984:25-26). However, this nurse’s anxiety level is now directed towards 
specific patient situations, but the gaps experienced by this nurse are the lack of 
speed and flexibility that evidently the proficient nurse practitioner demonstrates 
(Benner, 1984:25-26). 
2.4.2.4 Proficient practitioner 
As a proficient practitioner, the nurse has gained a deeper understanding of 
specialty patient care in totality and has the ability to synthesise knowledge and 
skills abstractly (Benner, 2004:195). This practitioner is more attuned to patient 
needs and concerns and accordingly adapts patient care, delivered according to a 
more holistic approach (Benner, 1984:28; 2004:196). Benner proposes that the 
practitioner has an open attitude to correction, seeks answers to difficult patient 
care situations, and intuitively knows when a situation needs further intervention 
(Benner, 2004:195).  
Furthermore, Benner (1984:31) deduces that proficient practitioners are those who 
have worked 3–5 years with a similar patient population, but acknowledges that 
this period is an estimate and needs further exploration. 
2.4.2.5 Expert practitioner 
Benner cites Taylor’s (1991) description of an expert as a person who “takes up 
theories and ends of practice in multiple ways, often creating new possibilities in 
the situation” (Benner, 2004:196). This nurse practitioner has substantial 





1984:32) of various patient clinical situations. Without wasting time this practitioner 
can swiftly assess the situation, diagnose the problem, decide on an action and 
implement a plan of action (Benner, 2004:196). This prompt delivery of an action 
plan minimises adverse patient reactions (Benner, 2004:197). The expert nurse 
has been working in the same specialty for at least 5 years (Benner, 1984:35). 
This person acts as a consultant to other practitioners of the same specialty 
because their clinical judgements are valued (Benner, 1984:35). 
Interestingly, Benner proposes that not all practitioners will reach this expert stage, 
as some may struggle with “understanding the goals of practice and have 
challenges with their skills of interpersonal and problem engaging” (Benner, 
2004:198). 
2.4.3 Rationale for application of Benner’s model 
According to Benner (2004:188), she and other researchers conducted three 
studies spanning different intervals over the period 1978 until 1997 on skills 
acquisition in nursing. Application of the Dreyfus model of skill acquisition and 
direct consulting with Professors Dreyfus and Dreyfus guided her work for each of 
the studies carried out over this period (Benner, 2004:188). 
Benner’s (1984) ‘Novice to Expert’ model was considered appropriate for 
analysing data from this study to establish the stage of respondents’ clinical 
practice which, it was presumed, would range from little experience to vast 
experience. 
This study is a descriptive survey of renal unit practitioners’ KAP regarding the 
medication UFH. The primary purpose is to describe renal unit practitioners’ KAP 
regarding the use and effects of UFH. The secondary purpose is to determine 
whether there is an association between category of renal unit practitioner, years 
of experience, duration of orientation to the adult chronic haemodialysis unit and 
in-service education on the pharmacology of UFH and the KAP of renal unit 





The null hypotheses are that the type of professional category, years of 
experience, duration of orientation to the chronic haemodialysis unit and in-service 
education regarding the pharmacology of UFH do not influence renal unit 
practitioners’ KAP regarding the use and effects of UFH. 
Therefore, the application of Benner’s model to the study will assist in gaining a 
perspective on whether this ‘from novice to expert’ model does have an 
association with renal unit practitioners’ KAP regarding UFH. Avillion and 
Abruzzese (1996:36) and Ulrich (2006:16) from the United States of America 
suggest that as practitioners adjust to a clinical specialty and become more skilful 
at performing routine tasks, they search and expand their knowledge level in the 
clinical specialty, which results in a shift from routine thinking to critical thinking 
and judgement in decision-making. Furthermore, an important point to note is that 
Benner strongly conveys the message that it is the responsibility of the nurse to 
monitor the patient’s safety and therapeutic responses to administered medication, 
and that this can have life and death implications (Benner, 1984:127). 
Avillion and Abruzzese (1996:30) and Ulrich (2006:15) from the United States of 
America affirm that Benner’s model is widely adopted for practice across the 
spectrum of nursing and other medical disciplines. Furthermore Ulrich, a 
Nephrology specialty nurse researcher from the United States of America seems 
to support using Benner’s model ‘novice to expert’ in Nephrology Clinical Nursing 
Practice (Ulrich, 2006:16; 2011:9). 
2.4.4 Limitations of Benner’s model 
Benner’s model has been criticised by others as not being a theory but a 
philosophical view (Altmann, 2007:114). Altmann (2007:114) claims that in the 
literature there is no consensus that Benner’s model is a theory, alleging that 
Benner’s work is critiqued as not being theoretical and quantitative because it 
relies too heavily on narrative research (Altmann, 2007:115-116). 
Gobet and Chassy (2008:132) from the United Kingdom argues that Benner’s 





(Gobet & Chassy, 2008:131) further highlight flaws of Benner’s model, such as 
that some of her competencies listed in different stages require access to explicit 
knowledge, and that she does not appropriately account for expertise and intuition. 
This is in comparison to empirical data; her assigning of nurses to stages is not 
reliable and does not correlate with expertise. Furthermore, Bonner and others 
(2003, 2005 & 2006) from Australia, who studied nephrology (renal) nurses’ levels 
of expertise, suggest that there are not five stages that lead to a nurse becoming 
an expert as suggested by Benner (1984), but three stages – namely the non-
expert, experienced non-expert and expert. 
Although these researchers have interrogated Benner’s model, the suitability of 
the application of Benner’s model to nephrology nursing will be reviewed upon the 
completion of this study. 
2.5 General medication KAP surveys and adverse effects 
A literature review shows that there are published medication KAP studies but 
none specific to KAP relating to UFH. Therefore, a general overview of medication 
studies, medication adverse effects studies and medication KAP studies is 
discussed. 
2.5.1 General medication studies 
A United Kingdom nurse’s knowledge of pharmacology study conducted “in 
surgical wards of a foundation hospital in the North of England” (Ndosi & Newell, 
2008:570) reported that 57.2% (n=24/42) of their study nurses had inadequate 
knowledge of pharmacology of the drugs they routinely administer. In addition, a 
cross-sectional study limited to nurses working in general hospitals of the 
Northern, Central and Southern areas of Taiwan reported on nurses’ knowledge of 
high-alert medication (Hsaio et al., 2010:177). The report stated that 3.6% 
(n=109.8/305) thought they had sufficient knowledge, 75.4% (n=229.9/305) felt 
their knowledge was insufficient, and 84.6% (n=258/305) hoped to gain further 





The findings of these studies (Ndosi & Newell, 2008; Hsaio et al., 2010) 
recommend that nurses should strive continuously to update their medication 
knowledge with supplementary pharmacology education programmes to be 
competent in medication administration. 
2.5.2 Medication adverse effects studies 
Research reports adverse drug [medication] reactions as being negative 
consequences of drug (medication) therapy (Rao, Archana & Jose, 2006:293). A 
study by Hanafi et al. (2012:21) showed that 91% of nurses had never reported an 
adverse drug reaction (ADR) directly to the Adverse Drug Reaction National 
Centre due to being unaware of the Centre’s existence; however, they are most 
likely to report them to the doctors (87.1%) and pharmacist (1.8%). A factor to 
consider for non-reporting directly to the database could be because nurses fear 
reprisal (Niccolai et al., 2004:148S) as they are blamed, and attention is not paid 
to the processes (Walker & Lowe 1998:101). 
Hanafi et al. (2012:24); recommend holding interventions such as pharmaco-
vigilance workshops to create better awareness of adverse events. A Chinese 
study conducted in 2004 reports that lack of knowledge on ADR and the voluntary 
reporting system are the main reasons for insufficient reporting (Li et al., 
2004:856). Furthermore, a KAP semi-experimental study (Hajebi et al., 2010:205) 
on ADR reports that continuous ADR education programmes are important until 
ADR reporting becomes habitual among nurses. This implies that diligent reporting 
will reveal the true extent of medication/drug (UFH) adverse reactions. 
A multinational systematic review of empirical evidence on the prevalence and 
nature of medication administration errors in health care settings showed a higher 
medication administration error (53.3%) in the intravenous route (as used with 
UFH) compared to other routes (Keers et al., 2013:1). The study reports that 
“medication adverse effects remain common despite the growth in improving 





2.5.3 Medication KAP studies 
A Malaysian general medication KAP study among 40 nurses working in a medical 
ward showed that nurses possess adequate medication knowledge (mean scores: 
knowledge 13.8, attitude 16.4, and practice 10.7) but lacked in-depth knowledge of 
aspects of pharmacology (Raja, Daud & Syed, 2009:17). A study by nurse 
lecturers, Barkhouse-Mackeen and Murphy (2013:91) on “innovative strategies for 
enhancing medication related knowledge, attitude, skills and behaviours” came 
about after recognising shortcomings in teaching pharmacology to nursing 
students. They reported poor student performance in medication calculation 
(Dillies et al., 2011:499), poor pharmacology knowledge retention (Dillies et al., 
2011:499) and practical implementation in clinical areas. To properly prepare 
these nursing students for their “role in medication management” in the clinical 
areas, they developed a 13 week pharmacology course and employed a 
pharmacist to teach the pharmacology course (Barkhouse-Mackeen & Murphy 
2013:92). Their findings revealed that students appreciated their innovative 
teaching strategy of pharmacology and this enhanced the students’ ability to 
“exercise clinical reasoning with regard to application of the medication related 
knowledge and skills”. Another positive outcome was that students were achieving 
100% passes in medication calculations quiz (Barkhouse-Mackeen & Murphy 
2013:99-100).  
A study by Dilles et al. (2011:499) on 29 nursing schools’ pharmacology curricula, 
found that the mean score for nursing students’ knowledge on pharmacology was 
55%, and for calculation skills was 66%. McMullan, Jones and Lea (2010:891) 
results from their 2006 United Kingdom study at one university relating to “Patient 
safety: numerical skills and drug calculation abilities of nursing students and 
Registered Nurses”, reported that 55% (126/229) of the students and 45% (20/44) 
of Registered Nurses failed the numeracy test, and 92% (211/229) of the students 
and 89% (39/44) of RNs failed the drug (medication) calculation test. With the lack 
of KAP surveys on UFH administration, published studies on the pharmacology of 





2.6 Pharmacology of UFH 
“Heparin is a natural anticoagulant found in mammals” (Pittard, 2001:73); it is 
present in the liver, lungs, mast cells and intestinal mucosa of bovine and porcine 
mammals (Pittard, 2001:73; Davenport, 2009:456). UFH is composed of 
glycosaminoglycans with molecular weights ranging from 3000 to 30 000 Daltons 
(Sonawane, Kasbekar & Berns, 2006:305; Winkler, Sheppard & Fantz, 2007:499; 
Fischer, 2007:181). However, an important feature of UFH is that heparin itself is 
not an anticoagulant, but when injected into the bloodstream heparin inhibits the 
clotting cascade of events (Fischer, 2007:181). Heparin combines with heparin 
cofactor anti-thrombin III, and this complex prolongs the time it takes the patients’ 
blood to clot (Pittard, 2001:74; Wimberley & Wiggins, 2004:47; Fischer, 2007:181). 
Research by Winkler et al. (2007:499) reports that determining the efficacy of 
heparin is by its bioavailability through its route of administration. The half-life of 
UFH is 30-120 minutes (Hertel cited by Latham, 2006:548), and it takes seven 
half-lives to remove over 99% of a single intravenous heparin injection (Pittard, 
2001:74). Even though about 35% of UFH is excreted by normal kidneys, in 
patients on chronic haemodialysis the excess heparin is not excreted, meaning 
that heparin is not dialysable (Pittard, 2001:75) and remains in the blood 
circulation. 
Tahir (2007:28) confirms that in renal and hepatic dysfunction, the half-life of UFH 
is prolonged and the rate of clearance of UFH is decreased. Therefore, it is 
important for nurses (renal unit practitioners) to be knowledgeable regarding the 
pharmacological aspects of medication such as UFH to minimise patient harm 
(and the safety of adult chronic haemodialysis patients) (Schull, 2006:xv). 
2.7 Dosage of UFH  
Pittard (2001:75) proposes that the dose of UFH should be based on body weight 
and/or clotting studies, since patients with chronic kidney disease (CKD) and 
patients with uraemia will require less heparin (Pittard, 2001:75). Furthermore, it is 





UFH (Davenport, 2009:456). In addition, performing baseline-clotting studies for 
new patients assists in determining their individual dose of UFH (Pittard, 2001:75). 
Other researchers (Winkler et al., 2007:499) also support the need for strict 
laboratory monitoring of UFH to establish therapeutic doses for patients and 
prevent under- or over-anticoagulation. 
Nevertheless, the renal guidelines and certain authors endorse standardised 
heparin dosing for all patients instead of individualised doses. In South Africa, the 
SARS chronic guideline recommends a loading dose of 50 IU/kg followed by 800–
1500 IU per hour. On the other hand, the European Best Practice Guidelines 
(EBPG) recommend 50 IU/kg initial dose, followed by 500-1500 IU of UFH per 
hour given continuously via arterial access needle (EBPG, 2002). Researchers 
Brunet et al. (2008:789) support using UFH 50 IU/kg for a 4-hour haemodialysis 
session by dividing the UFH dose into a 25 IU/kg bolus on commencing 
haemodialysis and 25 IU/kg for the remainder of the haemodialysis session. The 
recommendation from Baglin et al. (2006:27) is a bolus of UFH followed by 
continuous infusion of 250–1000 IU/hour until the procedure is completed. 
Ouseph and Ward (2000:181) argue that there is no uniformity, resulting in the 
usage of multiple strategies for UFH dosing, and this can result in inadequate or 
excessive anticoagulation in many patients. In addition, some (Winkler et al., 
2007:499) are of the opinion that laboratory monitoring for UFH dose will provide 
an opportunity to improve patient safety. However, Tahir and others (2007:28) 
propose using a weight-based nomogram for patient heparinisation regimes, as 
they feel that there is a relationship between dose of UFH administered and its 
safety and efficacy. 
The abovementioned UFH dosing regimens suggest that there are different 
variations and no consensus – hence the importance of re-examining practices 
regarding UFH. UFH protocols of the participating Cape Town Metropole dialysis 
centres reveal that the majority of renal unit practitioners in the haemodialysis 
centres administer a prescribed standard dose of 5000 IU of heparin three times a 





patient’s yearly dose of UFH means a single dialysis patient receives 
approximately 780 000 IU per year, thus predisposing the patient to long-term 
effects of UFH. The potential adverse effects of this enormous yearly UFH dose 
that a patient receives should be a concern for renal unit practitioners. A 
calculated guess is that renal unit practitioners probably do not think of patients’ 
yearly exposure to UFH because their focus is on the current dialysis session 
dose. 
2.8 Monitoring effects of UFH 
There is consensus (Pittard, 2001:75; Niccolai et al., 2004:146S; Schull, 
2006:523) that the following parameters need monitoring in a patient receiving 
UFH to enhance patient safety: clotting times, haemoglobin/haematocrit, activated 
partial thromboplastin time (aPTT), platelet count, serum potassium, stool guaiac 
and urinalysis. There is a risk of bleeding in 1.5% to 20% of patients (Tahir 
2007:29) post-infusion with UFH. Dahlman (1993) and Warkentin and Barkin 
(1999), (cited by Tahir, 2007:29) reported that the bleeding risk associated with 
UFH therapy is enhanced when the conditions listed in Table 2.3 are present. 
Consequently, renal unit practitioners must be vigilant when administering and 
monitoring patients receiving UFH. 
Table 2.3: Bleeding risk during UFH therapy 
Use of other antithrombotic therapy 
Concurrent anti-platelet drug or non-steroidal anti-inflammatory drug use 
Pre-existing source of bleeding 
Liver disease 
History of recent surgery or trauma 
Peptic ulcers 
Malignancy 
Age older than 65 years 
Falls 
Adapted from Tahir (2007) 
Other studies (Pittard, 2001:75; Furuhashi et al., 2002:1457) also verify the 





coagulation studies, because UFH can be associated with a number of potentially 
serious adverse effects after administration. Their perspective was that the 
adverse effects are not limited to and include haemorrhage, heparin-induced 
thrombocytopenia (HIT) and osteoporosis (Pittard, 2001:75; Furuhashi et al., 
2002:1457). 
HIT, although a rare, severe adverse effect of UFH administration, nevertheless 
has an impact on morbidity and mortality of patients (Szromba, 2010:185). As a 
result, it is important to monitor patients closely during administration of UFH in 
order to be alert to and detect the signs of HIT early, for example a low platelet 
count, and conduct the necessary investigations to rule out the presence of HIT. 
Additional concerns (Bircher et al., 2006:1433) are that immediate hypersensitivity 
reactions such as; bronchospasm, urticaria and facial oedema caused by heparin 
following administration, are rarely reported. This includes the potential problem of 
hyperkalaemia (Cronin & Reilly, 2010:512), which can be life threatening, 
especially if patients do not comply with dietary restrictions and treatment. 
Research confirms that when using UFH for catheter thrombosis prophylaxis it can 
have systemic effects and be associated with excessive bleeding (Sonawane et 
al., 2006:306). 
Suranyi and Chow agree that it is important to know that there is risk attached to 
haemodialysis heparinisation, such as accidentally overfilling when locking 
tunnelled catheters (Suranyi & Chow, 2010:387), therefore renal unit practitioners 
should be cautious when locking tunnelled catheters post-dialysis. Colvin and 
Barrowcliffe (1993:99) confirm that there must be awareness regarding relative 







Table 2.4: Contraindications to UFH therapy 
General contraindications 
Active bleeding 
Haemophilia or other haemorrhagic tendencies 
Cerebral haemorrhage 
Uncontrolled hypertension 
Hepatic dysfunction including oesophageal varices 
Peptic ulceration 
Known hypersensitivity to heparin 
Adapted from Colvin & Barrowcliffe (1993) 
In 2008, the US Centres for Disease Control (CDC) and Prevention conducted a 
nationwide investigation of UFH following reports of severe adverse reactions 
experienced in a single haemodialysis centre. The finding was that heparin 
contaminated with oversulfated chondroitin sulfate (OSCS) resulted in the death of 
some patients (CDC, 2008). In the June 2011 issue of the Nephrology News and 
Issues journal, it reported that “Baxter loses first contaminated heparin lawsuit”. 
The article stated that a man who was administered the allegedly contaminated 
heparin manufactured in China and sold by Baxter Healthcare Corporation was 
awarded $625 000 to his estate (“Baxter loses first contaminated heparin lawsuit”, 
2011). This companys’ financial loss highlights a potential risk for failing to ensure 
safety aspects for drugs used are maintained. 
Table 2.5 displays a summary of the most frequently reported drug products with 
errors due to improper dosage or quantity in a report of Hicks, Cousins and 
Williams (2003) regarding. 
Table 2.5: Most frequently reported medication error information (2002) 
Error category Product No. (%) of errors 
All error categories (n=44,593) UFH 1275 (2.9) 
 Insulin 1220 (2.7) 
 Morphine 959 (2.2) 
   
Most harmful types of errors (n=856) UFH 81 (9.5) 
 Morphine 79 (9.2) 
 Insulin 65 (7.6) 
   





The data in Table 2.5 indicate that of all error categories (n=44,593), UFH 
(n=1275) represents the highest percentage (2.9%), and that of the most harmful 
types of errors (n=856), UFH (n=81) is also involved in the highest percentage 
(9.5%). 
2.9 Summary 
Included in this chapter was a literature review of methods, maintaining quality 
assurance of KAP cross-sectional studies and Benner’s conceptual framework. A 
review of published literature on general medication studies, medication adverse 
effects studies as well as medication KAP studies was undertaken. Due to the 
paucity of local published literature on UFH studies, this chapter highlighted the 







CHAPTER 3: METHODOLOGY 
3.1 Introduction 
This chapter discusses the research methodology employed to survey renal unit 
practitioners’ knowledge (K), attitude (A) and practice (P) relative to the use and 
effects of UFH. A self-administered KAP questionnaire was used for the survey to 
ensure that there was no manipulation of information gathered, as each 
respondent gave their perspective regarding unfractionated heparin.  
Description includes the research design, research setting, study population, 
sample size, instrumentation (design, validation and reliability testing), data 
collection method, data management and statistical analysis methods. A 
description of the ethical aspects considered for this study concludes this chapter. 
3.2 Research design 
To address the research questions a descriptive cross-sectional design of a KAP 
survey was employed, using a self-administered questionnaire. The descriptive 
survey method (Polit & Beck, 2004:192) aims “to describe and document aspects 
of a situation as it naturally occurs”. 
3.3 Population 
The study population is composed of Registered and Enrolled Nurses and Clinical 
Technologists (Nephrology) working in two tertiary hospital adult chronic 
haemodialysis centres and in five adult chronic haemodialysis centres of one 
private dialysis service provider in the Cape Town Metropole. 
3.3.1 Inclusion criteria 
3.3.1.1 Professional categories 





 Certified Registered Nurses who had completed any of the following training 
programmes:  
o A Postgraduate Diploma in Nephrology Nursing (minimum 1 year) 
o A Renal Certificate (6 months) 
o A Diploma in Critical Care (1 year) 
o Critical Care Certificate (6 months). 
 Registered Nurses studying for an additional qualification in any of the 
specialist areas above during the study period February to December 2013, 
and working in the research settings. 
 Registered Nurses without the additional qualifications as listed above, working 
in the selected research settings. 
 Certified Clinical Technologists who had a Diploma in Nephrology Clinical 
Technology (3 years) or a Bachelor’s Technical Degree in Nephrology Clinical 
Technology (4 years), including students on these programmes working in the 
selected research settings. 
 Enrolled Nurses working in the selected research settings. 
3.3.1.2 Personal categories 
Renal unit practitioners of any gender, age and citizenship meeting the above 
professional category requirements were included. 
3.3.1.3 Location of the hospitals and dialysis centres 
The hospitals and private dialysis centres were within the geographical borders of 
the Cape Town Metropole. 
3.3.2 Exclusion criteria 
Excluded from the study were those renal unit practitioners who participated in 
pilot testing the questionnaire. 
3.3.3 Sample size 
To estimate sample size in the absence of published data, personal clinical 





have a satisfactory level of knowledge concerning the use and effects of UFH in a 
chronic dialysis unit. The following information entered into StatCalc of EpiInfo 
version 7 was:  
 Population size = 104 renal unit practitioners 
 Incidence of satisfactory KAP n= 52; 50% 
 Margin of error = 1.0% 
 Confidence Interval (CI) = 95% 
It was estimated that a sample size of 82 was needed. The assumption is that the 
participating practitioners would have specialist knowledge, skills and a confident, 
informed attitude concerning the use and effects of the high-alert medication UFH. 
3.3.4 Sampling method 
The study employed a non-probability convenience sampling method. Due to the 
small numbers, all renal unit practitioners meeting the inclusion criteria were asked 
to volunteer, to accommodate for the potential loss of non-participatory 
respondents and to enhance the reliability and validity of the study. Despite the 
potential for bias, this was an appropriate sampling method for the following 
reasons: 
 Some dialysis centres do not employ all the categories of renal unit 
practitioners needed for inclusion in the study. Therefore to ensure that this 
criterion was met, a purposive sampling of centres was done. 
 All categories of renal unit practitioners ought to be present during the 
sampling period; therefore each category has the potential to be included in 
the study. 
Limitations of the non-probability convenience sampling include difficulty in 







Recruitment occurred in purposively selected adult chronic haemodialysis facilities 
in the Cape Town Metropole, namely two tertiary government hospitals and five 
dialysis centres of one private dialysis service provider. Anonymity and 
confidentiality were protected by using a randomly assigned number to each 
hospital and privately owned dialysis centre participating in the study. Consistency 
was maintained by using the assigned number for each institution throughout the 
study when referenced (Table 3.1). 
Table 3.1: Dialysis centres included in the study  
Information 
categories 
Number of dialysis 
units included in study: 
























Administration body Public Public Private  Private Private Private Private 
Number of dialysis 
units 
1 1 1 1 1 1 1 
Classification Tertiary Tertiary N/A N/A N/A N/A N/A 
























0 1  
(16.7%) 
Clinical Technologists 8 (38.1%) 7 (24.1%) 3 (25%) 2 (15.4%) 3 (15.8%) 0 0 
Total number of 
permanent renal unit 
practitioners (N = 104) 
21 29 12 13 19 4 6 
Furthermore, to uphold renal unit practitioners' confidentiality, anonymity and a 
non-biased response, the researcher did not have direct access to them. The 
means of communication with renal unit practitioners was through the Unit 
Managers of the purposively selected dialysis centres, after obtaining written 
permission from the relevant tertiary hospitals’ Medical Superintendents, Nursing 
Managers and the Renal Unit Medical Heads of the department and the private 
dialysis provider management. 





3.4 Data collection 
Data collection describes the appropriate development of instruments or tools 
used to collect data to inform the study, based on the research design and 
methodology (Delport & Roestenburg, 2011:171). 
Polit and Hungler (1993:20) affirm that this phase can be very challenging, 
because if no high-quality and accurate data collection tools are developed, this 
can compromise the robustness of the study. 
3.4.1 Design of data collection tool 
Design of the self-administered survey questionnaire cannot be separated from 
content validity so at this stage these processes will be described concurrently. 
First, content validity was determined using the Index of Content Validity (CVI) 
approach described in the classic article by Lynn (1986). “A review of the ISI 
Citation Index reveals 186 citations of the Lynn reference in the disciplines of 
nursing, medicine, sociology, psychology, pharmacology, physical therapy, 
occupational therapy, social work, and education” (Schilling et al., 2007:362). Lynn 
defined content validity as “the determination of the content representativeness or 
content relevance of the elements/items of an instrument by the application of a 
two-stage (development or judgment) process” (1986:382). Lynn described the 
process by which content validity should be determined and a method to quantify 
it. 
There were three steps in the development stage of determining content validity: 
domain identification (knowledge, attitude and practice), item generation (personal 
experience and a review of the published literature), and instrument formation 
(development of the survey questionnaire and deciding on a suitable sequence of 
the items). The structured questionnaire consisted of fixed, closed questions (pre-
coded response choices) for easy to count answers for quantitative data and 
analysis (Bowling & Ebrahim, 2007:405), comprehensive enough to prevent 





Open-ended questions were included to minimize successful guessing (Bowling & 
Ebrahim, 2007:405). 
The information used to design a self-administered questionnaire (Appendix 1) 
was based on the aims and objectives of the study, personal experience, 
applicable available published literature (Agency for Healthcare Research and 
Quality (n.d.), Institute for Safe Medication Practices (2006, 2007), National 
Patient Safety Agency (2006) World Health Organisation (2008) and published 
journal articles on UFH to ensure content validity. Presented in Table 3.2 is a 
description of the design of the questionnaire and the sources for the development 





Table 3.2: Design of questionnaire and source for questions 
Section  Information Question design and source 
Section A Personal information Q001: Age, Q002: Gender, Q003: Citizen (WHO, 2008) 
Section B Professional profile Q004: Professional Category, Q005: Qualifications, Q006: Experience, Q007: Orientation mentor, Q008: Duration 
of Orientation programme, Q009: In-service education (Researcher-designed) 
Section C Knowledge regarding UFH Q010: Bleeding Tendencies (Pittard, 2001) 
Q011: UFH effect on clots (Pittard, 2001) 
Q012: UFH effects (Pittard, 2001) 
Q013: UFH administration when blood pressure elevated (Lankshear, Harden & Simms, 2010) 
Q014: UFH effects on platelets (AHRQ, 2006; Baglin et.al., 2006; Lankshear et al., 2010) 
Q015: Protamine sulphate dose to arrest bleeding (European Best Practice Guidelines Expert Group on 
Haemodialysis, 2002; Baglin et al., 2006) 
Q016: UFH oral delivery (Lee et al., 2001) 
Q017: Importance of baseline urea value (Pittard, 2001) 
Q018: UFH delivery method (De Vos et al., 2000; SARS, 2006) 
Q019: Type of UFH (Shen & Winkelmayer, 2012) 
Q020: UFH temperature storage (Bodene, 2008) 
Q021: UFH effects on potassium (Lankshear et al., 2010; AHRQ, 2011) 
Q022: UFH dose calculation (researcher-designed) 
Section D Attitude regarding UFH Q023: UFH adverse effects (Wimberley & Wiggins, 2004) 
Q024: UFH and attitude (Researcher-designed, Niccolai et al., 2004; ISMP, 2007, Chevalier et al., 2011) 
Q025: Patient information re UFH (ISMP, 2007) 
Q026: Patient information re UFH adverse effects (ISMP, 2007) 
Section E Practice regarding UFH Q027: Prescription UFH (Researcher-designed) 
Q028: Checking new patient coagulation results (Pittard, 2001) 
Q029: Checking current patient coagulation results (Researcher-designed) 
Q030: Review UFH literature (Researcher-designed) 
Q031: Concerns regarding UFH (ISMP, 2007) 
Q032: Adjusting UFH dose (Researcher-designed) 
Q033: Witness UFH reaction (Researcher-designed) 
Q034: Consult for UFH information (Sulosaari, Suhonen & Leino-Kilpi, 2010) 






An outline of the study objectives and related questions by type are presented in Table 3.3. 
Table 3.3: An outline of study objectives and related questions by type 
Objective Section Question(s) Types of questions  
1.7.2 To describe the demographic and professional 
profiles of respondents and to determine 














Q001: Age – open-ended – number 
Q002: Gender -closed-ended – category 
Q003: Citizen – closed-ended – category 
Q004: Professional category – closed-ended – category 
Q005: Qualifications – closed-ended  category  
Q006: Experience –- open-ended –- number 
Q007: Orientation mentor –- closed-ended – category 
Q008: Duration of orientation programme – category 
Q009: In-service education –- closed-ended – category 
1.7.1.1 To describe respondents’ self-reported 
knowledge of UFH 
C 10 to 22 Q010: Bleeding tendencies – closed-ended –- category 
Q011: UFH effect on clots -closed-ended – category 
Q012: UFH effects – closed-ended - category 
Q013: UFH administration when blood pressure elevated – closed-ended – category 
Q014: UFH effects on platelets – closed-ended – category  
Q015: Protamine sulphate dose to arrest bleeding – closed-ended – category 
Q016: UFH oral delivery – open-ended 
Q017: Importance of baseline urea value – open-ended 
Q018: UFH delivery method – open-ended 
Q019: Type of UFH – open-ended 
Q020: UFH temperature storage – open-ended 
Q021: UFH effects on potassium – open-ended 
Q022: UFH dose calculation – open-ended 
1.7.3.1 To determine whether there is an association 
between selected variables and knowledge 
concerning the use and effects of UFH 
A, B, C 1 to 9  
10 to 22 relative 
to knowledge 
 
1.7.1.2 To describe respondents’ self-reported 
attitude regarding the use and effects of 
UFH 
D 23 to 26 Q023: UFH adverse effects – closed-ended – rating 
Q024: UFH and attitude – closed-ended – rating 
Q025: Patient information re UFH –- closed-ended – rating 





Objective Section Question(s) Types of questions  
1.7.3.2 To determine whether there is an association 
between selected variables and attitude 
concerning the use and effects of UFH 
A, B, D 1 to 9  
23 to 26 relative 
to attitude 
 
1.7.1.3 To describe respondents’ self-reported 
practice regarding UFH 
E 27 to 35 Q027: Prescription UFH – closed-ended – rating 
Q028: Checking new patient coagulation results – closed-ended – rating 
Q029: Checking current patient coagulation results –- closed-ended – rank 
Q030: Review UFH literature –- closed-ended – multiple choice 
Q031: Concerns regarding UFH – closed-ended – category 
Q032: Adjusting UFH dose – closed-ended – multiple choice 
Q033: Witness UFH reaction – closed-ended –- multiple choice 
Q034: Consult for UFH information – closed-ended – rating 
Q035: UFH practice-related – closed-ended –- rating 
1.7.3.3 To determine whether there is an association 
between selected variables and practice 
concerning the use and effects of UFH 
A, B, E 1 to 9 
27 to 35 relative 
to practice 
 
Legend: Q = Question 
41 
3.4.1.1 Questions for measuring knowledge 
Section C of the questionnaire (Appendix 1) comprised 13 questions to measure 
knowledge of UFH that renal unit practitioners are presumed to have. Six 
questions were closed-ended and seven questions were open-ended. The 
intention with the open-ended questions was to give respondents the opportunity 
to use their own words (Bowling & Ebrahim, 2007:394), to test higher cognitive 
levels such as comprehension and application than merely recall from closed-
ended questions and to minimize successful guessing (Bowling & Ebrahim, 
2007:405). 
3.4.1.2 Attitude-measuring questions 
Section D of the questionnaire (Appendix 1) was composed of four questions with 
one question (024) subdivided into six statements, for which there was a 5-point 
Likert attitude scale to illicit responses ranging from "Strongly Agree" to "Strongly 
Disagree”. Likert scales in use vary from two points up to eleven or more but “the 
reason why five has become the norm is probably because it strikes a 
compromise between the conflicting goals of offering enough choice (since only 
two or three options means measuring only direction rather than also strength of 
opinion) and making things manageable for respondents (since few people will 
have a clear idea of the difference between, say, the eighth and ninth point on an 
eleven‐point agree-disagree scale). Research confirms that data from Likert items 
(and those with similar rating scales) becomes significantly less accurate when the 
number of scale points drops below five or above seven. However, these studies 
provide no grounds for preferring five rather than seven‐point scales” (Johns, 
2010:6). All the statements for this question (024) were positively worded. The 
remaining three questions consisted of a numerical rating scale. One question 
required ranking and the other two were closed-ended. Some of the attitude-
measuring statements began with a guiding statement, "I feel….." to encourage 
respondents to verbalise feelings about a particular situation. 
3.4.1.3 Practice behaviour-measuring questions 
Section E of the questionnaire (Appendix 1) focused on the respondents’ practice 
behaviour. It consisted of nine questions with one question subdivided into six 
statements. A few of the questions required ranked responses. The design of one 





scale for frequency of practice (Always, Usually, Sometimes, Never). Some 
questions were closed questions and four were open-ended. 
After construction of the eight-page self-administered questionnaire, it was 
distributed to experts for validation (see below). Missing data would be assigned a 
number of ‘1001’ and not be taken into account when computing the results as 
missing data can reduce the overall interpretation of the results. Thereafter it was 
pilot tested for reliability to verify consistency (Delport & Roestenburg, 2011:177). 
This ensured that the self-administered questionnaire measured what it was 
supposed to measure (validity), thereby producing the same or similar results 
every time it was administered to respondents under similar conditions (Delport & 
Roestenburg, 2011:178). 
3.4.2 Validity 
The judgement-quantification stage involved recruiting three experts (acceptable 
minimum number) (Lynn, 1986) in the content/domain areas of the survey 
questionnaire who were given a checklist (Appendix 3) with a scale for 
quantifying the content validity. 
3.4.2.1 Procedure for establishing content validity of the questionnaire  
Three experts in the clinical field, namely a Nephrologist, a Research Pharmacist 
and a qualified Nephrology Nurse, reviewed the questionnaire for content validity. 
Quantification of content validity was achieved by using the index of content 
validity (CVI) as outlined by Lynn (1986) and adapted from Kyriacos’ (2011) study 
with permission. The CVI was derived from rating the content relevance 
(Appendix 3) of each questionnaire item using a 4-point ordinal rating scale. A 
rating of 1 was perceived as irrelevant and a rating of 4 as extremely relevant 
(Lynn, 1986). Validity was predetermined and set at the proportion of items that 
received a rating of 3 or 4. Comments and/or omissions were listed separately. 
These experts were provided with the final draft of the questionnaire (Appendix 1) 
and a covering letter with the CVI instrument (Appendix 3), with instructions on 





approach by experts for validation of the questionnaire. Thereafter, relevant 
changes were made.  
 Validation results for Index of Content Validity (CVI) of the questionnaire 
The expert reviewers returned their completed CVI questionnaire within two 
weeks of receiving the questionnaire. Data in Table 3.4 show the analysis 
of three experts’ opinions on the index of content validity (CVI) of each 






Table 3.4: Experts’ index of content validity (CVI) of each question  
Question 
number 
1 = irrelevant 2 = unable to assess relevance 
without item revision or item is 
in need of such revision that it 
would no longer be relevant 




4 = extremely 
relevant 
001  1 (33.3%)  2 (66.6%) 
002    3 (100.0%) 
003   1 (33.3%) 2 (66.6%) 
004   1 (33.3%) 2 (66.6%) 
005   1 (33.3%) 2 (66.6%) 
006   1 (33.3%) 2 (66.6%) 
007    3 (100.0%) 
008   1 (33.3%) 2 (66.6%) 
009    3 (100.0%) 
010   2 (66.6%) 1 (33.3%) 
011    3 (100.0%) 
012    3 (100.0%) 
013    3 (100.0%) 
014 1 (33.3%)  1 (33.3%) 1 (33.3%) 
015    3 (100.0%) 
016   1 (33.3%) 2 (66.6%) 
017   1 (33.3%) 2 (66.6%) 
018   2 (66.6%) 1(33.3%) 
019 1 (33.3%)   2 (66.6%) 
020   1 (33.3%) 2 (66.6%) 
021   1 (33.3%) 2 (66.6%) 
022   1 (33.3%) 2 (66.6%) 
023  2 (66.6%) 1 (33.3%)  
024a   1 (33.3%) 2 (66.6%) 
024b    3 (100.0%) 
024c    3 (100.0%) 
024d    3 (100.0%) 
024e   1 (33.3%) 2 (66.6%) 
024f    3 (100.0%) 
025   1 (33.3%) 2 (66.6%) 
026   1 (33.3%) 2 (66.6%) 
027   1 (33.3%) 2 (66.6%) 
028    3 (100.0%) 
029    3 (100.0%) 
030   1 (33.3%) 2 (66.6%) 
031    3 (100.0%) 
032   1 (33.3%) 2 (66.6%) 
033   1 (33.3%) 2 (66.6%) 
034    3 (100.0%) 
035a    3 (100.0%) 
035b   2 (66.6%) 1 (33.3%) 
035c   1 (33.3%) 2 (66.6%) 
035d    3 (100.0%) 
035e   1 (33.3%) 2 (66.6%) 
035f    3 (100.0%) 
Overall, the experts' evaluation of the questionnaire was positive as most of their 
responses (44/45, 97.8%) as to the importance of the questions fell in the 





were rated a 4 by the three (100%) experts. Twenty-two of 44 questions (50.0%) 
were rated a 4 by two (66,6%) experts. The remaining 4 of 44 questions (9.1%) 
were rated a 4 by one (33.3%) expert.  
Data show that 25/45 (55.6%) items were rated 3 (relevant but needs minor 
alteration). Of these, 22 of 25 questions (88.0%) were rated a 3 by one (33.3%) 
expert and 3 of 25 questions (12.0%) were rated a 3 by two (66.6%) experts; and 
2/45 (4.4%) were rated 2 (unable to assess relevance without item revision or item 
is in need of such revision that it would no longer be relevant). Of this rating, there 
was 1 of 2 questions that was rated a 2 by one (33.3%) expert. The other question 
rated a 2 was by two (66.6%) experts. The rating of 1 (irrelevant) was applicable to 
2/45 (4.4%) questions. Both questions had one expert rating the question as 1. 
As recommended by the experts, the following questions were modified: Q003 
was changed to include the words "how long working in South Africa"; and the 
instruction "complete the following questions below in your own words" was added 
to Q006 and 016 – 022. To achieve clarity, questions 014, 018, 019 and 023 were 
re-formulated. Questions 024a, 024e, 025, 033, 035e and 035f words of “side-
effects” were changed to “adverse effects” to achieve consistency with wording. 
One of the two questions rated 2 related to age in Section A Q001 which was not 
considered important by one expert reviewer. No change was made to this 
question, as it would provide useful information about the respondents’ 
demographic characteristics in relation to the objectives of the study. The second 
question was in Section D, Q023 (Table 3.5), where two reviewers felt the 
question design was confusing and therefore could not answer the question. Q023 
was amended by removing the Likert scale answer key and replacing with a linear 






Table 3.5: Amendment to Question 023, Section D 
Original Question 023 Amended Question 023 
Patients on haemodialysis receiving UFH may 
experience side effects. On a scale of 5 to 1 how 
would you rank the side effects for patients receiving 
UFH (where 5 indicate great concern and 1 indicates 
the least concern]? 
Patients on haemodialysis receiving UFH may 
experience adverse effects. On a scale of 5 to 1 make a 
mark to show how you would rank your concerns about 
these adverse effects [for patients receiving UFH - 5 
indicates great concern and 1 indicates the least 
concern] 
[   ] Neutral 
[   ] Extremely concerned 
[   ] Fairly concerned 
[   ] Highly concerned 
[   ] Least concerned 
1               2                   3                    4                    5  
Least                                                              Great  
concern                                                         concern 
The ratings of two questions were 1, and both were in the knowledge section C. 
Q014 related to “For which platelet count would UFH not be administered?”. The 
fact that the reviewer was “Not sure” did not mean the question was not relevant, 
as this is an important knowledge question. A minor change was made, as follows: 
“Which of the following platelet counts would you not administer UFH?” For the 
other question, Q019 “What type of UFH is used in your dialysis unit”, the reviewer 
did not substantiate a score of 1. No change was made as the question is a 
relevant knowledge question. Since this was the opinion of only one reviewer, the 
two questions were slightly adjusted and not discarded. 
After the amendments were made, the questionnaire was taken as having 
achieved content validity. 
3.4.2.2 Procedure for establishing face validity of the questionnaire 
For determining face validity of the questionnaire (layout, format, quality of 
printing, length, if visually easy to read and comprehend and if instructions at the 
beginning of the questionnaire were clear and easy to understand) (Bowling & 
Ebrahim, 2007:404), a further section was added to the checklist (Appendix 3) with 
four criteria (very skilful, satisfactory, needs improvement, unacceptable) but no 
rating scale. The same three experts who determined the CVI of the questionnaire 







 Validation results for face validity of the questionnaire 
Data analysis for reviewers’ evaluation of face validity of the questions is 
presented in Table 3.6. 






Layout 1 (33.3%) 2 (66.7%)   
Format  3 (100%)   
Quality of printing 3 (100%)    
Length of the questionnaire 3 (100%)    
Visually easy to read 3 (100%)    
Visually easy to comprehend  3 (100%)   
Are instructions at the beginning of the 
questionnaire clear and easy to 
understand  
3 (100%)    
(Adapted from Bowling and Ebrahim, 2007). 
Concerning the experts' evaluation of the face validity of the questionnaire, most 
responses (5/7, 71.4%) indicated that the quality of printing, length, visual 
presentation (easy to read and understand) and clear instructions had been ‘very 
skilfully’ executed (Table 3.6). The remaining two criteria were satisfactory (layout 
and format). Their suggestions were accepted and changes were made to the 
layout of the final questionnaire: use of an appropriate font size and symmetrical 
spacing of paragraphs to ensure a professional appearance of the questionnaire. 
A suggestion of putting the numbers in answer boxes in ‘shadow’ outline was 
accepted, and these changes were implemented. Ambiguous questions in the 
questionnaire were refined, namely Section C, Q014, Q018 and Q019 and Section 
D, Q023. Lastly, the suggestion to group closed-ended questions and open-ended 
questions was accepted and changes made. The reviewers noted no omissions. 
Following content and face validation, the data instrument was pilot tested for 
reliability by a pilot group. 
3.4.3 Reliability testing 
For this purpose the Pearson’s r correlation co-efficiency test (for inter-rater 





internal consistency) for reliability analysis was used. This was to determine 
whether the difference between the two scores (test 1 and test 2) for each 
respondent across the KAP questionnaire was statistically significant and to 
assess the score reliability.  
The pilot group comprised renal unit practitioners who would not participate in the 
main study. This group assisted in reliability testing of the self-administered 
questionnaire. Testing for reliability is important because the data instrument must 
yield the same results when the same variable is tested each time that the 
instrument is used, thus ensuring that the instrument is consistent, dependable 
and predictable (Delport & Roestenburg, 2011:177). This study used inter-rater 
and internal consistency reliability methods to estimate the reliability of the 
instrument (questionnaire) for use in the main study (Trochim, 2006:96). 
3.4.3.1 Pilot study 
The pilot study was a small scale preliminary attempt to improve upon the self-
administered questionnaire prior to performance of the full-scale study. This 
provided the researcher with an opportunity to review aspects relating to the 
interpretation of the questionnaire, whether instructions were clear, and the time it 
took to complete (Delport & Roestenburg, 2011:195). 
To determine the acceptable time interval between the test-retest reliability 
method, the researcher reviewed results from previous research to make an 
informed decision. The Medical Research Council (MRC) in the United Kingdom 
(2013) discussed three examples of acceptable time intervals for administering 
test-retest self-administered questionnaires. In 2000 Patterson (cited by the MRC, 
2013) reported 1–3 days but no more than 7 days for physical activity self-reports, 
and 4–8 weeks for a dietary assessment, to reduce the chance of the first 
assessment influencing the second. For a short time frame (1–7 days) the report 
says it was difficult to observe significant differences, but this could be possible 
with a longer interval between tests. 
Nonetheless, Trochim (2006:97) acknowledges that the time interval between the 





However, the study by Marx et al. (2003:730) confirmed that two different time 
intervals between test-retest for reliability yielded no statistically significant 
differences when carried out at 2 days or 2 weeks. Due to the different viewpoints, 
an informed decision was made to grant an allowance of one week between the 
delivery and return of both self-administered questionnaires to pilot study 
personnel. 
3.4.3.2 Pilot study personnel 
The pilot study group was not part of the main study and comprised one 
Registered Nurse (RN), one Enrolled Nurse (EN) and One Clinical Technologist 
(CT, Nephrology). They were from the same professional categories as the main 
study to authenticate the reliability of the instrument (self-administered 
questionnaire) (Karanicolas et al., 2009:99). Similar to the main study professional 
category, they were responsible for administration of UFH in dialysis centres, 
except that the location was in KwaZulu-Natal Province. The researcher 
telephonically informed the pilot study group of the study and requested their 
voluntary participation, and all three pilot study personnel agreed to participate. 
The researcher requested them to answer honestly and to maintain the 
questionnaire’s confidentiality. 
The self-administered questionnaire (Appendix 1) for the first test was emailed to 
the pilot study personnel for them to complete. They returned the completed self-
administered questionnaires via email within the allocated timeframe of one week. 
Then the same (blank) self-administered questionnaire was emailed to the same 
pilot study personnel for the retest. They completed and returned by email within 
the one-week time period. The pilot study personnel confirmed that 30–60 minutes 
was required to complete the questionnaire. They expressed difficulty in 
answering some questions due to their limited knowledge of UFH. 
Thereafter, the pilot study raw data were captured on a Microsoft® Excel 
spreadsheet and analysed for consistency of responses between test 1 and test 2. 
The answer sheet to the questionnaire (Appendix 11) guided the scoring of the 





attitude items were allocated a score of 41, and practice items a score of 50. 
Missing responses in both test 1 and test 2 were regarded as incorrect and a zero 
score was allocated. To measure the percentage of agreement of the results 
between test 1 and test 2 an inter-rater reliability estimate was conducted 
(Trochim, 2006:96) including an internal consistency to measure the consistency 
of results across items within a test. 
It is desirable when measuring reliability that more than one statistical estimate 
should be considered to determine the relationship between measurement errors 
(Karanicolas et al., 2009:103) to test the stability, equivalence and homogeneity of 
the instrument (Burns & Grove, 2011:333). Using the SPSS statistical program the 
researcher performed the Pearson’s r correlation co-efficiency test (for inter-rater 
reliability) in correlation analysis and Cronbach’s Alpha co-efficiency test (for 
internal consistency) in reliability analysis. This was to determine whether the 
difference between the two scores (test 1 and test 2) of each respondent across 
the KAP questionnaire was statistically significant, and to assess the score 
reliability.  
A point worth noting is that there will always be a degree of uncertainty when 
using humans as control measures, because the results they yield may not be 
consistent or reliable due to distracters (Trochim, 2006:96), and a change in value 
or score may be a consequence of a random or systematic error (Burns & Grove, 
2011:333). Moreover, there is no absolute value at which inter-rater reliability is 
unacceptable; however, values below 0.80 should be of concern regarding the 
reliability of the tool (Burns & Grove, 2011:333). Polit et al. (1993:284) consider 
reliability coefficients of 0.70 upwards as acceptable, but measurements of 0.85 – 
0.95 were preferred. 
Results for inter-rater reliability and internal consistency of scores for the RN, CT 














Test 2 score 
(%) 
Test 1 score 
(%) 
Test 2 score 
(%) 
Test 1 score 
(%) 
Test 2 score 
(%) 
Knowledge  
(10-22) out of 
18 marks 





Test 1 M=11.0; SD±2.0 







Test 1 M=11.0; SD±2.0 
Test 2 M=9.7; SD±3.1 
Attitude  
(23-26) out of 
41 marks 




0.939 (p=0.224)  
Test 1 M=31.3; SD±5.9 







Test 1 M=31.3; SD±5.9 
Test 2 M=31.0; SD±4.0 
Practice  
(27-35) out of 
50 marks 




1.000 (p=0.016)  
Test 1 M=23.7; SD±15.6 







Test 1 M=23.7; SD±15.6 
Test 2 M=23.3; SD±17.0 
M = mean; SD = standard deviation. 
The data in Table 3.7 display the Pearson’s r and Cronbach’s alpha results. The 
Pearson’s r results (r=0.982, p=0.121) show a very high correlation (Taylor, 1990: 
37) for knowledge, and therefore a strong relationship but with no statistical 
significance between the professional categories and knowledge scores for test 1 
and test 2. Similarly, the output generated using Cronbach’s alpha reliability 
analysis (alpha=0.947) shows a high level of internal consistency between the test 
and retest scores between professional categories for knowledge scores. 
The attitude scores for test 1 and test 2 across the professional categories, using 





therefore a reliable relationship that did not achieve statistical significance. The 
Cronbach’s alpha reliability analysis for attitude (alpha=0.933) shows a high level 
of reliability between test 1 and test 2 scores across the professional categories.  
There was a very high positive correlation between professional category and 
practice scores (r=1.000, n=3, p=0.016) for Pearson’s r analysis, and this reached 
statistical significance, indicating that variability is due to true differences between 
scores (Karanicolas et al., 2009: 99). The Cronbach’s alpha reliability analysis for 
practice shows high internal reliability between test 1 and test 2 scores across the 
professional categories (alpha=0.998). 
However, the results have to be interpreted with caution due to the small pilot 
sample (n=3/77, 3.8%), which falls far short of an estimated pilot sample size of 
10% (8/77) of the larger study recommended by Lackey and Wingate (1998:380). 
Raters were from the same professional categories as the main study to 
authenticate the reliability of the instrument (self-administered questionnaire) 
(Karanicolas et al., 2009:99). Despite the small sample size, the results of the 
Pearson’s r and Cronbach’s alpha suggest that the test instrument is stable, 
reliable and reproducible.  
3.4.3.3 Summary of the validation process 
The self-administered questionnaire (Appendix 1) was subject to content and face 
validity testing, after which changes were made to the instrument. The amended 
self-administered questionnaire was thereafter subject to inter-rater reliability 
testing, which showed a very high positive correlation and therefore strong 
relationship between the variables examined for Pearson’s r. However, statistical 
significance was only achieved between professional category and practice 
scores. For all of the variables examined, Cronbach’s alpha suggested that the 
test instrument is stable, reliable and reproducible. 
The final amended questionnaire as recommended by the pilot study group was 
ready for use in the main study. This concluded the validation process of the 





3.5 Procedure for data collection 
The discussion below outlines the steps followed for the data collection process. 
3.5.1 Data collection method 
3.5.1.1 Gaining access 
Formal permission-seeking letters were written to the Management Head of the 
private dialysis provider, the Medical Superintendent of the tertiary hospitals and 
the Medical and Nursing Heads of the various dialysis centres (Appendix 4) 
requesting their permission for inclusion of their staff to participate in the study. 
The letter outlined the purpose of study, ethical principles, which the researcher 
would adhere to, details of the UCT Faculty of Health Sciences Human Research 
Ethics Committee and ethics clearance number (Appendix 5A), the researcher and 
supervisor, the process for collecting data and the timeframe for returning the 
completed questionnaires. 
Upon receiving written permission from the relevant authorising bodies, the 
researcher made telephonic contact with the Unit Managers to arrange a meeting. 
The purpose of the face-to-face meeting was to inform them of the study and to 
provide them with copies of the ethics clearance and the permission letters from 
the various employing authorities that allowed the researcher access to the 
dialysis centres and the Unit Manager.  
A discussion of the entire process for data collection occurred in the privacy of 
each of the six Unit Managers’ offices. Everyone verbalised that they understood 
the process of data collection and no clarification was required. No contact was 
made with the seventh dialysis centre Unit Manager due to waiting for 
authorisation from the employing body. A timeframe was agreed on with the six 
Unit Managers for when written consent was to be obtained from all potential 
respondents who met the inclusion criteria. An agreement was made regarding the 
distribution of the self-administered questionnaire (Appendix 1), the completion 
date of the survey (the researcher and Unit Managers agreed on a 2-week 





The researcher prepared packs of questionnaires for each participating dialysis 
centre. The questionnaire cover page (Appendix 1) was individualised for each 
participating dialysis centre, with the contact person’s name for a new 
questionnaire, date for completion for the questionnaire, and the name of the 
person to whom the respondent needed to hand the sealed envelope with the 
completed questionnaire. 
Contact was made with Unit Managers to deliver the blank questionnaires in 
unsealed envelopes. As part of a quality control measure, the researcher 
documented the number of blank questionnaires delivered to compare against 
returned completed questionnaires. Unit Managers were informed during the data 
collection period that the researcher could be contacted via telephone or email for 
clarity on any aspects of the questionnaire. 
Permission was received for access to the seventh dialysis centre 2 weeks after 
commencing data collection at the other six-dialysis centres. The limitation 
encountered for access to the seventh dialysis centre was having no personal 
contact with the Unit Manager of that dialysis centre –communication was through 
the Nursing Department of the hospital. The questionnaire envelopes were hand-
delivered to the hospital Nursing Department secretary; she was informed of the 
data collection process, so that in turn she could convey the process of data 
collection to the Unit Manager. 
3.5.2 Data management 
Neuman (2011:383) asserts that before data can be analysed to test the 
hypotheses, it must be set up in a specific form so that interpretation via different 
statistical software on computer can occur. The process adopted is discussed in 
the sections below. 
3.5.2.1 Analysis of data from closed-ended questions 
Data from 36 closed-ended questions (of the total 45 questions) for each 
completed questionnaire (Appendix 1) were read and checked before being 





Q035 had sub-sections. In total, one questionnaire yielded 44 or 45 responses 
(allowing for options). Q031 had 4 options (Appendix 1), so if option 4 was 
chosen, this required an answer for Q032 and 45 questions would have been 
answered. If a response other than 4 was chosen, respondents bypassed Q032 
and only gave 44 responses.  
Missing data were labelled as ‘1001’ for each questionnaire item with a blank 
column. This missing data label (1001) was used when calculating descriptive and 
frequency statistics. Missing data labels were removed when calculating inferential 
statistics; these were changed to a blank space to reduce skewed interpretations. 
For the management of numbers the second decimal was left out; for example, 
45.87% became 45.9% and 45.83% became 45.8%. Due to numbers rounding off, 
the total percentage does not always compute to 100.0% but to 99.9% or 100.1%. 
Statistical results were rounded off to the first decimal, for example mean age 
41.05 rounded off to 41.1 and standard deviation 10.818 rounded off to 10.8, 
however the p-values were read with three decimal points. 
3.5.2.2 Analysis of data from open-ended questions 
Data from the remaining 9 open-ended questions in Section A (Q001), Section B 
(Q006) and Section C (Q016 - Q022) (Appendix 1) were captured verbatim. 
Responses to the open-ended questions were analysed for thematic content and 
tallied for frequency of occurrence. A frequency table of codes (Appendix 11) 
depicts common themes. 
Due to the small cohort of renal unit practitioners, the researcher treated 
incomplete questionnaires in the same manner as those with 100% responses 
and used the code ‘1001’ to identify missing data in the initial raw data captured 
as shown in Table 3.8. However, the researcher is aware that the missing data 


























































































































































4 47 1 1 1 2 2 2 1001 1001 IV 
 48 1 1 4 2 2 3 Because 
it is short- 
acting 
1001 IVI 










Note to table: IV/IVI = intravenous route 
The Microsoft® Office Excel® 2007 spreadsheet with the captured raw data was 
password- protected and only the researcher had access to the laptop. The 
completed questionnaires will be stored in a steel locked cupboard and will be 
kept for two years after the completion of the study, should post-analysis be 
required, after which data will be shredded. As a back-up plan, a flash drive stored 
the captured information in case the laptop malfunctioned. The flash drive was 
kept in the steel locked cupboard storing the raw data. Deletion of the information 
on the flash drive will occur after a period of two years. 
3.5.2.3 Statistical analysis 
Statistical analysis involved the systematic reorganising and decoding of raw data 
from closed-ended questions into numerical codes. An electronic database was 
established which was password-protected to store the original Microsoft® Office 
Excel® 2007 spreadsheet in which raw data were captured. This database was 
used as a point of reference to clarify any errors noted before further statistical 
analysis. The Microsoft® Office Excel® 2007 spreadsheet had headings to 
capture the raw data from the 77 respondents. Each participating respondent’s 





respondent’s allocated number for ease of identification and for reference 
purposes if discrepancies were noted. 
The computer-allocated number was the same assigned to the hard copy of the 
respondent’s questionnaire for easy identification and referencing purposes 
(Appendices 6–9). This quality control measure was adopted to ensure accuracy 
of data captured. The entire capturing of raw data took 2 weeks to complete. 
IBM SPSS Statistics version 21 (2012) and 22 (2014) was used to analyse raw 
data for descriptive and inferential statistical analysis. At this stage, a statistician 
assisted in checking the pre-codes allocated for the different items on the 
questionnaire. What was determined was that the initial score system allocated 
was incorrect; therefore item reversal had to be done and the data were 
rechecked for consistency before any statistical analysis could be performed.  
Scores of 1 and 2 were assigned to the correct answers for knowledge and 
practice questions and 0 was assigned to wrong answers. The answers to attitude 
questions were ranked 1–5 so that the score of 5 represented the best score for 
attitude. 
A quartile test was performed to determine the inter-quartile KAP score for each 
dependent variable on the questionnaire. The 1st quartile represented the 
respondents’ unacceptable low scores and the 3rd quartile the respondents’ high 
scores; the median score of 50% was the 2nd quartile. There was speculation that 
KAP scores for most of the respondents from each professional category would be 
reflected in the 2nd quartile based on assumed baseline pharmacology knowledge 
of UFH from work experience and in-service education on UFH. 






Table 3.9: Variables and statistical analysis 
Demographic variables Indicator 
variables 




 Continuous  Measures of central 
tendency: Mean if 
normally distributed;  
Shapiro Wilk test for 
normality of data 
Spearman’s rho test 
ANOVA,  
Scheffe post hoc test 
Gender (Q002) 
Citizenship (Q003) 
Professional Category (Q004) 
Qualification (Q005) 
Orientation duration (Q008) 
UFH effects on clots (Q011) 
UFH effects (Q012) 
UFH administration in elevated blood 
pressure (Q013) 
UFH effects on platelets (Q014) 
Protamine sulphate dose to arrest 
bleeding (Q015) 
UFH not administered orally (Q016) 
Value of baseline urea levels (Q017) 
Route of administration of UFH (Q018) 
Type of UFH used (Q019) 
Temp. storage UFH (Q020) 
Effects of UFH on potassium (Q021) 
UFH dose calculation (Q022) 
Concerns regarding UFH (Q031)  
Consult for UFH information (Q034) 
Male = 1; 
female = 2; 
South African =1; 





























Fisher’s Exact Test 
Spearman’s rho test 
ANOVA 













Proportion & percentage 
Fisher’s Exact Test and 
Spearman’s rho test 
 (test objectives 1.7) 
Mentor (Q007) 
In-service (Q009) 
Bleeding tendencies (Q010) 




Fisher’s Exact Test 
UFH adverse effects (Q023) 
Attitude (Q024) 
Patient info re UFH (Q025) 
Patient info re - UFH adverse effect (Q26) 
Prescription UFH (Q027) 
Checking new patient coagulation results 
(Q028) 
Checking current patient coagulation result 
(Q029) 
Review UFH literature (Q030) 
Adjusting UFH dose (Q032) 
Witness UFH reaction(Q033) 
UFH practice related (Q035) 
 Ordinal 





deviation (SD), Fisher‘s 
Exact test and 
Spearman’s rho test (to 








Descriptive statistical analysis was performed as a baseline to obtain frequency 
distribution and measurement of central tendencies (for continuous data) for 
personal and professional demographics and KAP data. To analyse the 
categorical variables, cross-tabulations were performed using the Fisher’s exact 
test to determine whether there was an association between selected variables 
(category of renal unit practitioner, years of experience, duration of orientation to 
the adult chronic haemodialysis unit and in-service education on the 
pharmacology of UFH) and KAP concerning the use and effects of UFH.  
Application of the logistic regression model was to test the association between 
selected variables (as mentioned above) and KAP variables. Expression of 
strength of association was as an odds ratio (OR). A p-value of ≤0.05 and a CI of 
95% denoted the association as statistically significant. Tables and graphs are 
used to illustrate the analysed data (Edwards & Talbot, 1999:134; Banerjee, 
2004:10). 
3.5.3 Quality assurance of data entries 
For sampling, a random selection of 8 of 77 completed questionnaires (10.4%) 
was performed using the Microsoft® Office Excel® 2007 software. A nurse 
possessing a Master’s degree in nursing assessed the quality of data entries 
copied from the hard copies of the questionnaires onto a Microsoft® Office Excel® 
2007 spreadsheet. Of the sampled questionnaires (n=8), disagreements between 
recordings on the spreadsheet and on the questionnaires related to two (2.6%) of 
77 respondents’ captured data that had errors in three questions as shown in 
Table 3.10. 
Table 3.10: Data entry sampling disagreements 
Sample  Section C: Knowledge Section D: Attitude Section E: Practice  
n = 8 1 (12.5%) 0 (100%) 2 (25.0%) 
 
There was a 6.7% (3/45 questions) disagreement and 93.3% (42/45) agreement 
between recordings which was deemed acceptable as the predetermined level of 





2007 spreadsheet were corrected for these two respondents. For consistency, a 
further check of the remaining 69 respondents’ captured raw data was done 
against their completed questionnaires. 
3.6 Ethical considerations 
Approval of the study proposal was received from the Research Committee on 30 
November 2012 and the UCT Faculty of Health Sciences Human Research Ethics 
Committee awarded the study approval number (FHS HREC Ref. 642/2012) on 9 
January 2013 (Appendix 5). During March 2013 and April 2013, the researcher 
received approval from the participating tertiary hospitals and private dialysis 
companies to conduct the study. The principles of the Helsinki Declaration (2008) 
were maintained, including informed consent, non-maleficence and beneficence, 
privacy and confidentiality, autonomy and justice. 
3.6.1 Informed consent 
Potential research respondents were told of all relevant study information 
(Appendix 2), affirming that participation is voluntary. No monetary incentives were 
offered to respondents. However, as a token of appreciation the researcher gave 
cakes to the various units participating in the study. 
3.6.2 Non-maleficence and beneficence 
The self-administered questionnaire did not cause any psychosocial harm, no 
respondent contacted the researcher to verbalise experiencing emotional distress 
when completing the questionnaire, and no Unit Manager reported any staff 
experiencing emotional distress when completing the questionnaire. Three Unit 
Managers reported that some categories of staff refused to participate in the 
study, and one Unit Manager was keen to have the answers to the questionnaire 
for in-service training. The researcher honoured a pledge to do no harm to the 
respondents’ psychosocial well-being. 
All necessary precautions to protect respondents by employing sound scientific 





upholding the principles of privacy, confidentiality, anonymity, autonomy and 
justice. 
3.6.3 Privacy and confidentiality 
To protect respondents and the employing dialysis centres, no names were 
divulged and respondents and dialysis centres were assigned code numbers for 
easy identification of data. Protection of privacy and confidentiality was maintained 
by providing self-sealing envelopes for the return of completed questionnaires. 
Using a computer statistical program the collected data collected were converted 
into figures and graphs, resulting in generalising the findings beyond a specific 
respondent or dialysis centre. Only the researcher and supervisor had access to 
the raw data that were stored in a locked cupboard, and the electronic version was 
password-protected. 
3.6.4 Autonomy 
Respondents had the final authority to either accept being part of the study or to 
decline, without any repercussions arising from their decision. 
3.6.5 Justice 
All respondents and their employing dialysis centres received fair and equal 
treatment and respect, ensuring no favouritism. The researcher did not manipulate 
information to meet the study outcomes. 
3.7 Summary 
This chapter examined the procedures followed for the study methodology, 
including the research design, study population, sample size, sampling method, 
recruitment, data collection instrument (design, validation and reliability testing) 
and pilot study. A discussion followed on the data collection method, data 
management and statistical analysis methods, quality assurance of data entries 





CHAPTER 4: RESULTS 
4.1 Introduction 
This chapter presents the results of the study. The research questions, aims, 
objectives and study hypothesis guided the results. Seven purposively selected 
adult dialysis centres in the Cape Town Metropole participated in the study, two 
(28.6%) tertiary government hospital dialysis centres and five dialysis centres 
(71.4%) from one private dialysis provider. 
The primary purpose of the study was to describe renal unit practitioners’ KAP 
regarding the use and effects of UFH in selected adult chronic haemodialysis 
centres in the Cape Town Metropole. The secondary purpose was to determine 
whether there is an association between selected variables (category of renal unit 
practitioner, years of experience, duration of orientation to the adult chronic 
haemodialysis unit and in-service education on the pharmacology of UFH) and 
renal unit practitioners’ KAP concerning the use and effects of UFH. 
The first research question addressed renal unit practitioners’ KAP relative to the 
use and effects of UFH in selected adult chronic haemodialysis centres in the 
Cape Town Metropole. The second research question addressed an association 
between selected variables (professional category, years of experience, duration 
of orientation to the adult chronic haemodialysis unit and in-service education on 
the pharmacology of UFH) and renal unit practitioners’ KAP concerning the use 
and effects of UFH. 
Presented first in this chapter are the response rates as per dialysis centres and 
individuals, and thereafter, an overview of the questionnaire responses is 
presented. This is followed by presentation of the guidelines used to score the 
questionnaire and then the actual total results of the respondents’ self-reported 
answers to the questionnaire, including the different tests employed to describe 
and analyse the objectives. An account of the STROBE checklist precedes the 





4.2 Response rate 
The estimated sample size was 82 (1.0% margin of error, 95% CI) and the return 
rate was 77 (94.0%), nevertheless, no questionnaires were excluded from the final 
data analysis even those with missing data. 
4.2.1 Participating dialysis centres and individual responses 
Heads of departments of all seven purposively selected dialysis centres allowed 
access to their renal unit practitioners for participation in the study. Data in Table 
4.1 show the questionnaire return rates for each of the participating dialysis 
centres (n=7). Of the total population (N=104) of renal unit practitioners who met 
the inclusion criteria, 77 (74.0%) participated in the study compared to the 
estimated sample size (n=82, 93.9%). 





No. of  
questionnaires 
distributed 






Hospital 1 21 21 20  95.2 
Hospital 2 29 29 15  51.7 
Sub-total 
hospitals 
50 50 35  70.0 
Dialysis centre 1 12 12 11 91.7 
Dialysis centre 2 13 13 7 53.8 
Dialysis centre 3 19 19 17 89.5 
Dialysis centre 4 4 4 4 100 




54 54 42 77.8 
Total                7 104 104 77 74.0 
 
The data in Table 4.1 indicate that there was a 70.0% response rate (35/50) from 
tertiary hospital dialysis settings, and from the private dialysis centres, this was 
77.8% (42/54). Overall the response rate was 74.0%, with 35/77 (45.5%) from the 





dialysis centre had a 95.2% (20/21) response rate and three private dialysis 
centres had response rates ranging between 89.5% (17/19) and 100% (4/4). 
Potential reasons for not all of the renal unit practitioners participating in the study 
may possibly be because some:  
 were on annual, study or sick leave; 
 did not want to participate; 
 did not want to expose their true KAP regarding unfractionated heparin; 
 did not feel the study was of importance; 
 did not want to take time out of their personal or work schedule to 
complete the questionnaire; 
 may have felt that their handwriting would have been recognized by the 
researcher. 
4.2.2 Number of responses by questionnaire 
One questionnaire yielded 44 or 45 answers. The 77 questionnaires of all 
respondents yielded 3388 responses, with missing data (Table 4.2) accounting for 
169 (5.0%) of these. 
Table 4.2: Missing data from responses to the questionnaire 
Respondents (n=77) 
Question No. (missing data) 
 Personal and 
professional 
Knowledge Attitude Practice 












































6/693 (0.80) 83/1001 (8.2) 42/693 (6.0) 38/1001 (3.8) 





Data in Table 4.2 show that the highest proportion of missing data recorded was in 
Section C for knowledge regarding UFH (Q017 – 22.0%, 17/77; Q021 – 19.4%, 
15/77). Overall most of the missing data were from the knowledge section (8.2%, 
83/1001). Personal and professional demographics sections recorded the lowest 
proportion of missing data (0.8%, 6/693). 
4.2.3 Guideline for scoring responses to questionnaires 
Guidelines for scoring the correct responses were according to the literature 
reviewed for the development of the questionnaire (Appendix 10). The overall 
achievable scores for the questionnaire are shown in Table 4.3.  
Table 4.3: Interquartile test scores for KAP variables 









Valid 77 77 77 
Missing 0 0 0 
25 (1st
 
quartile) 8.5 24.0 32.5 
50 (median, 2nd quartile) 10.0 27.0 37.0 
75 (3rd quartile) 13.0 29.0 40.0 
The data in Table 4.3 show the overall achievable scores for the questionnaire by 
calculating the median and quartile range for each dependent variable: 
Knowledge, Attitude and Practice. 
The total scores possible in the different sections if answered correctly were as 
follows:  
 Knowledge, Section C (18 marks): For Q012 a score of up to 4 was 
allocated and for Q018 the respondent could score up to 3 marks. The 
other 11 questions scored a maximum of 1 mark each.  
 Attitude, Section D (41 marks): Seven questions could achieve up to 5 





 Practice, Section E (50 marks): Q032 was not taken into account when 
computing the score based on the assumption that not many respondents 
would have selected Q031d as a response. Therefore, nine questions 
could achieve 4 marks each; one question could have scored 3 marks; two 
of the questions could achieve scores of 5 marks and one could have 
scored 1 mark. 
The 1st quartile represents respondents’ low scores which were unacceptable, 
and the 3rd quartile represents the respondents’ high scores which were highly 
impressive, with the median score of 50% or 2nd quartile as the average score or 
minimum acceptable score. 
This implied that, for example, if a respondent scored 8.5 in the knowledge section 
the respondent had poor knowledge of UFH, and this was unacceptable. 
However, if the respondent scored 13 in the knowledge section this would be 
highly impressive, suggesting that they were knowledgeable regarding UFH. 
4.2.4 KAP test results 
Respondents’ overall test scores achieved for KAP (objectives 1.7.1.1, 1.7.1.2 and 
1.7.1.3) are presented in Table 4.4. 













(out of 18) 
77 4 18 10.8 3.1 
Attitude 
scores 
(out of 41) 
77 0 35 25.9 6.0 
Practice 
scores 
(out of 50) 
77 19 44 35.8 6.0 
The mean score: for knowledge was 10.8/18 (60.0%); for attitude 25.9/41 (63.2%); 





Descriptive statistics were used for analysing respondents’ demographic 
characteristics. 
4.3 Description of respondents’ demographic characteristics  
This is a secondary objective (1.7.2) but will be described first as it relates to all 
the other objectives. This objective was to describe respondents’ demographic 
and professional profiles (independent variables) and to determine the differences 
between the groups. Sections A and B (questions 1-9 of the questionnaire, 
Appendix 1) addressed these aspects. 
4.3.1 Frequencies of demographic characteristics 
Descriptive statistics were used to show the frequencies of the demographic 
characteristics (Raw data in Appendices 6-9, example of descriptive statistics 
Appendix 12A), which are presented in Tables 4.5 to 4.11 and Figures 4.1 to 4.6. 
4.3.1.1 Descriptive analysis of demographic/professional characteristics 
The mean age of 74/77 (96.1%) respondents was 41.1 years (range 23–64 years). 
The mean age of RNs was 44.9 years, for CTs the mean age was 31.4 for ENs 
this was 44.4 years. 
Age distribution is presented in Table 4.5 and Figure 4.1. 
 
Table 4.5: Respondents’ age distribution (n=74/77)  
 
Variable Category Number % 
Age (years) 21-25 6 8.1 
 26-30 9 12.2 
 31-35 11 14.9 
 36-40 8 10.8 
 41-45 10 13.5 
 46-50 15 20.3 
 51-55 10 13.5 
 56-60 3 4.1 
 61-65 2 2.7 
 Subtotal 74 100 
 Missing 3 3.9 







Figure 4.1: Age group distribution 
The respondents’ age data (range of 23 to 64 years) had wide differences and 
were therefore grouped into 5-year intervals. Data in Table 4.5 and Figure 4.1 
show that of the 74/77 (96.1%) respondents, most (15/74, 20.3%) were in the 46-
50-year age group.  
Presented in Table 4.6 and Figure 4.2 is the gender and citizenship distribution. 
Table 4.6: Distribution of gender and citizenship status 
Variable Category Frequency % 
Gender M 19 24.7 
 F 58 75.3 
  Total 77 100 
Citizen SA 73 96.1 
 Other 3 3.9 
 Subtotal 76 100 
 Missing 1 1.3 
  Total 77 100 






Figure 4.2: Gender distribution 
Data in Table 4.6 and Figure 4.2 indicate that there were more female 
respondents (75.3%, 58/77) than males, and that the majority (94.8%, 73/77) of 
respondents were South African citizens. 
Presented in Table 4.7 is the distribution of respondents’ professional categories 




























Table 4.7: Distribution of professional categories and qualifications/training experiences 
Variable Category Frequency % 
Professional category Registered Nurse 51 66.2 
 Clinical Technologist 21 27.3 
 Enrolled Nurse 5 6.5 
 Total 77 100 
Qualification PGDNN 7 9.1 
 Dip CC 8 10.4 
 Dip Nephro CT 11 14.3 
 
B Tech Nephro 
CT 8 10.4 
 OJT 32 41.6 
 PGDNN + Dip CC 2 2.6 
 Dip CC + OJT 6 7.8 
 
Dip Nephro CT + B Tech 
Nephro CT  1 1.3 
 
Dip Nephro CT + 
OJT 1 1.3 
 
PGDNN + Dip CC 
+ OJT 1 1.3 
  Total 77 100 
PGDNN = Postgraduate Diploma in Nephrology Nursing; Dip CC = Diploma in Critical Care; Dip Nephro CT = Diploma 
in Nephrology Clinical Technology; B Tech Nephro CT= Bachelor Technical Degree in Nephrology Clinical Technology; 
OJT = on the job training. 
 
Figure 4.3: Distribution of professional category 
Data in Table 4.7 and Figure 4.3 show that of the 77 respondents, Registered 
Nurses accounted for 66.2% (n=51). Most respondents (41.6%, 32/77) indicated 
that they had received on-the-job training. 







































Years of Experience  0-5 41 53.2 
 6-10 10 13.0 
 11-15 10 13.0 
 16-20 5 6.5 
 21-25 3 3.9 
 26-30 6 7.8 
 31-35 1 1.3 
 36-40 1 1.3 
  Total 77 100 
 
Figure 4.4: Distribution of years of experience 
Respondents’ years of experience were grouped into 5-year intervals. Data in 
Table 4.8 and Figure 4.4 indicate that most respondents (53.2%, 41/77) had 0–5 
years of experience. 
The numbers of participants who had/had not (yes/no) received orientation by a 
mentor are presented in Table 4.9. 




Orientation by mentor Yes 54 71.1 
 No 22 28.9 
 Subtotal 76 100 
 Missing 1 1.3 





Data in Table 4.9 indicate that the majority of respondents (71.1%, 54/76) reported 
that they had received orientation by a mentor, whereas 28.9% (22/76) had 
received no orientation. 
Presented in Table 4.10 and Figure 4.5 are the distributions of respondents’ self-
reported duration of orientation (days, weeks, months, and not applicable).  
Table 4.10: Distribution of duration of orientation 
Variable Category Frequency % 
Duration of orientation Orientation in progress 1 1.3 
 Days 1 1.3 
 Weeks 25 32.5 
 Months 30 39 
 N/A 20 26 
  Total 77 100 
N/A = not applicable because no orientation received. 
 
Figure 4.5: Duration of orientation 
Data in Table 4.10 and Figure 4.5 indicate that 25/77 (32.5%) of renal unit 
practitioners received weeks of orientation, while 38.9% (30/77) had received 
months of orientation. Only one respondent was currently on orientation during the 
period of study. 
The number of participants who had and who had not (yes/no) received in-service 






Table 4.11: Distribution of in-service education on UFH pharmacology 
Variable Category Frequency %* 
In-service education on UFH Yes 29 37.7 
 No 47 61.0 
 Subtotal 76 98.7 
 Missing 1 1.3 
  Total 77 100 
*Calculation out of 77. 
 
 
Figure 4.6: Frequency of in-service education on UFH 
Data in Table 4.11 and Figure 4.6 indicate that 61.0% (47/77) of respondents 
reported that they did not receive in-service education on UFH pharmacology, 
while 29/77 (37.7%) stated they did receive in-service education on UFH 
pharmacology while working in haemodialysis centres. Only one respondent (1/77, 
1.3%) did not respond whether he/she did /did not receive in-service education on 
UFH pharmacology. 
In summary, data in Table 4.5 show that there were more missing data for the age 
variable (3/77, 3.9%) than for citizenship, orientation and in-service education, 
which each had one set (1.3%) of missing data. The data in Table 4.7 show that 
Registered Nurses (10/51, 19.6%) and Clinical Technologists (9/21, 42.8%) had 





Thereafter, inferential statistical analyses showed the association between 
variables in relation to respondents’ demographic and professional characteristics. 
4.3.1.2 Inferential statistical analysis: respondents’ demographic characteristics 
and professional category 
To assess for normal distribution of the data for the variables age and years of 
experience (continuous data) the Shapiro-Wilk test of normality (Table 4.12) was 
performed. The data for age in Table 4.12 were normally distributed (p=0.3) but 
not so for years of experience (p<0.001) which was lower than the reporting alpha 
of 0.05. The mean and standard deviations were calculated for age (M=41.1, 
SD±10.8).  
Table 4.12: Test of normality for age and years of experience 
Variables 
Shapiro-Wilk 
Statistic df p-value 
Age 0.978 65 0.312 
Years of experience  0.837 65 <0.001 
df = degrees of freedom. 
Inferential statistical analysis of data in Table 4.13 shows the association between 
variables relating to respondents’ demographic characteristics (age, gender, 






















Age (years)  
21-25 1 (2.0) 5 (23.8) 0 (0.0) 
41.1 10.8 0.002 
26-30 4 (7.8) 5 (23.8) 0 (0.0) 
31-35 4 (7.8) 6 (28.6) 1 (20.0) 
36-40 6 (11.8) 2 (9.5) 0 (0.0) 
41-45 7 (13.7) 2 (9.5) 1 (20.0) 
46-50 12 (23.5) 0 (0.0) 3 (60.0) 
51-55 9 (17.6) 1 (4.8) 0 (0.0) 
56-60 3 (5.9) 0 (0.0) 0 (0.0) 
61-65 2 (3.9) 0 (0.0) 0 (0.0) 
  Missing  3 (6.0)  0 (0.0) 0 (0.0)       
  Total  51 (100.0) 21 (100.0) 5 (100.0)       
Gender  
M 6 (11.8) 13 (61.9) 0 (0.0)   
<0.001 
F 45 (88.2) 8 (38.1) 5 (100.0)   
  Total 51 (100.0) 21 (100.0) 5 (100.0)       
Citizen  
SA 48 (94.1) 20 (95.2) 5 (100.0) 
  1.000 
Other 2 (3.9) 1 (4.8) 0 (0.0) 
  Missing 1 (2.0) 0 (0.0) 0 (0.0)       
  Total 51 (100.0) 21 (100.0) 5 (100.0)       
Qualification 




Dip in CC 8 (15.7) 0 (0.0) 0 (0.0) 
Dip in Nephro CT 0 (0.0) 11 (52.4) 0 (0.0) 
B Tech Nephro CT 0 (0.0) 8 (38.1) 0 (0.0) 
0JT 27 (52.9) 0 (0.0) 5 (100.0) 
PGDNN+Dip CC 2 (3.9) 0 (0.0)  0 (0.0) 
Dip CC+OJT 6 (11.8) 0 (0.0)  0 (0.0) 
Dip Nephro CT+B 
Tech Nephro CT 0 (0.0) 1 (4.8)  0 (0.0) 
Dip Nephro 
CT+OJT 0 (0.0) 1 (4.8)  0 (0.0) 
PGDNN+Dip 
CC+OJT 1 (2.0) 0 (0.0)  0 (0.0) 
  Total 51 (100.0) 21 (100.0) 5 (100.0)       
Experience  
(years) 
0-5 29 (56.9) 10 (47.6) 2 (40.0) 
9.4 9.3 0.140 
6-10 4 (7.8) 4 (19.0) 2 (40.0) 
11-15 5 (9.8)  4 (19.0) 1 (20.0) 
16-20 5 (9.8) 0 (0.0) 0 (0.0) 
21-25 1 (2.0) 2 (9.5) 0 (0.0) 
26-30 6 (11.8) 0 (0.0) 0 (0.0) 
31-35 0 (0.0) 1 (4.8) 0 (0.0) 
36-40 1 (2.0) 0 (0.0) 0 (0.0) 
 Total 51 (100.0) 21 (100.0) 5 (100.0)    
Orientation 
by mentor  
Yes 35 (68.6) 17 (81.0) 2 (40.0) 
  0.300 
No 16 (31.4) 4 (19.0) 2 (40.0) 
  Missing 0 (0.0) 0 (0.0) 1 (20.0)    
  Total 51 (100.0) 21 (100.0) 5 (100.0)    
Duration of 
orientation  On orientation 1 (2.0) 0 (0.0) 0 (0.0) 
    
0.073 
 Days 0 (0.0) 1 (4.8) 0 (0.0) 
  
 Weeks 14 (27.5) 6 (28.6) 5 (100.0) 
 Months 22 (43.1) 8 (38.1) 0 (0.0) 
 Not applicable 14 (27.5) 6 (28.6) 0 (0.0) 
  Total 51 (100.0) 21 (100.0) 5 (100.0)       
In-service of 
UFH  
Yes 13 (25.5) 11 (52.4) 5 (100.0) 
     <0.001 
No 37 (72.5) 10 (47.6) 0 (0.0) 
  Missing 1 (2.0) 0 (0.0) 0 (0.0)       
  Total 51(100.0) 21 (100.0) 5 (100.0)       





Dip Nephro CT = Diploma in Nephrology Clinical Technology; BTech Nephro CT= Bachelor Technical Degree in Nephrology Clinical Technology; OJT 
= on the job training; M = male; F = female; UFH = unfractionated heparin 
Data in Table 4.13 indicate that the mean age of the respondents was 41.1 years. 
Registered Nurses were the oldest, that is >60 years (2/48, 4.2%) (mean age 44.9 
years by one-way ANOVA with 3 missing data, Appendix 12A), and the Clinical 
Technologists were the youngest, that is <25 years of age (5/21, 23.8%) (mean 
age 31.4 years, Appendix 12A). The mean age was 44.4 years for ENs (Appendix 
12A). There was a statistically significant association (p=0.002, SD±10.8) between 
the variable professional category and age. A Scheffe post hoc test (Appendix 
12A) showed that the difference in age between RNs and CTs reached statistical 
significance (p<0.001, 95% CI 7.56-19.41) and between ENs and CTs (p=0.02, 
95% CI 1.70-24.24) but not between RNs and ENs. 
Most of the Registered Nurses (88.2%, 45/51) were female, while most of the 
Clinical Technologists (61.9%, 13/21) were male. The association between gender 
and professional category reached statistical significance (p<0.001). 
The majority (52.9%, 27/51) of the Registered Nurses reported that they received 
on-the-job training, whereas all of the Enrolled Nurses (100%, 5/5) were on-the-job 
trainees. Ten of the 51 (19.6%) Registered Nurses had a Postgraduate Diploma in 
Nephrology Nursing qualification, while 42.8% (9/21) of the Clinical Technologists 
had a Bachelor Technical degree in Nephrology Clinical Technology. There was a 
statistically significant association (p<0.001) between the variable professional 
category and qualifications. 
The majority of the Registered Nurses (56.9%, 29/51) and Clinical Technologists 
(47.6%, 10/21) had <5 years’ experience in haemodialysis. The respondents’ 
mean years of experience was 9.4 (SD±9.3). There was no statistically significant 
association (p=0.140) between the variable professional category and years of 
experience. 
Of the 51 Registered Nurses, 31.4% (16/51) reported that they had not received 
orientation by a mentor and 27.5% (14/51) reported that the duration of orientation 





reported that they had not received orientation by a mentor and 28.6% (6/21) 
reported that the duration of orientation did not apply to them. Of the five Enrolled 
Nurses, 20.0% (1/5) did not respond to the question of orientation by a mentor. 
The same number (40%, 2/4) of Enrolled Nurses had/had not received orientation 
by a mentor. The duration of the orientation period for the Enrolled Nurses 
(100.0%, 5/5) was a matter of weeks. There was no statistically significant 
association between the variables orientation by mentor (p=0.300), duration of 
orientation (p=0.073) and professional category. 
The majority of Registered Nurses (74.0%, 37/50) reported that they had not 
received in-service education on UFH, while the majority (52.4%, 11/21) of the 
Clinical Technologists reported that they had received such in-service education. 
There was a statistically significant association (p=0.001) between the variable 
professional categories and the in-service education on UFH that they had/had not 
received. 
4.4 Respondents’ self-reported knowledge of UFH  
The first primary objective of the study (1.7.1.1) was to describe the respondents’ 
self-reported knowledge (Appendix 7) of the use and effects of UFH (Table 4.14). 
Section C (Q010–022 of the questionnaire) (Appendix 1) addresses these 
aspects. The correct responses according to literature review are in bold. Table 







Table 4.14: Respondents’ self-reported knowledge results by professional category 
Questions Responses 
Professional category (n=77) 




EN (n=5)  
No. % 
Q010. Query bleeding 
tendencies before UFH is 
administered. 













Q011. UFH breaks down 
blood clots? 
Yes 25 (49.0) 4 (19.0) 1 (20.0) 













Q012. Effects of 
administering UFH with low 
aPTT. 
 
Bleeding 22 (43.1) 11 (52.4) 3 (60.0) 





















Q013. Blood pressure 
 reading of 240/140 mmHg. 
Administer UFH or not. 
Yes 5 (9.8) 1 (4.8) 1 (20.0) 













Q014. UFH not administered 
following platelet count.  
420-450 x 109/1 4 (7.8) 0 (0.0) 0 (0.0) 
50-80 x 109/1 41 (80.4) 15 (71.4) 4 (80.0) 












Q015. Method to arrest 
bleeding post-haemodialysis 
session to counteract effects 
of UFH.  
PS 1 mg/ 100 IU 
UFH 
23 (45.1) 5(23.8) 1 (20.0) 
PS 2 mg/1000 IU 
UFH 
10 (19.6) 8 (38.1) 3 (60.0) 













Q016. Reason UFH not 
administered orally. 
Effectiveness 4 (7.8) 0 (0.0) 0 (0.0) 
Effects 23 (45.1) 9 (42.9) 2 (40.0) 
Pharmacokinetics 9 (17.6) 1 (4.8) 0 (0.0) 
Destroyed by 
stomach acids 


















Questions Responses Professional category (n=77) 






Q017. Importance of having 
the patient's baseline urea 
values before administering 
the first dose of UFH. 
Bleeding risk 31 (60.8) 12 (57.1) 1 (20.0) 
Increased urea 
levels 
1 (2.0) 0 (0.0) 1 (20.0) 
Risk of 
complications 
4 (7.8) 3 (14.3) 0 (0.0) 
Unsure 4 (7.8) 1 (4.8) 0 (0.0) 













Q018. Route of 
administration of UFH. 
Intravenously 37 (72.5) 11 (52.3) 2 (40.0) 
Via dialysis 
machine 













Q019. Type of UFH used. Porcine 20 (39.2) 7 (33.3) 1 (20.0) 
Bovine 10 (19.6) 6 (28.6) 0 (0.0) 










 0 (0.0) 
2 (40.0) 
5 (100.0) 
Q020. UFH temperature 
storage.  
Patient temp 1 (2.0) 0 (0.0) 0 (0.0) 
<25 degrees C 32 (62.7) 18 (85.7) 2 (40.0) 













Q021. Effect UFH has on 
potassium level. 
Hyperkalemia 22 (43.1) 8 (38.1) 2 (40.0) 
Nil 9 (17.6) 1 (4.8) 2 (40.0) 

























Q022. A patient needs to 
receive 2 000 IU in stock 
20 000 IU of UFH. Calculate 
the dose of UFH. 
10 ml 32 (62.7) 15 (71.4) 0 (0.0) 
2000 IU 0 (0.0) 2 (9.5) 0 (0.00 
10 ml-100 IU 0 (0.0) 1 (4.8) 0 (0.0) 
01-5 ml 5 (9.8) 0 (0.0) 0 (0.0) 
10-100 5 (9.8) 0 (0.0) 1 (20.0) 
1000 IU 3 (5.9) 0 (0.0) 0 (0.0) 













Note to table: 
aPTT = activated partial thromboplastin time; C = Celsius; CT = Clinical Technologist; EN = Enrolled Nurse; IU = 
International Unit; PS = Protamine Sulphate; RN = Registered Nurse. 






The data in Table 4.14 indicate that 97.4% (75/77) of respondents correctly 
reported querying bleeding tendencies before administering UFH (Q010). One 
Clinical Technologist (1.3%, 1/77) opted not to respond. The question: does UFH 
break down blood clots (Q011) had an overall response rate of 98.7% (76/77). 
Collectively 57.1% (44/77) of respondents correctly reported “no” while 38.9% 
(30/77) incorrectly reported “yes”; only 2.5% (2/77) reported they were “unsure”. 
Q012 item (effects of administering UFH with a low aPTT) yielded a 94.8% (73/77) 
response rate. Only 31.1% (24/77) of respondents correctly selected the option of 
“bleeding and unscheduled hospitalisation” while most 46.7% (36/77) opted for 
“bleeding”, and 16.8% (13/77) selected “no ill-effects” will be experienced. 
Altogether, 5.2% (4/77) of respondents chose not to respond. 
Q013 of whether to administer or not administer UFH to a patient with a blood 
pressure reading of 240/140 mmHg had an overall response rate of 96.1% 
(74/77). The majority of respondents 80.5% (62/77) correctly selected “no” as a 
response to not giving UFH in this instance, while 3.9% (3/77) of respondents did 
not respond. 
The question: at which platelet count is UFH not administered (Q014) had a 
response rate of 92.2% (71/77). Overall 77.9% (60/77) of respondents accurately 
selected they would not give UFH if the patient’s platelet count was 50-80 x 109/1, 
with 7.8% (6/77) of respondents not answering this question.  
For Q015, method of arresting bleeding post-haemodialysis session to counteract 
effects of UFH, 37.6% (29/77) of respondents correctly chose protamine sulphate 
1 mg per 100 IU of UFH as the dose to arrest bleeding. A small minority (2.6%, 
2/77) did not respond to this question. 
For Q016, an open response question about reasons that UFH is not administered 
orally, with answers grouped according to themes, 23.3% (18/77) of respondents 






Q017 (importance of having the patient's baseline urea values before 
administering the first dose of UFH) had a correct response rate of 57.1% (44/77). 
This item yielded a large, 22% (17/77) non-response rate.  
All responses to Q018 regarding administration of UFH via intravenous route or 
via the haemodialysis machine or bolus dose are in line with the expected 
response. In total 98.7% (76/77) selected one or the other response and only one 
(1.3%) respondent did not respond.  
For Q019 regarding the type of UFH used in their dialysis centres, 36.3% 
(n=28/77) of respondents correctly reported the type of heparin which their unit 
used, with 9.0% (7/77) failing to respond. 
Q020 was an open question that asked at which temperature UFH was stored. 
This received multiple responses, which are grouped according to themes. Of 
these grouped themes, 67.5% (52/77) of responses were acceptable, while 10.4% 
(8/77) opted not to respond.  
For another open-ended question, Q021 on the effects of UFH on potassium level, 
themes were used to group the responses. Overall, two responses were 
acceptable, that is “aldosterone inhibits the secretion of potassium resulting in 
hyperkalemia” and “hyperkalemia”. These options were chosen by 48.1% (37/77) 
of respondents; however, 19.5% (15/77) did not respond to this question. 
Finally, for Q022 that required calculation of the dose of UFH there was an 89.6% 
(69/77) response rate, with 61.0% (47/77) correctly calculating the dose while 






4.4.1 Association between selected independent variables and knowledge 
The sub-objective (1.7.3.1) of the study was to determine whether there is an 
association between selected independent variables and knowledge concerning 
the use and effects of UFH. Section C (Q010–022 of the questionnaire) (Appendix 
1) addresses these aspects. Table 4.3 and Appendix 10 guided the scoring of the 
respondents’ responses to the knowledge questions to determine whether they 
had acceptable or unacceptable knowledge. 
Cross-tabulations (Appendix 12B) were used to determine the association 
between the preselected independent variables and knowledge. Due to its 
reliability, the Fisher’s exact chi-squared test was chosen as the reporting 
measurement of the p-value and results are presented in Table 4.15. However, 
subsequently, a Spearman’s rho test was conducted for the variables years’ of 
experience and knowledge to determine the correlation between the two variables 






Table 4.15: Association between selected independent variables and knowledge  










RN (n=51) 42 (72.4) 9 (47.4) 
0.011 
 
CT (n=21) 15(25.9) 6 (31.6) 
EN (n=5) 1 (1.7) 4 (21.1) 
Experience in years n=77* 
0-5 (n=41) 32 (55.2) 9 (47.4)  
0.604 6-40 (n=36) 26 (44.8) 10 (52.7) 









Days (n=1) 1 (1.7) 0 (0.0) 
Weeks (n=25) 20 (34.5) 5 (26.3) 
Months (n=30) 22 (37.9) 8 (42.1) 
Not Applicable 
(n=20) 
15 (25.9) 5 (26.3) 
In-service education of UFH  
n=76 
Yes (n=29) 19 (32.8) 10 (55.6) 
0.101 
No (n=47) 39 (67.2) 8 (44.4) 
CT = Clinical Technologist; EN = Enrolled Nurse; RN = Registered Nurse; UFH= Unfractionated Heparin 
*Adjustment of years of experience by knowledge both as continuous variables gave a Spearman’s rho correlation of 
0.571. 
 
Data in Table 4.15 show that overall, 75.3% (58/77) of respondents had an 
acceptable level of knowledge regarding UFH while 24.6% (19/77) had poor 
knowledge. Within the three categories of respondents, most 82.3% (42/51) of the 
registered nurses had an acceptable level of knowledge. The majority 80.0% (4/5) 
of the enrolled nurses, although a small cohort, had a poor level of knowledge. 
There was a statistically significant association (p=0.011) between the variable 
professional category and self-reported knowledge of UFH.  
The majority of respondents 41.5% (32/77) who had an acceptable level of 
knowledge of UFH had 0-5 years of experience. Ten of the 77 respondents 
(12.9%) who had 11-35 years of experience displayed poor knowledge of UFH. 
There was no statistically significant association between level of knowledge and 
the variables: years of experience (p=0.604), duration of orientation (p=0.549) and 
in-service education (p=0.101). For in-service education on UFH 1.3% (1/77) of 





4.5 Description of self-reported attitude regarding UFH  
The second primary objective of the study (1.7.1.2) was to describe the 
respondents’ self-reported attitudes (Appendix 8) regarding the use and effects of 
UFH (Table 4.16). Section D (Q023–026 of the questionnaire) (Appendix 1) 
addressed these aspects. Interpretation of attitudes is subjective so, to increase 
objectivity, interpretation of participants’ responses was guided by the reviewed 
literature and personal experience of the researcher. Acceptable responses are 



















Least concern 0 (0.0) 1 (4.8) 0 (0.0) 
Concern 3 (5.9) 2 (9.5) 1 (20.0) 
Neutral 15 (29.4) 5 (23.8) 1 (20.0) 














education of UFH is 
important. 
Neutral 0 (0.0) 1 (4.8) 0 (0.0) 













Q024b. Feel comfortable 
administering UFH 
prepared by others. 
SD 29 (56.9) 6 (28.6) 3 (60.0) 
MD 4 (7.8) 2 (9.5) 0 (0.0) 
N 4 (7.8) 10 (47.6) 0 (0.0) 













Q024c. The reporting 
UFH adverse effect is 
punishable. 
SD 31 (60.8) 6 (28.6) 2 (40.0) 
MD 6 (11.8) 8 (38.1) 0 (0.0) 
N 6 (11.8) 6 (28.6) 1 (20.0) 













Q024d. UFH adverse 
effects are reported in 
my dialysis centre. 
SD 2 (3.9) 0 (0.0) 0 (0.0) 
MD 1 (2.0) 4 (19.0) 1 (20.0) 
N 7 (13.7) 5 (23.8) 1 (20.0) 













Q024e. Patients are 
monitored closely for 
UFH adverse effects. 
SD 2 (3.9) 0 (0.0) 0 (0.0) 
MD 2 (3.9) 1 (4.8) 1 (20.0) 
N 6 (11.8) 8 (38.1) 0 (0.0) 













Q024f. Seeking advice 
for UFH dose 
preparation is ridiculed 
by colleagues. 
SD 24 (47.0) 8 (38.1) 2 (40.0) 
MD 2 (3.9) 6 (28.6) 0 (0.0) 
N 4 (7.8) 5 (23.8) 2 (40.0) 


























Q025. Patients are 
informed regarding UFH 
potential adverse effects. 
Always 11 (21.6) 2 (9.5) 4 (80.0) 













Q026. Patients are 
informed how to manage 
UFH adverse effects. 
Always 19 (37.3) 3 (14.3) 4 (80.0) 














CT = Clinical Technologist; EN = Enrolled Nurse; MA = moderately agree; MD = moderately disagree; 
N = neutral; RN = registered nurse; SA = strongly agree; SD = strongly disagree. 
Data in Table 4.16 regarding the adverse effects patients may experience from the 
administered UFH (Q023) indicate that overall, 25.9% (20/77) reported “great 
concern” regarding patients experiencing adverse effects from the administered 
UFH, while 24.6% (9/77) were moderately concerned and 27.2% (21/77) chose to 
remain neutral. There was a 13% (10/77) non-response rate for the question. 
For Q024a there was 84.4% (65/77) agreement by respondents that in-service 
education on UFH should be provided before accepting responsibility for 
administering the medication to patients. Of all the respondents, 5.9% (3/51) of 
Registered Nurses did not respond to the question. 
There was a 49.3% (38/77) response to indicate that respondents “did not feel 
comfortable administering the drug prepared by others” (Q024b), with a minority of 
Registered Nurses (7.8%; 4/51) not answering this question. 
Half of the respondents (50.6%, 39/77) felt that “reporting of adverse effects will 
not result in punishment” (Q024c), while 3.8% (3/77) felt that “reporting of adverse 
effects of UFH will result in punishment”. Overall 5.19% (4/71) of respondents did 
not answer this question. 
Thirty-four of 77 respondents (44.1%) reported that “adverse effects are reported 






Of the 77 respondents, 34 (44.1%) reported that they strongly agreed that patients 
are monitored for the side-effects of UFH (Q024e), while 3 out of 51 (5.9%) 
Registered Nurses did not respond to the question. 
Most respondents (44.1%, 34/77) strongly disagreed that seeking advice from 
colleagues regarding their uncertainty in dose preparation would be treated with 
ridicule, whereas 18.18% (14/77) strongly agreed that this was the case (Q024f). 
Five of the 51 Registered Nurses (9.5%) refrained from responding to this 
question. 
Most respondents (62.3%, 48/77) reported that they “sometimes” informed 
patients of the potential adverse effects of UFH (Q025); however, 6.5% (5/77) of 
respondents did not participate in the question. 
Forty of the 77 respondents (51.9%) reported that they “sometimes” informed 
patients about how to manage the adverse effects of UFH (Q026). Three of the 51 
Registered Nurses (5.9%) declined to give their opinion. 
In summary, data show that respondents’ lack of knowledge concerning the use 
and administration of UFH is reflected in their attitude to its use and 
administration. Interpretation of participants’ responses, guided by the reviewed 
literature and personal experience of the researcher revealed that RNs displayed 
an acceptable attitude (≥ 50% of respondents) for 5/9 (55.6%) of the questions. 







4.5.1 Association between selected independent variables and attitude  
The sub-objective (1.7.3.2) of the study was to determine whether there was an 
association between selected independent variables and attitude concerning the 
use and effects of UFH (Appendix 1; Section D, Q023–026). Cross-tabulations 
were used to determine the association between the preselected independent 
variables and attitude. Due to its reliability the Fisher’s exact chi-squared test was 
chosen as the reporting measurement of the p-value and results are presented in 
Table 4.17. However, subsequently, a Spearman’s rho test was conducted for the 
variables years’ of experience and attitude to determine the correlation between 
the two variables and the result confirms that the correlation was not statistically 
significant. 












RN (n=51) 38 (69.1) 13 (59.1) 
0.637 CT (n=21) 14 (25.5) 7 (31.8) 
EN (n=5) 3 (5.5) 2 (9.1) 
Experience in years* 
n=77 
0-5 (n=41) 27 (49.1) 14 (63.6) 0.315 
6-40 (n=36) 28 (50.9) 8 (36.4) 




0 (0.0) 1 (4.5) 
0.119 
Days (n=1) 0 (0.0) 1 (4.5) 
Weeks (n=25) 17 (30.9) 8 (36.4) 
Months (n=30) 21 (38.2) 9 (40.9) 
Not 
Applicable(n=20)  
17 (30.9) 3 (13.6) 
In-service education on 
UFH 
n=76 
Yes (n=29) 20 (37.0) 9 (40.9) 
0.798 
No (n=47) 34 (63.0) 13 (59.1) 
CT = Clinical Technologist; EN = Enrolled Nurse; RN = Registered Nurse; UFH=Unfractionated Heparin 
*Adjustment of years of experience by attitude, both as continuous variables gave a Spearman’s rho  






Data in Table 4.17 show that most Registered Nurses (74.5%; 38/51) and Clinical 
Technologists (66.6%; 14/21) had a positive attitude concerning the use and 
effects of UFH. Among the small cohort of enrolled nurses (60.0%; 3/5), there was 
a positive attitude towards the use and effects of UFH. There was no statistically 
significant association between professional category and attitude (p=0.637). 
Overall, renal unit practitioners with 0–5 years of experience (65.9%; 27/41) 
presented the most positive attitude towards the use and effects of UFH. A 
minority of respondents, 10.3% (8/77) with 6–30 years of experience, had 
negative attitudes toward the use and effects of UFH. Twenty-eight of the 77 
respondents (36.3%) who had 6–40 years of experience had a positive attitude 
towards the use and effects of UFH. The association between years of experience 
and attitude towards UFH did not reach statistical significance (p=0.315). 
Seventy-one per cent (55/77) of the respondents showed a positive attitude 
towards the use and effects of UFH during their duration of orientation but the 
association was not statistically significant (p=0.119). Although 72.3% (n=34/47) of 
respondents did not receive in-service education for UFH, results reveal that they 
had a positive attitude concerning the use and effects of UFH. The association 
between in-service education for UFH and attitude was not statistically significant 
(p=0.798).  
The results of the Fisher’s exact chi-squared test revealed that there were no 
significant association between the selected variables and attitude.  
4.6 Description of self-reported practice regarding UFH 
The third primary objective of the study (1.7.1.3) was to describe the respondents’ 
self-reported practice (Appendix 9) with regard to the use and effects of UFH. 
Section E, Q027–035 of the questionnaire (Appendix 1), addresses these aspects. 
Data in Table 4.18 display the results for the different professional categories of 
respondents (N=77) for each question. The reviewed literature and the 





practice results. The words in bold in each question item indicate the appropriate 
responses. 












Q027 How often is the UFH 
dose administered as 
prescribed by the 
Nephrologists? 
Always 30 (58.8) 14 (66.7) 5 (100.0) 
Usually 13 (25.5) 4 (19.0) 0 (0.0) 













Q028 How often is a new 
dialysis patient’s laboratory 
coagulation results checked 
prior to the administration of 
the first dose of UFH? 
Always 11 (21.6) 2 (9.5) 2 (40.0) 
Usually 7 (13.7) 6 (28.6) 0 (0.0) 













Q029 How often is a current 
dialysis patients’ laboratory 
coagulation results 
checked? 
Monthly 6 (11.8) 4 (19.0) 1 (20.0) 
Quarterly 12 (23.5) 7 (33.3) 1 (20.0) 
Annually 2 (3.9) 1 (4.8) 0 (0.0) 













Q030 When did you last 
refer to published literature 
on UFH?  
Days 5 (9.8) 1 (4.8) 0 (0.0) 
Weeks 5 (9.8) 2 (9.5) 0 (0.0) 
Months 18 (35.3) 11 (52.4) 2 (40.0) 













Q031 When I am concerned 
about the prescribed dose 





1 (2.0) 0 (0.0) 0 (0.0) 

















Q032 If I adjust the UFH 






























Q033 How long ago did you 
witness an adverse effect of 
UFH? 
Days 5 (9.8) 2 (9.5) 1 (20.0) 
Weeks 8 (15.7) 3 (14.3) 0 (0.0) 
Months 17 (33.3) 8 (38.1) 1 (20.0) 













Q034 In order of 
preference, indicate which 
of the following you will 
consult for information 
about UFH or other 
medication used in your 
adult chronic haemodialysis 
unit.  
Doctor 23 (45.1) 9 (42.9) 3 (60.0) 
Formulary 
book 
11 (21.6) 2 (9.5) 0 (0.0) 













Q035a I ask patients about 
bleeding tendencies prior to 
administering UFH dose. 
Never 3 (5.9) 1 (4.8) 0 (0.0) 
Usually 3 (5.9) 3 (14.3) 0 (0.0) 













Q035b I monitor patients 
for anaphylactic shock. 
Never 4 (7.8) 2 (9.5) 0 (0.0) 
Usually 5 (9.8) 4 (19.0) 0 (0.0) 













Q035c I verify allergies with 
patients prior to 
administering UFH. 
Never 7 (13.7) 6 (28.6) 0 (0.0) 
Usually 3 (5.9) 1 (4.8) 0 (0.0) 













Q035d I confirm the UFH 
dose with another qualified 
renal unit practitioner 
before I administer it. 
Never 1 (2.0) 1 (4.8) 0 (0.0) 
Usually 9 (17.6) 2 (9.5) 0 (0.0) 













Q035e I document adverse 
effects of UFH. 
Never 2 (3.9) 0 (0.0) 0 (0.0) 
Usually 5 (9.8) 3 (14.3) 0 (0.0) 





























Q035f I inform the Unit 
Manager of patient adverse 
effects to UFH. 
Never 1 (2.0) 0 (0.0) 0 (0.0) 
Usually 3 (5.9) 1 (4.8) 0 (0.0) 














Note to table: UM = Unit Manager. 
*Q032 linked to Q031. 
 
The data in Table 4.18 show the frequency of prescribed UFH (Q027) as: 65.3% 
(49/75) of respondents indicated that they always give a dose of UFH as 
prescribed by the Nephrologists. Most of the positive responses were from the 
Registered Nurses (61.2%, 30/49) and Enrolled Nurses 100.0% (5/5). A small 
cohort of respondents (12.0%, 9/75) selected undesirable responses such as 
“never” and “usually”. Of the Registered Nurses 3.9% (2/51) declined to respond 
to the question. 
Regarding the checking of new patients’ laboratory coagulation studies (Q028), 
only 19.2% (14/73) of respondents reported that they “always” checked them prior 
to administering the first dose of UFH, while 79.4% (58/73) stated that they 
“usually”, “sometimes” or “never” check a new patient’s laboratory coagulation 
results prior to administering the first dose of UFH. Of respondents, 5.2% (4/77) 
did not respond to the question. 
There were different practices noted on how often a current patient’s laboratory 
coagulation result was checked (Q029). Overall 35.6% (26/73) of the respondents 
selected “other”, while 17.8% (13/73) selected “never”. Of the registered nurses, 
25.5% (12/47) selected “quarterly”, while 33% (7/21) of Clinical Technologists 
selected this option as the time-period for checking a patient’s coagulation studies. 
Of Registered Nurses, 7.8% (4/51) did not respond to the question. 
Results for respondents’ most recent reference to the published literature on UFH 
(Q030) revealed that 10.6% (n=8/75) of respondents never referred to published 





doing so “years ago”. Most Clinical Technologists (52.4%, 11/21) claimed having 
done so in the “past months”. Only 2.6% (2/77) of the respondents did not respond 
to the question. 
If concerned about the prescribed dose of UFH (Q031) 54.1% (39/72) of the 
respondents would contact the prescribing doctor. Of the respondents, 58.3% 
(28/48) were Registered Nurses. Thirty-five per cent (25/72) of respondents said 
they would inform the Unit Manager if concerned regarding the patient’s 
prescribed dose of UFH, and 9.7% (7/72) said they would self-adjust the dose of 
UFH. 
Responses to Question 032 were linked to option 4 of Q031 about respondents’ 
practice of adjusting the dose of UFH. Of the 9.8% (7/72) of respondents who 
chose option 4 in Q031, 85.7% (6/7) reported that they would document the 
adjusted dose they had administered on the patient’s records. 
The time when respondents last witnessed an adverse event relating to UFH 
(Q033) varied: 8/73 (10.9%) selected “days”, 17.8% (13/73) of respondents 
selected “years”, and 20.5% (15/73) selected “never”. No statistically significant 
difference was noted (p=0.890). There were 5.2% (4/77) of respondents, who did 
not respond to this question. 
Information-seeking behaviour on UFH (Q034) revealed that most respondents 
48.6% (35/72) selected “Doctors” as their point of reference for information on 
UFH and other medication, with only 18.0% (n=13/72) selecting the formulary 
book as their first point of reference. Of the respondents, 6.5% (5/77) did not 
respond to the question. 
Responses for verification of bleeding tendencies before administering UFH 
(Q035a) showed that most respondents (42.1%, 32/76) reported “always” asking 
patients about bleeding tendencies before administering UFH, while 44.8% 
(34/76) reported that they “sometimes” ask, and 7.9% (6/76) that they “usually” 





In terms of monitoring patients for anaphylactic shock (Q035b), 59.2% (45/76) of 
respondents confirmed that they “always” monitor patients for anaphylactic shock 
post-administration of UFH, while 7.89% (6/76) of respondents “never” do so. Two 
per cent (1/51) of the Registered Nurses did not respond to the question. 
On verifying allergies with patients prior to administering UFH (Q035c), 50.0% 
(38/76) of respondents reported that they “always” do so, and most of the 
Registered Nurses (56.0%, 28/50) confirmed that they did so. However, 17.1% 
(13/76) of the respondents revealed that they do not check allergies with patients 
prior to administering UFH. Only 1.3% (1/77) of respondents did not respond to 
the question. 
Regarding confirming the dose of UFH with another qualified practitioner (Q035d), 
43 of 76 (56.5%) respondents reported that they “always” confirm the UFH dose 
with another qualified practitioner before administering it. Among the Enrolled 
Nurses, there was a 100% (5/5) response to always checking the dose with 
another qualified practitioner. Only 2.6% (2/76) of renal unit practitioners report 
that they “never” check the UFH dose with another person. One Registered Nurse 
refrained from answering the question. 
Most respondents (82.1%, 60/73) reported that they document adverse effects of 
UFH (Q035e). Four of the 77 (5.2%) respondents did not participate. 
Sixty of the 73 (82.1%) respondents reported that they “always” inform the Unit 
Manager of patients experiencing adverse effects to UFH (Q035f). Four of the 77 
(5.2%) respondents did not answer the question. 
4.6.1 Association between selected independent variables and practice  
The last sub-objective (1.7.3.3) of the study was to determine whether there was 
an association between selected variables and practice concerning the use and 
effects of UFH. Section E (Appendix 1, Q027–035 of the questionnaire) addresses 
these aspects. Cross-tabulations were used to determine the association between 
the preselected independent variables and practice. Due to its reliability, the 





p-value and results are presented in Table 4.19. However, subsequently, a 
Spearman’s rho test was conducted for the variables years’ of experience and 
practice to determine the correlation between the two variables and the result 
confirms that the correlation was statistically significant. 
Table 4.19: Association between selected independent variables and practice  
  Practice Fisher’s 








RN (n=51) 38 (65.5) 13 (68.4) 
0.517 
 CT (n=21) 15 (25.9) 6 (31.6) 
EN (n=5) 5 (8.6) 0 (0.0) 
Experience in years n=77* 
0-5 (n=41) 26 (44.8) 15 (78.9)  
0.016 
 
6-40 (n=36) 32 (55.2) 4 (21.1) 
Duration of orientation 
n=77 





Days (n=1) 1 (1.7) 0 (0.0) 
Weeks (n=25) 19 (32.8) 6 (31.6) 
Months (n=30) 23 (39.7) 7 (36.8) 
Not applicable (n=20) 15 (25.9) 5 (26.3) 
In-service education of UFH 
n=76 
Yes (n=29) 26 (45.6) 3 (15.8) 0.028 
No (n=47) 31 (54.4) 16 (84.2) 
CT = Clinical Technologist; EN = Enrolled Nurse; RN = Registered Nurse; UFH = Unfractionated Heparin. 
*Adjustment of years of experience by practice, both as continuous variables gave a Spearman’s rho  
correlation of 0.009. 
 
 
Across the different professional categories of renal unit practitioners, the results 
reveal that most had acceptable practice competency regarding UFH. The 
association between the independent variable professional category and the 
dependent variable practice was not statistically significant (p=0.517). 
Of the respondents with 0–5 years’ experience, 63.4% (26/41) had acceptable 
practice competency and 36.5% (15/41) unacceptable practice competency. 
Therefore, in terms of years of experience, an acceptable practice competency 
was evident amongst most of the respondents. The association between years of 





(p=0.016), therefore further analysis was done using a logistical regression model 
test. 
Across the range of duration of orientation, there was good practice even from the 
respondents (15/20, 75.0%), who reported having received no orientation. There 
was no statistically significant association (p=0.601) between duration of 
orientation variable and self-reported practice of UFH. 
The results of the Fisher’s exact chi-squared test revealed that the association 
between in-service education and practice reached statistical significance 
(p=0.028) and this was further analysed using the logistic regression model test.  
4.7 Bivariate analysis: variables associated with knowledge and 
practice 
Since there was no statistically significant association between respondents’ 
attitude regarding the use and effects of UFH and the four pre-selected variables2, 
no further analysis was performed on the dependent variable attitude.  
Bivariate logistic regression analysis was performed on the dependent variable 
knowledge for strength of association between this variable and one pre-selected 
variable, that is professional category, and for statistical significance before 
making further judgements about the null hypothesis. Data in Table 4.15 (Section 
4.4.1) showed that only the variable professional category (p=0.011) was 
significantly associated with poor knowledge. The outcome of that analysis 
determined the exact degree of the relationship between these variables. 
Data in Table 4.20 reflect the results of the bivariate logistic regression analysis 
(Appendix 12C) of the relationship between professional category and poor 
knowledge scores. To test the professional category of registered nurses against 
the other categories of renal unit practitioners, the registered nurses data was 
used a reference in the first line of Table 4.20. 
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Table 4.20: Relationship between the variable professional category and poor knowledge  
Factors B SE 
Wald 
Chi-
square df P value OR 
95% CI for EXP (B) 
Lower Upper 
Professional category 
(reference)   6.509 2 0.039    
Clinical Technologist 0.624 0.607 1.058 1 0.304 1.867 0.568 6.132 
Enrolled Nurse 2.927 1.177 6.185 1 0.013 18.667 1.859 187.406 
Constant -1.540 0.367 17.588 1 <0.001 0.214   
Factors are compared with the Registered Nurse category. 
B = coefficient for the constant; SE = Standard error around the coefficient for the constant; df = degrees of freedom for 
the Wald chi-square test; EXP (B) = Exponentiation of the B coefficient which is an OR – strength of the relationship. 
Data in Table 4.20 show that the odds of the Enrolled Nurses having poor 
knowledge regarding UFH compared to the Registered Nurses were 18.7 times 
higher at a 95% CI (1.9-187.4), and this difference reached statistical significance 
(p=0.013). The odds of the Clinical Technologists having poorer knowledge than 
the Registered Nurses were 1.9 times higher, at a 95% CI (0.6-6.1), but this 
difference did not reach statistical significance (p=0.304). 
Bivariate logistic regression analysis was performed on the dependent variable 
practice for strength of association between this variable and two pre-selected 
variables, that is years of experience and in-service education (yes/no), and for 
statistical significance before making further judgements about the null 
hypotheses. Data in Table 4.19 (Section 4.6.1) showed that years of experience 
influenced poor practice, and this difference reached statistical significance 
(p=0.016). Data in Table 4.21 reflect the results of analysis of the exact degree of 






Table 4.21: Relationship between years of experience and poor practice 
Factor B SE 
Wald 
Chi-
square df P value OR 
95% CI for Exp 
(B) 
Lower Upper 
0 to 5 years of 
experience 
1.529 0.622 6.054 1 0.014 4.615 1.365 15.607 
Constant -2.079 0.530 15.374 1 <0.000 0.125   
Factors compared with six to forty years of experience. 
B = coefficient for the constant; SE = Standard error around the coefficient for the constant; df = degrees of freedom for 
the Wald chi-square test; EXP (B) = Exponentiation of the B coefficient which is an OR – strength of the relationship. 
Data in Table 4.21 showed that the respondents who had five years and less 
experience were 4.6 times more likely to deliver poor practice at a 95% CI (1.4–
15.6) than respondents who had more than six years of experience, and this 
difference reached statistical significance (p=0.014). 
Data in Table 4.19 (Section 4.6.1) showed that those who did not receive in-
service education on the pharmacology of UFH had poor practice, and this 
difference reached statistical significance (p=0.028). Data in Table 4.22 reflect the 
results of analysis of the exact degree of the relationship between the variable in-
service education on the pharmacology of UFH and poor practice. 
Table 4.22: Relationship between in-service education and poor practice 
Factor B SE 
Wald 
Chi-
square df P value OR 
95% CI for Exp 
(B) 
Lower Upper 
No In-service 1.466 0.682 4.619 1 0.032 4.333 1.138 16.505 
Constant -2.159 0.610 12.543 1 <0.001 0.115   
Factors compared with response ’Yes ’to having received in-service education. 
B = coefficient for the constant; SE = Standard error around the coefficient for the constant; df = degrees of freedom for 
the Wald chi-square test; EXP (B) = Exponentiation of the B coefficient which is an OR – strength of the relationship. 
Data in Table 4.22 showed that the respondents who had no in-service education 
on the pharmacology of UFH were 4.3 times more likely to deliver poor practice at 
a 95% CI (1.1–16.5) than respondents who did receive in-service education on the 






The outcome of the logistic regression test confirms rejection of the null 
hypotheses, that the variables professional category, years of experience and in-
service education (on the pharmacology of UFH) do not influence renal unit 
practitioners’ KAP. However, the variable duration of orientation does not affect 
the renal unit practitioners’ KAP therefore the null hypothesis is accepted for this 
variable. 
4.8 STROBE checklist 
To ensure clarity in the reporting of the results, the 2007 STROBE guidelines 
(Vandenbroucke et al., 2007) were used to ensure that every important aspect of 
a cross-sectional study was attended to. Table 5.1 in the discussion chapter which 
follows displays the procedure followed to complete the study. 
4.9 Summary 
This chapter delivered a detailed report of the results of the study according to the 
research questions, aims, objectives and the null hypothesis. To conclude this 
section the STROBE checklist was mentioned as a point of reference to ensure 
that the different aspects of a cross-sectional design study were followed and are 






CHAPTER 5: DISCUSSION, LIMITATIONS, IMPLICATIONS, 
RECOMMENDATIONS AND CONCLUSION 
5.1 Introduction 
Chronic haemodialysis treatment is the most common renal replacement therapy 
for patients diagnosed with Stage 5 adult End Stage Kidney Failure (ESKF). The 
main purpose of chronic haemodialysis therapy is to restore the body's 
homeostasis, during which 200-250 mls/minute of the patient‘s blood volume is 
extracorporeal and heparinised to prevent clotting. The patient is at risk of 
bleeding if the administered individualised dose of unfractionated heparin is not 
appropriate. 
The primary purpose of the study was to describe renal unit practitioners’ 
knowledge, attitude and practice (KAP) regarding the use of unfractionated 
heparin in selected adult chronic haemodialysis centres in the Cape Town 
Metropole. The secondary aim was to determine whether there is an association 
between selected variables (category of renal unit practitioner, years of 
experience, duration of orientation to the adult chronic haemodialysis unit and in-
service education on the pharmacology of unfractionated heparin) and the KAP of 
renal unit practitioners. The aims of the study were achieved by objectives.  
5.2 Study findings in relation to published studies 
5.2.1 Renal unit practitioners’ personal and professional demographic 
characteristics 
Findings relate to secondary objective 1.7.2 (respondents’ demographic and 
professional profiles and differences between the groups). Using Erik Erikson’s 
1959 theory of the eight stages of psychosocial development (McLeod, 2008:1), it 
is possible to classify the respondents in the present study into stages six (the 
young adult group aged 18 to 40 years) and seven (the middle adulthood group 
aged 40 [41] to 65 years). Erikson’s theory suggests that individuals experience 
various psychological crises at different ages and their needs may conflict with 





employed at the research sites were in stage seven, the middle adulthood age 
group of 40-65 years. A potential psychological disadvantage for this age group is 
that if their needs are unfulfilled, they may experience ‘stagnation and feel 
unproductive’ (McLeod, 2008:4). 
Five of the 15 ENs in the research sites participated in the study, comprising the 
smallest category of renal unit practitioners to do so. The overall scope of practice 
of ENs in South Africa is limited and they are not allowed to practice independently 
only under the direct or indirect guidance of the Registered Nurse (SANC, 
Regulation No. 2598 of 1984, as amended). This has implications for the 
usefulness of employing ENs in the haemodialysis services and the most suitable 
number of ENs needed. Legislative constraints for scope of practice hinders 
specialist training of the EN. The South African Nursing Council has no additional 
accredited postgraduate training programme available for them, besides the 
bridging programme of (SANC, Regulation No. 683 of 1989, as amended) which 
does lead to a qualification as a General Nurse or Psychiatric Nurse. 
The majority of participants (70.1%, 54/77) reported that a mentor orientated them 
when they commenced working in the haemodialysis centre. It is good practice 
(Community Tool Box, 2013:2) in haemodialysis centres to ensure that new staffs 
are assigned to a mentor for orientation before they are assigned to care for a 
patient. Although respondents reported that the orientation training had been 
conducted over months this did not include in-service education on unfractionated 
heparin, a high alert medication, for 61.0% (47/77) of respondents.  
5.2.2 Renal unit practitioners’ self-reported knowledge 
Findings relate to primary objective 1.7.1.1 (knowledge of UFH). Renal unit 
practitioners lacked knowledge regarding UFH and thought that unfractionated 
heparin breaks down blood clots (39.0%, 30/77). Research reports that UFH 
prevents clots forming, but does not break down formed clots (Fischer, 2007:178; 
Lankshear, Harden & Simms, 2010:49) as UFH is not a fibrinolytic agent. Another 
important study finding is that 59.7% (46/77) of respondents did not know the 





Published literature reports that the correct dose to neutralise 100IU of UFH is 
1mg of protamine sulphate (European Best Practice Guidelines Expert Group on 
Haemodialysis, 2002:65; Baglin et al., 2006:28; Lankshear et al., 2010:51; Lemon 
& Crannage, 2011:212). The majority of renal unit practitioners (65.0%, 50/77) did 
not know the reason for not administering UFH orally, which is that it is poorly 
absorbed (Hirsch et al., 1998:409S). 
More than half of the respondents were not aware of the type of unfractionated 
heparin used in their dialysis centres. The UFH information pamphlet retrieved 
from the seven dialysis research sites confirmed that the UFH in use in these 
settings is a porcine (pork) derivative (Appendix 12). This finding is of concern 
because if patients are allergic to pork it is uncertain whether the allergic reaction 
will be associated with the administered UFH. Additionally, it is not known whether 
patients who do not eat pork for religious reasons are informed that they are 
receiving UFH which is a porcine derivative. According to Shen and Winkelmayer 
(2012:475), “porcine heparin carries a greater risk of anaphylaxis”. Respondents’ 
inability to calculate correct dosages of unfractionated heparin was surprising and 
of deep concern because this can have life-threatening consequences for 
patients. Ashby (1997:90) and Barkhouse-Mackeen and Murphy (2013:91) 
reported that nurses could not correctly calculate medication dosages and that 
their calculation knowledge was limited. Bayne and Bindler (1988:261), Polifroni, 
McNulty and Allchin (2003:458) and Wright (2007a:279) also reported concerns 
about medication errors resulting from poor calculation skills. 
In summary, the appeal from International Health Organisations (NPSA, 2006; 
ISMP, 2008; Institute for HealthCare Improvement, 2008; Agency for Healthcare 
Research and Quality, n.d.) and Suranyi and Chow (2010:386) that nurses [renal 
unit practitioners] must regularly review and update their knowledge regarding 
unfractionated heparin cannot be over emphasised. This includes teaching renal 





5.2.3 Renal unit practitioners’ attitude to UFH administration 
Findings relate to primary objective 1.7.1.2 (attitude regarding the use and effects 
of UFH). Renal unit practitioners’ lack of knowledge regarding the use and 
administration UFH was reflected in their responses in the attitude section of the 
questionnaire. Extrapolation of meaning that poor knowledge translates to having 
a poor attitude has to be interpreted with caution. Nevertheless, for question 023 
only 20/77 respondents were greatly concerned about patients experiencing side-
effects of UFH, and this implies a casual attitude regarding such a high alert 
medication. Furthermore, less than half of the respondents, (38/77, 49.4%) did not 
feel comfortable administering UFH that had been prepared by others and this is 
supported in the published literature (Chevalier et al., 2011:344).  
The respondents combined response rates of 71.4% (55/77) for choosing 
“sometimes” and “never” to inform patients of the potential adverse effects of UFH 
is disconcerting. It is the haemodialysis patients’ right to always be informed of 
benefits and potential adverse effects of medication prescribed and administered 
to them (National Institute for Health and Clinical Excellence, 2009:4). Of equal 
concern, 48/77 (62.3%) respondents reported that they “sometimes” or “never” 
informed patients how to manage UFH adverse effects.  
5.2.4 Renal unit practitioners’ practice 
Findings relate to primary objective 1.7.1.3 (practice regarding UFH). Study 
findings suggest that currently, in the seven research sites, haemodialysis patients 
do not have a set schedule for having their coagulation studies checked. Pittard 
(2001:75) and Winkler et al. (2007:499) support the need for strict laboratory 
monitoring of coagulation studies of patients, to establish a therapeutic dose to 
prevent under-or over-anticoagulation. Respondents did not consider prolonged 
bleeding or clotting of patients’ blood circuits (Pittard, 2001:74) to be adverse 
effects of UFH which may account for them not having recently witnessed an 
adverse event. Respondents had not kept up to date with literature specifically on 
UFH, a concern echoed by Ndosi and Newel (2008:570) and Raja et al. (2009:17) 





5.3 Application of Benner’s conceptual framework  
Findings relate to sub-objective 1.7.3 (association between selected variables and 
KAP). An interpretation of how the renal unit practitioners’ years of experience 
may be associated with the different stages of Benner’s model follows. The 
findings of the study reveal that the majority of the Enrolled Nurses had a poor 
knowledge level of UFH. If renal unit practitioners are not knowledgeable about 
the medication they administer to patients, they can negatively affect patient 
safety. Benner reported that it is the responsibility of the nurse to monitor the 
safety and therapeutic responses to administered medication and that it can have 
a life and death implication (Benner, 1984:127). Nevertheless, other variables 
such as years of experience, duration of orientation and in-service education on 
the pharmacology were not significantly associated with self-reported knowledge 
level. However, for self-reported practice variable, years of experience and in-
service education on the pharmacology of UFH does seem to affect the renal unit 
practitioners’ clinical practice. The results suggest that renal practitioners with five 
years and less experience have a statistically significance chance of having poorer 
practice skills than those with greater than six years of renal unit experience. 
Those renal unit practitioners who had in-service education on the pharmacology 
of UFH had better clinical practice application as compared to those with no in-
service education for UFH. 
5.3.1 Novice practitioner 
Eight of the 77 (10.4%) renal unit practitioners were considered to be a neophyte 
in the new discipline, since they had less than one year of experience. Benner 
(1984:22) suggested that this level of practitioner lacks sound expertise. It was 
therefore assumed that renal unit practitioners with less than two years of practice 
are at the level of novice or advanced beginner. When classifying a novice 
practitioner Benner did not stipulate time lines. Benner, Tanner and Chesla 
(1996:37) suggested that a new student entering nursing is a novice. However, 
analysing the overall outcome of knowledge scores for all respondents for what is 





experience, duration of orientation and in-service education (on pharmacology for 
unfractionated heparin). This finding is perplexing, implying that these variables do 
not make a difference to knowledge. Of the novices, the odds were greater that 
RNs would have more knowledge than CTs or ENs. 
5.3.2 Advanced beginner 
Benner’s (1996:48) study looked at the practices of new graduates with less than 
six months as practicing at the level of an advanced beginner. In haemodialysis 
practice, an assumption is that a renal unit practitioner practicing at an advance 
beginner level can possibly safely oversee the treatment plan of uncomplicated 
haemodialysis patients unaided. The researcher presumes that, as ten of the 77 
(12.9%) renal unit practitioners had 1-2 years of experience (Appendix 6), 
Benner’s definition of an advanced beginner may be applicable to them. Amongst 
the ten respondents, ENs and CTs with 1-2 years of experience had not received 
in-service education on the pharmacology of UFH and had a greater risk of poor 
knowledge compared to the Registered Nurses. 
5.3.3 Competent practitioner 
Benner (1984:25) estimates a competent practitioner as having 2-3 years of 
experience in the same job. However, a practitioner can progress to a competent 
level after one to two years of practice, depending upon the specialty area, but 
some complex patient assignments will occur after a certain time has elapsed 
(Benner, 2004:193). In the haemodialysis centre, there is a strong likelihood that 
the above can occur if there is a shortage of skilled specialty staff. The staffs 
assessed to be quick learners are fast-tracked in their clinical experiential learning, 
and accept greater patient care responsibility. Eleven of 77 (14.3%) renal unit 
practitioners had 3-4 years of experience and were considered to be practicing at 
the level of competent practitioner according to Benner (1984:25). 
5.3.4 Proficient and expert practitioner 
The two stages were collapsed for the purpose of this study Within the 





confident to argue for and against the patient’s prescribed treatment and defends 
his/her rationale for adjusting the renal care that the patient needs. The Unit 
Manager (with years of experience) of the haemodialysis centre or the shift leader 
are supposedly the experts and will be the decision makers for care of the renal 
patient in the absence of the Nephrologists. 
Although 45/77 (58.4%) renal unit practitioners had between 4-40 years of 
experience it is difficult to presume that they were proficient or expert without 
further exploration of the data which was beyond the scope of the study. Benner 
(1984:31) acknowledges that after 3-5 years of experience with a similar patient 
population it could be assumed that a practitioner is proficient but she suggests 
that the time is an estimate and needs further exploration.  
From a practice perspective, data from the present study suggest that the odds of 
delivering poor practice having ≤ five years of experience and no in-service 
education on the pharmacology of UFH were 4.6 times higher at a 95% CI (1.4–
15.6) than for renal unit practitioners who had ≥ six years of experience (the 
difference reaching statistical significance p=0.014) and 4.3 times higher (CI 1.1–
16.5) than for respondents who did receive in-service education (the difference 
reaching statistical significance p=0.032) respectively. Benner (2004:198) reported 
that not all nurses will achieve expert status because of the challenges they 
experience. Because the renal unit practitioners’ data were not analysed in-depth 
for application to Benner’s construct, it will be incorrect to presume that 
respondents were experts. 
To summarise, the results of the KAP study for renal unit practitioners’ years of 
experience do not fully support Benner’s grouping of the years of experience from 
novice to expert as the novices seem to be knowledgeable, regarding UFH and 
one reason is perhaps they had a structured orientation programme that included 
an in-service education on UFH pharmacology. However, from a practice 
perspective it does seem as if years of experience and in-service education on the 





and therefore may support the different stages of Benner’s model for practice, but 
needs further exploration. 
5.4 Strengths and limitations of the study in relation to published 
studies 
5.4.1 Limitations of the study methods 
Limiting the search strategy to published studies on renal unit practitioners’ KAP 
regarding the use and effects of UFH limited the scope of the literature review. 
Had the search strategy included studies related to KAP among health 
practitioners and thromboprophylaxis more broadly, more studies would have 
been located. The services of a librarian should have been sought early in the 
study to source more published literature pertinent to this study. Not using the 
same search terms for all databases may have introduced bias and limited access 
to relevant literature. 
A descriptive cross-sectional design using a self-administered questionnaire, was 
adopted for this KAP study, to address the research questions since descriptive 
research presents the picture of the “why “and “how” of people behaviour or 
situation (Fouche & DeVos, 2011:96) as it occurs naturally (Polit & Beck, 
2004:192). However, in hindsight structured individual interviews may have 
resulted in less missing data (total missing data = 169/3388 (5.0%) than a self-
administered questionnaire. Missing data should have been addressed in the 
section on validity of the test instrument and interpretation of the data. 
A negative characteristic of a KAP study is that the respondents may give socially 
desirable answers and this could have an influence on the outcome of the study 
(Aubert et al., 1998:1143). However, as the self-administered questionnaire 
ensured respondents’ anonymity, responses were honest. 
The attitude section of the questionnaire was the most difficult to develop as this is 
a subjective component. In this study attitude was measured directly using Likert 
scales. Questions to elicit attitude were based on respondents’ knowledge and 





responses. A limitation was that once the questionnaire design was completed, a 
statistician should have been consulted to check the internal consistency of 
construction of questions before the experts validated the questionnaire. However, 
for this study a post hoc internal consistency of the questionnaire was performed, 
but not included in dissertation. 
There are ten other dialysis centres in the Cape Town Metropole, that could have 
been included in this study, but because they are private dialysis centres, 
permission to have access to their renal unit practitioners was difficult to obtain. 
This resulted in only seven dialysis centres in the Cape Town Metropole being 
involved in the study, therefore findings cannot be generalised to other dialysis 
centres. The protocol for obtaining approval for performing research at public 
sector Tertiary Hospitals has stringent measures in place and this delayed the 
planned early execution of the study. 
The study did not achieve the estimated sample size of 82 (1.0% margin of error, 
95% CI) instead of which 77/82 (93.9%) respondents participated and this has 
implications for informing the implementation of the results 
Three expert reviewers reported the questionnaire as having content and face 
validity, but they stated that the construction of some of the questions needed 
amendment, and these were attended to. There were problems with the pilot study 
sample size (n=3 of an estimated 82, 4%) for testing the instrument reliability, as it 
fell short of an estimated pilot sample size of 10% (8/82; n=12) as recommended 
by Lackey and Wingate (1998:380). Therefore, the results will have to be 
interpreted with caution. Despite the small pilot sample size, the results of the 
Pearson’s r and Cronbach’s alpha suggest that the test instrument is stable, 
reliable and reproducible. However, the reliability testing of the instrument may 
have been strengthened had Intra-class Correlation coefficient, Cohen’s kappa or 
Fleiss kappa test been performed as well as construct validity of the instrument. 
Data for years of experience were not equally distributed, therefore the median for 





Professional category as an independent variable should not have been included 
as a measure against dependent variables KAP because of the unequal 
distribution of the different professional categories. This may have affected the 
statistical power of the different results. Therefore the overall interpretation of 
results wherever professional category was tested, will have to be interpreted with 
caution. In hindsight, perhaps the term dialysis personnel without differentiating 
between the categories of professionals should have been used as an 
independent variable. Alternatively, the ENs could have been excluded as they do 
not have a specialist nephrology qualification. 
Another shortcoming of the self-administered questionnaire was including both 
open- and closed questions. In retrospect, the questionnaire design should have 
consisted only of closed questions to better quantify the responses. The open-
ended questions allowed broad responses that required grouping into themes with 
the risk of error of interpretation. A further shortcoming was question 006, which 
required the respondents to state their experience in months or years which some 
failed to do. Inaccuracies resulted which may have influenced the test of normality 
result as the degree of freedom count for age and years of experience (df = 65 
and not 77) was reduced. There ought to have been better construction of 
question 031 so that question 032 was not linked to it. Retrospectively, the 
incomplete questionnaires should have been discarded instead of including them 
in the data analysis phase. 
The study would have been strengthened if a minimum acceptable knowledge 
score had been set such as a more clinical criterion based on patient safety and 
what practitioners should know, benchmarked at the 75% quartile level. 
The analysis of the data for application of Benner’s model was superficial as it was 
not a research objective. 
5.4.2 Strengths and evaluation of the study  
This study was evaluated using the STROBE checklist (Table 5.1) to ensure that 





Table 5.1: STROBE Statement—Checklist of items that should be included in reports of cross-
sectional studies  
 Item  
No 
Recommendation Application to 
study 
Relevant sections 
Title and abstract 1 (a) Indicate the study’s design with a commonly 
used term in the title or the abstract 
Title page 
(b) Provide in the abstract an informative and 




Background/rationale 2 Explain the scientific background and rationale for 














Setting 5 Describe the setting, locations, and relevant dates, 
including periods of recruitment, exposure, follow-




Participants 6 Give the eligibility criteria, and the sources and 
methods of selection of participants 
3.3 
Variables 7 Clearly define all outcomes, exposures, predictors, 
potential confounders, and effect modifiers. Give 
diagnostic criteria, if applicable 
1.6 
Data sources/ measurement 8* For each variable of interest, give sources of data 
and details of methods of assessment 
(measurement). Describe comparability of 




Bias 9 Describe any efforts to address potential sources of 
bias 
3.3.5 
Study size 10 Explain how the study size was arrived at 3.3.3 
Quantitative variables 11 Explain how quantitative variables were handled in 
the analyses. If applicable, describe which 
groupings were chosen and why 
3.5.2 
Statistical methods 12 (a) Describe all statistical methods, including those 
used to control for confounding 
3.5.2 
(b) Describe any methods used to examine 
subgroups and interactions 
3.5.2 
  (c) Explain how missing data were addressed 3.5.2 
(d) If applicable, describe analytical methods taking 




  (e) Describe any sensitivity analyses 3.5.2 
Table 3.9 
Results  
Participants 13* (a) Report numbers of individuals at each stage of 
study—eg; numbers potentially eligible, examined 
for eligibility, confirmed eligible, included in the 
study, completing follow-up, and analysed 
4.2. 
(b) Give reasons for non-participation at each stage 4.2.1 
(c) Consider use of a flow diagram not applicable 
Descriptive data 14* (a) Give characteristics of study participants (eg 
demographic, clinical, social) and information on 
exposures and potential confounders 
4.3 
Tables 4.5; 4.11 
Figures 4.1; 4.6 
(b) Indicate number of participants with missing 






 Item  
No 
Recommendation Application to 
study 
Relevant sections 





Main results 16 (a) Give unadjusted estimates and, if applicable, 
confounder-adjusted estimates and their precision 
(eg, 95% confidence interval). Make clear which 




Tables 4.14; 4.16; 
4.18 
(b) Report category boundaries when continuous 
variables were categorized 
Not applicable 
Main results continued  (c) If relevant, consider translating estimates of 
relative risk into absolute risk for a meaningful time 
period 
Not done 
Other analyses 17 Report other analyses done—eg analyses of 






Tables 4.12; 4.13; 
4.15; 4.17; 4.19 
Tables 4.20; 4.21; 
4.22 
Discussion  
Key results 18 Summarise key results with reference to study 
objectives 
5.2.1-5.2.4 
Limitations 19 Discuss limitations of the study, taking into account 
sources of potential bias or imprecision. Discuss 
both direction and magnitude of any potential bias 
5.4 
Interpretation 20 Give a cautious overall interpretation of results 
considering objectives, limitations, multiplicity of 
analyses, results from similar studies, and other 
relevant evidence 
5.2; 5.3 
Generalisability 21 Discuss the generalisability (external validity) of the 
study results 
5.5; 5.6 ;5.7 
 
Other information  
Funding 22 Give the source of funding and the role of the 
funders for the present study and, if applicable, for 
the original study on which the present article is 
based 
Page 111 
5.5 Implications of the study findings 
The study findings have implications for nephrology practice, clinical management 
teams, education and research. 
Study findings confirm that the limited statutory scope of practice of ENs (SANC, 
Regulation No. 2598 of 1984 as amended) was reflected in their poor knowledge 
of UFH and this has implications for their placement in haemodialysis units. In 
South Africa, there is no opportunity for Enrolled Nurses to pursue specialist 
training. The only career pathway for them is the South African Nursing Council 
bridging training programme (SANC, Regulation No. 683 of 1989, as amended) to 





Study findings show that safety measures with regard to the use and 
administration of UFH may not have been optimum and this includes 
haemodialysis patients not having a set schedule for having their coagulation 
studies checked to assess their risk profile for bleeding or clotting. There was little 
evidence that respondents kept up to date with literature concerning UFH. Data 
suggest that haemodialysis patients may not know how to manage the adverse 
effects of UFH that they may potentially experience. 
If, in terms of Erikson’s theory, most respondents (who are in the middle adulthood 
group) feel that their needs are unfulfilled, they may experience stagnation and 
feelings of unproductiveness (McLeod, 2008:3). This has implications for further 
research. 
5.6 Recommendations 
Recommendations are based on the findings of this study and are applicable to 
nephrology practice, clinical management teams, patient teaching and educational 
curricula and for research in nephrology practice.  
5.6.1 Recommendations for clinical management teams 
If the patients’ clinical management team is functioning optimally, renal unit 
practitioners’ KAP should improve. For the management team to function 
optimally, it is recommended that the questionnaire (Appendix 1) relating to all 
aspects of UFH should be administered to new and existing renal unit practitioners 
(RNs, CTs and ENs) to assess their KAP and to monitor their progress. To prevent 
medical litigation, management teams should be proactive, ensuring there is a 
well-co-ordinated and active in-service education programme that includes 
aspects such as pharmacology, pharmacokinetics, pharmacodynamics, 
medication calculation and pharmaco-therapeutics. Teaching should be problem-
based and applicable to the clinical area of haemodialysis. Staff should be made 
aware of increasing patient’s mortality risk that can result in medico-legal liabilities 
and increase financial claims and losses against them as individuals and their 





patients and families exposure to avoidable physical and psychosocial trauma. 
Such an education approach to practice should be aimed at improving evidence-
based renal practice. Management team of renal units and renal unit practitioners 
should enrol for programmes such as the webinar by ISMP (2013:1) “Improving 
Medication Safety through Staff Education and Competency Assessment: An 
Important Challenge for Healthcare Organizations” to encourage staff to improve 
aspects related to patient safety. 
Management teams should establish pharmacovigilance units to encourage 
reporting of incidents without repercussions and provide guidelines on what and 
how to report pharmacovigilance. Staff who report incidents should be given 
constructive feedback without blaming. Managers should adopt a culture of non-
punitive reporting of adverse effects no matter how negligible, such as bleeding for 
15-20 minutes post dialysis including a patient bleeding at home on non-dialysis 
days, emergency visits to hospital for bleeding episodes and post surgical 
procedure bleeding. To measure patients’ activated partial thromboplastin time at 
the bedside staff should be provided with a calibrated point of care testing 
apparatus instead of waiting for the laboratory to send the results.  
This information will make a valuable contribution to the database to evaluate the 
overall effects of unfractionated heparin experienced by patients and contribute 
new knowledge on the dangers of UFH. Competitions can be organised for staff to 
design educational poster and pamphlets for patients, alerting them on the 
benefits and potential dangers of UFH, thus empowering patients and 
encouraging their participation in the standard of care delivered. 
Study findings should assist renal unit practitioners to critically review their current 
practice regarding unfractionated heparin and to adopt safe practice measures. 
Renal unit practitioners’ have the right to reduce their exposure to medical 
litigation but they have the obligation to deliver good quality renal care. Newly 
appointed staff should have the right to refuse to administer unfractionated 
heparin if they feel that they need in-service education on UFH before taking 





UFH prepared by others they should be allowed to refuse to administer the UFH 
without repercussions. 
It is important for the clinical management team to include the pharmacokinetics of 
UFH and simulated or problem-based patient management scenarios in the 
orientation programme. Before new staff administers UFH to a patient, their 
competency level should be evaluated before and after the orientation. If renal unit 
practitioners do not pass the predetermined set score, remedial intervention 
should be part of the in-service education programme. It is also recommended that 
staff competency tests should be conducted annually. If staff fair poorly, retraining 
and retesting should be offered to eliminate poor quality practice. 
5.6.2 Recommendations for education 
Pre- and post-registration nursing education programmes should emphasise 
medication calculation, pharmacokinetics, pharmacotherapeutics and 
pharmacodynamic aspects of UFH. Nurses in pre- and post-registration 
programmes should prove competence in delivering safe quality practice. Life-long 
learning should be instilled, particularly with regard to updates in medications as 
these change frequently. Students should be taught how to navigate formulary 
books and how to do literature searches to enhance their medication knowledge. 
5.6.3 Unanswered questions and recommendation for future Research 
A question needing further exploration is why UFH in-service education did not 
occur during the orientation period for the respondents in this study. A possible 
explanation is that maybe it was a system error as the Unit Managers’ may have 
assumed that since the staff are RNs, CTs and ENs they must have previously 
received in-service education on the pharmacology of unfractionated heparin. 
Therefore, during the orientation period there was no interrogation of the staff 
members’ knowledge of UFH. 
In relation to checking a new patient’s laboratory coagulation results prior to 
administering unfractionated heparin a minority, 15/77 (19.5%) suggest they 





patient may have a bleeding disorder when they administer unfractionated heparin 
to the patient for the first time? 
There was an assumption that most would have selected “always” for the 
questions relating to how often do you inform patients of the potential adverse 
effects of UFH (17/77; 13.0%) and how to manage adverse effects of UFH (26/77; 
33.8%), leaving the researcher speculating why do the respondents not always 
inform patients of the potential adverse effects of UFH and how to manage the 
adverse effects. 
Thirty-one out of 77 (40.3%) respondents reported “months” as last referencing 
literature for UFH, while 29.9% (23/77) said it has being years since they last 
reference literature on UFH and eight out of 77 (10.4%) said “never”. This triggers 
a question, how do the respondents’ keep up to date with new development on 
UFH? 
From this study, other aspects that are researchable, as not covered in-depth in 
this study are: 
 What characteristics determine if a renal unit practitioner is an expert in the 
haemodialysis speciality? 
 What is the best evidence-base approach to improve renal unit 
practitioners’ safe medication calculation? 
 Does a renal unit practitioner‘s years of experience in the speciality 
negatively influences critical thinking about the clinical practice area? 
 Improving renal patient safety: Open communication between renal unit 
practitioners and patients regarding different aspects of renal care. 
 What factors influence more females to work in haemodialysis? 
 What factors contribute to poor mathematical abilities of practitioners? 
 Should qualified renal unit practitioners’ that is, the Registered Nurse with a 





adjust haemodialysis patients medication and treatment, in the absence of 
the prescribing doctor? 
Nephrology is an evolving speciality. Current literature states 1:8 persons will 
develop Chronic Kidney disease; therefore, it does not seem as if the patient 
numbers will decrease especially with an increase in burden of diseases such as 
Human Immunodeficiency Virus, Diabetes Mellitus Type II and Hypertension. 
Therefore, the need to conduct more research and the setting of appropriate 
standards of care practices. 
This study can be amended and extended to other renal unit practitioners in South 
Africa and globally. The evidence those studies will achieve, will support or reject 
a concern regarding renal unit practitioners KAP on the pharmacological aspects 
of UFH. This will enlighten the Nephrology practitioner population and bring new 
evidence to support the adoption of new perspectives for practice that are 
introduce and implemented in the speciality. 
Applying Benner’s complete model including the seven domains in a replicated 
future study may assist renal unit practitioners in developing best practice 
guidelines. 
5.7 CONCLUSION 
The primary study objectives were reached by describing in-depth the 
respondents’ self-reported knowledge, attitude and practice concerning the use 
and effects of UFH. The secondary objective was reached by describing 
respondents’ demographic and professional profiles and determining differences 
between professional nurses, clinical technologists and enrolled nurses. Sub-
objectives were achieved by determining the association between professional 
categories, years of experience, duration of orientation to the adult chronic 
haemodialysis unit and in-service education on the pharmacology of UFH on KAP 
of renal unit practitioners with regard to the use and effects of UFH. 
The study showed that renal unit practitioners have inadequate knowledge of the 





safety. Benners’ model (novice to expert) was not helpful to interpret the data as 
the novices had knowledge of UFH, possibly attributed to an in-service education 
on UFH pharmacology, but this study data support Benner’s model (novice to 
expert) that professional category influences knowledge. Additionally, that years 
of experience of renal unit practitioners influences their use and effects of UFH in 
clinical practice and that having no in-service on the pharmacology of UFH 
influences clinical practice. 
Taking the limitations of this study into consideration, if adapted for testing in other 
haemodialysis centres, some of the unanswered questions related to the KAP of 
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APPENDIX 1: Questionnaire 
Participant Code No.:__ 
 
QUESTIONNAIRE 
A DESCRIPTIVE SURVEY OF RENAL UNIT PRACTITIONERS' KNOWLEDGE, 
ATTITUDE AND PRACTICE RELATIVE TO THE USE AND EFFECTS OF 
UNFRACTIONATED HEPARIN IN SELECTED ADULT CHRONIC HAEMODIALYSIS 
CENTRES IN THE CAPE TOWN METROPOLE 
RESEARCHER’S DETAILS      SUPERVISOR’S DETAILS: 
Student: Master of Science in Nursing     Dr U. Kyriacos 
Mrs Debra Ockhuis             UNIVERSITY OF CAPE TOWN 
UNIVERSITY OF CAPE TOWN             Division of Nursing & Midwifery 
Division of Nursing and Midwifery         TEL: 021- 4066410 
TEL: 021-4066173 
 
HUMAN RESEARCH ETHICS COMMITTEE DETAILS: 
Faculty of Health Sciences 
Human Research Ethics Committee 
Room E52-24 Groote Schuur Hospital Old Main Building 
OBSERVATORY 
7925 
TEL: 021-406 6626 
Thank you for agreeing to participate in this study. The questionnaire is in English. My 
details are provided above if you require clarity on any questions. I have an obligation to 
protect your privacy and anonymity even if you contact me. You may also contact my 
supervisor or the Human Research Ethics Committee. This is not a test and if you do not 
know the answers to all the questions, it does not matter. 
INSTRUCTIONS 
Please follow the instructions above each question section heading and use a pen to 
complete the questionnaire. 
If you make mistakes, you may use correction ink (tippex). If you feel you would like to 
complete a new questionnaire, kindly contact XXX who will provide you with one. 
The deadline date for completion is the 19th April 2013. Kindly place the completed 





SECTION A: PERSONAL INFORMATION 





DO NOT  
WRITE IN  
THIS 
BLOCK 
001 How old are you? [Age in years] 
 
  
 Choose one response for each item by placing X in the relevant 
box 
  




003 Are you a South African citizen? 
[01] Yes 
[02] No 
[03] If no, state your country of origin and how long you are 
working in South Africa. 
__________________________________________________ 
  
SECTION B: PROFESSIONAL PROFILE 
NO. PROFESSIONAL INFORMATION   
Choose the appropriate response by placing X in relevant box 
 
004 What is your Professional Category? 
[01] Registered Nurse 
[02] Clinical Technologist (Nephrology) 








005 Tick one or more box to indicate which of the following 
qualifications/ training experiences apply to you? 
 
[01] Post graduate Diploma in Nephrology Nursing (1 year) 
[02] Renal Certificate (6 months) 
[03] Diploma in Critical Care (1 year) 
[04] Critical Care Certificate (6 months) 
[05] Diploma in Nephrology Clinical Technology (3 years) 
[06] Bachelor Technical Degree in Nephrology Clinical Technology 
       (4years)  
[07] On the job training 
 
006 Complete the following question below in your own words.  
 How many months/ years of experience do you have in an Adult 




007 Was a mentor/ buddy assigned to you for orientation when you 




008 What was the duration of your orientation? 
[    ] Weeks 
[    ] Months 
[    ] Not applicable 
 
009 Have you ever received in-service education on unfractionated 
heparin pharmacology while working in an Adult Chronic 









SECTION C: KNOWLEDGE REGARDING THE USE AND EFFECTS OF 
UNFRACTIONATED HEPARIN 
        Choose ONE response for each item by placing X in the relevant box 
010 Patients should always be asked about bleeding tendencies before 
unfractionated heparin is administered. 
[01] Yes 
[02] No  
 
011 Does unfractionated heparin break down blood clots? 
[01] Yes 
[02] No 
[03] Unsure  
 
012 A patient has an activated Partial Thromboplastin Time of less than 
50 seconds. 5000 international units of unfractionated heparin is 
administered during the haemodialysis session. Which of the 
following effects could unfractionated heparin cause? 
[01] Bleeding 
[02] Unscheduled Hospitalisation 
[03] No ill effects 
[04] Bleeding and unscheduled hospitalisation 
 
013 A patient arrives for the appointed haemodialysis session. Pre-
dialysis the patient is normally mildly hypertensive, with a blood 
pressure of 140mmHg/95mmHg. Today, the pre dialysis blood 
pressure systolic reading is 240mmHg and diastolic is 140mmHg. 





014 For which of the following platelet counts would you not administer 
unfractionated heparin? 
 
[01] 420-450 x 109/1 
[02] 50 -80 x 109/1 







015 A patient has completed a haemodialysis session and supposedly 
received the prescribed 5000 International Unit of unfractionated 
heparin during haemodialysis. Twenty minutes later the patient’s 
arterio-venous fistula is still actively bleeding. 
 
Select ONE of the following options below to arrest the bleeding. 
[01] Protamine sulphate 1 milligram per 100 international unit of 
       unfractionated heparin 
[02] Protamine sulphate 2 milligrams per 1000 international unit of 
       unfractionated heparin  
[03] Vitamin K 1milligram 
[04] Unsure 
 
 Complete the following questions below in your own words.  
016 Why is unfractionated heparin not administered orally? 
_____________________________________________________ 
 
017 Why is it important to have the patients' baseline urea values before 
administering the first dose of unfractionated heparin? 
_____________________________________________________ 
 




 Complete the following questions below in your own words  
019 What type of unfractionated heparin is used in your dialysis unit? 
[01] Porcine 
[02] Bovine 
[03] Other __________________________________ 
[04] Unsure 
 
020 At what temperature should unfractionated heparin be stored? 








021 What effect does unfractionated heparin have on potassium levels? 
_____________________________________________________ 
 
022 A patient needs to receive 2 000 International Units of 
unfractionated heparin. Unfractionated heparin in stock is 20 000 
International Units per 1ml. The 20 000 International Units of 
unfractionated heparin is added to 100 millilitres of sodium chlorine 
0.9%. 
Calculate the dose of unfractionated heparin for this patient 












Patients on haemodialysis receiving unfractionated heparin may 
experience adverse effects. On a scale of 5 to 1 make a mark to 
show how you would rank your concerns about these adverse 
effects for patients receiving unfractionated heparin. 5 indicates 
great concern and 1 indicates the least concern 
 
1                   2                        3                         4                           5 
Least                                                                                  Great                                                                                          
Concern                                                                                           Concern 
024 Choose one response for each item by placing X in the relevant box  





















the drug to 
patients  
      













 c I feel reporting 
of adverse 







      




reported in my 
dialysis centre 
      







      








      






026 How often are patients informed about how to manage the adverse 
effects of unfractionated heparin? 
[01] Always 
[02] Sometimes 







SECTION E: PRACTICE REGARDING THE USE AND EFFECTS OF 
UNFRACTIONATED HEPARIN 
Choose one response for each item by placing X in the relevant box 
027 How often is the unfractionated heparin dose administered as 




[04] Never  
 
028 How often is a new dialysis patient’s laboratory coagulation results 
checked prior to the administration of the first dose of 













[06] Other ____________________ 
 
030 When did you last refer to published literature on unfractionated 











031 When I am concerned about the prescribed dose of unfractionated 
heparin for a patient I … 
[01] Continue to administer the prescribed dose 
[02] Verbalise concerns to the Unit Manager 
[03] Contact the prescribing Doctor 
[04] Adjust the dosage…If you gave this response go to 
Question 032; if not go to Question 033. 
 
032 If I adjust the unfractionated heparin dose, I then ... 
 
[01] Document the adjusted dose I administered on patient's 
records  
[02] Document only what was prescribed 
[03] Do not record adjusted dose on patient record 
[04] Other ____________________________________________ 
 
033 How long ago did you witness an adverse effect of unfractionated 




[04] years ago 
[05] Never, state reason 
___________________________________________________ 
 
034 In order of preference, indicate which of the following you will 
consult for information about unfractionated heparin or other 
medication used in your adult chronic haemodialysis unit. For 
example, 1=most preferred; 4=least preferred  
[   ] Nurses 
[   ] Doctors 
[   ] Pharmacists 







035 Choose one response for each item by placing an x in the relevant 
box  
 
 Item Statement Always 4 Sometimes 3 Usually 2 Never 1  
 a I ask patients about 
bleeding tendencies 





   




   
 c I verify any allergy 






   
 d I confirm the 
unfractionated heparin 
dose with another 
qualified renal unit 




   






   
 f I inform the Unit 
Manager of patient's 












APPENDIX 2: Information and Consent form 
Participant Code No. 
 
INFORMATION AND CONSENT FORM 
RESEARCHER’S DETAILS     SUPERVISOR’S DETAILS: 
Student: Master of Science in Nursing:  Dr U. Kyriacos 
Mrs Debra Ockhuis     UNIVERSITY OF CAPE TOWN 
UNIVERSITY OF CAPE TOWN   Division of Nursing & Midwifery 
Division of Nursing and Midwifery    TEL: 021- 4066410 
TEL: 021-4066173        
 
HUMAN RESEARCH ETHICS COMMITTEE DETAILS: 
Faculty of Health Sciences 
Human Research Ethics Committee 
Room E52-24 Groote Schuur Hospital Old Main Building 
OBSERVATORY 
7925 
TEL: 021-406 6626 
Dear colleague 
Information Sheet : 
I, Debra Ockhuis am a Nephrology Nurse with 23 years experience. I am currently a 
Master of Science in Nursing Degree student at the University of Cape Town and I am 
undertaking a study on renal unit practitioners' knowledge, attitude and practice regarding 
unfractionated heparin. The study has ethical approval from the Faculty of Health 
Sciences Human Research Ethics Committee (FHS HREC Ref 642/2012 dated 9th 
January 2013). 
Unfractionated heparin is a medication commonly used during haemodialysis to prevent 
the patients' blood from clotting in the extracorporeal blood circuit. I wish to gain a deeper 
understanding and knowledge of your viewpoints regarding unfractionated heparin. 
Some background information, in 2002, the United Kingdom reported 480 cases of patient 
harm from the use of anticoagulation therapy and furthermore, in 2006 the National 
Patient Safety Agency (NPSA) reported about 120 deaths related to anticoagulation 
usage, of which 23% (28 reports) were associated with the use of heparin. Did you know 
unfractionated heparin is on the list of the Institute for Safe Medication Practices as one of 





Reading the abovementioned information directed the development and title of my 
proposed study, A DESCRIPTIVE SURVEY OF RENAL UNIT PRACTITIONERS' 
KNOWLEDGE, ATTITUDE AND PRACTICE RELATIVE TO USE AND EFFECTS OF 
UNFRACTIONATED HEPARIN IN SELECTED ADULT CHRONIC HAEMODIALYSIS 
CENTRES IN THE CAPE TOWN METROPOLE. 
My main purpose of the study is to describe renal unit practitioners' knowledge attitude 
and practice regarding the use and effects of unfractionated heparin. Secondly, to 
determine whether there is a relationship between knowledge, attitude and practice and 
selected variables (category of renal unit practitioner, years of experience, duration of 
orientation to the adult chronic haemodialysis unit and in-service education on the 
pharmacology of unfractionated heparin). 
From a South African perspective I, as the researcher could find no statistical data on 
deaths of any adult chronic haemodialysis patients from the Cape Town Metropole that 
may be relative to UFH usage. The South African Renal Society does not have an active 
statistical database on current morbidity and mortality of the renal population in South 
Africa. Interestingly as well, is that I could not find any other such studies in my literature 
review locally or globally. I believe the findings of my study will inform all renal unit 
practitioners' locally and globally regarding, how important it is that we take cognizance of 
employing good medication knowledge, attitude and practice to either improve or sustain 
our service delivery of quality renal care. This data will be useful for designing in-service 
training programmes for renal unit practitioners to promote patient safety. This proposed 
study will attempt to fill this theoretical gap.  
Equally important is that when you review the post study findings, your knowledge, 
attitude and practice (KAP) of unfractionated heparin will hopefully now be base on sound 
evidence. 
Your selection to participate in the study is because you administer unfractionated heparin 
to your patients on chronic haemodialysis. For this study all renal unit practitioners' who 
meet the below inclusion criteria from seven purposively selected haemodialysis centres 
in the Cape Town Metropole will be asked to participate. Namely, Certified Registered 
nurses who have completed any of the following training programmes such as a 
Postgraduate Diploma in Nephrology Nursing, a Renal Certificate, a Diploma in Critical 
Care, a Critical Care Certificate. The Registered Nurses currently study for an additional 





the research settings. The Registered Nurses without additional qualifications as listed 
above who are working in the selected adult chronic haemodialysis centres. Certified 
clinical technologists who have a Diploma in Nephrology Clinical Technology (3 years) or 
a Bachelor’s Technical Degree in Nephrology Clinical Technology (4years) or the 
students on these programmes working in the selected research settings. Enrolled nurses 
employed in the selected haemodialysis centres. Renal unit practitioners of any gender, 
age and citizenship meeting the above professional category requirements will be 
included. 
To protect your anonymity the study does not request you to provide your name and 
surname on the questionnaire. Furthermore, to uphold your confidentiality, anonymity and 
a non-biased response, I as the researcher will not have direct access to you. Means of 
communication with you will be through your Unit Manager however, if you wish to contact 
me, you may do so on the abovementioned details.  This same information letter will be 
used to request permission from your dialysis centres colleagues to participate in the 
study. They will need to be administering unfractionated heparin and meet the inclusion 
criteria. The research process is non-invasive, as it does not entail your direct monitoring 
of administering unfractionated heparin. You can complete the nine page self-
administered questionnaire in private, whether in the comfort of your home or at your 
place of employment. The completing of the questionnaire is a once off process and does 
not entail you resubmitting. It may take you about an hour to complete the self-
administered questionnaire. You will however, need to ensure the delivery of the 
completed, semi-completed questionnaire or uncompleted questionnaire by the end of the 
study period (two weeks). You can make a copy of your completed questionnaire so you 
can compare your responses against the overall study findings. 
If you feel undue distress completing the self-administered questionnaire, either contact 
me directly so I listen to your concerns, clarify your concerns and/or offer reassurance per 
telephone. Alternatively, you can speak to your Unit Manager who will on your behalf, 
liaise with me so we can schedule a personal appointment to meet with you to allay your 
concerns and fears. Remember this is not a test; however, your honest completion of the 
self-administered questionnaire information will be useful to inform the findings for this 
study and the designing of any future interventions that needs to be applied. Another 
factor for you to consider if you decide to participate in completing the questionnaire is 
that you as an individual will be aware of your own strengths and limitations of your 





findings of the published study. I hope that you will feel self-confident that your knowledge 
of unfractionated heparin you impart to new colleagues in the haemodialysis centres is 
accurate.  
A point worth noting, is that it is not compulsory for you to partake in this study, you have 
the right to refuse and you may withdraw during the study should you feel you do not wish 
to participate any further. In no manner will your refusal or withdrawal from the study 
reflect negatively on you. You will not experience victimization, no explanation is required 
and there will be no repercussions to be borne by you. If you do decide to participate in 
the study, you as the study subject are in control of how much information you provide on 
the questionnaire. However, I extend appreciation, for your honest opinions to validate the 
study and add credibility. 
Your responses are confidential; therefore, I will not disclose your responses to your 
employer, only to my supervisor and a statistician. I will treat all information submitted 
justly and there will be no manipulation of information to meet my research outcomes. 
Storage of the returned questionnaires will be in a steel locked cupboard for a time-period 
of two years after the study in case post analysis is required to assist in the designing of 
an in-service training programme and thereafter shredded. There will be no monetary 
compensation for participating in the study however; I will give acknowledgement for all 
unidentified participating renal unit practitioners in my dissertation. There is no planned 
compensation or treatment in the event of injury for this study. 
If you are willing to participate in completing the questionnaire, kindly complete the 
consent form below and return to your manager who will contact me, researcher to 
collect.  
If you participate in the study and are interested in the findings, please do not hesitate to 
contact my supervisor or me. 
If you have any further questions regarding the study, you may contact me, the 
researcher directly or my supervisor, Dr U Kyriacos. You may also contact the Human 
Research Ethics Committee for more information about your rights and welfare as a 
research participant at telephone number 021- 4066626.  





APPENDIX 2 (continued) 
Participant Code No. 
 
CONSENT FORM 
University of Cape Town 
A DESCRIPTIVE SURVEY OF RENAL UNIT PRACTITIONERS' KNOWLEDGE, 
ATTITUDE AND PRACTICE RELATIVE TO USE AND EFFECTS OF 
UNFRACTIONATED HEPARIN IN SELECTED ADULT CHRONIC HAEMODIALYSIS 
CENTRES IN THE CAPE TOWN METROPOLE. 
I___________________________________ have read the provided Information Sheet. I 
understand what is required of me, as a renal unit practitioner. I have had all my 
questions answered. I do not feel that I am forced to take part in this study and I am doing 
so of my own free will. I know that I can withdraw at any time if I wish and that it will have 
no bad consequences for me. 
I hereby give permission for the researcher to keep my completed questionnaire for two 
years post analysis of the study as per legal requirement. 
 
_____________________                                           _____________________________ 






APPENDIX 3: Checklist for Content and Face Validity  








Researcher: Debbie Ockhuis     Supervisor: Dr Una Kyriacos 
MSc candidate 
Division of Nursing & Midwifery 
Department of Health & Rehabilitation Sciences 
Faculty of Health Sciences 
University of Cape Town 
OBSERVATORY 7925 
Telephone Number: (021)406 6173       (021) 406 6410 
email: d.ockhuis@uct.ac.za 
Title of study: A descriptive survey of renal unit practitioners' knowledge, attitude 
and practice relative to use and effects of unfractionated heparin in 
selected adult chronic haemodialysis centres in the Cape Town 
Metropole 
INFORMATION:  
Thank you for agreeing to evaluate the content and face validity of the self-administered 
questionnaire (Appendix 1). Please e-mail or post the completed checklist to the 
researcher at the above address. 
The purpose of this checklist is to ensure uniform evaluation by all experts using a 
structured procedure.  
You, the expert, will establish the index of content validity (CVI) for each question using a 
4-point ordinal rating scale and this will be taken as the proportion of items that received a 
rating of 3 or 4.1 If, in your opinion, there are omissions, these can be listed separately.2 
For evaluation of face validity, the checklist includes a rating scale for quantification of 
layout, format, quality of printing, the length of the questionnaire, the response scale of 1-
4, if visually easy to read and comprehend and if instructions at the beginning of the 
questionnaire are clear and easy to understand.2 
Expert opinion on index of content validity (CVI) of EACH QUESTION on the 
questionnaire: 
CHECKLIST 
For Content and Face Validity of the 












item is in need 
of such 




3 = relevant but 
needs minor 
alteration 
4 = extremely 
relevant 
001     
002     
003     
004     
005     
006     
007     
008     
009     
010     
011     
012     
013     
014     
015     
016     
017     
018     
019     
020     
021     
022     
023     
024a     
024b     
024c     
024d     
024e     
024f     
025     
026     
027     
028     
029     
030     
031     
032     
033     
034     
035a     
035b     
035c     












item is in need 
of such 




3 = relevant but 
needs minor 
alteration 
4 = extremely 
relevant 
035e     
035f     
 






















Evaluation of FACE VALIDITY 













































Layout     
Format     
Quality of printing     
Length of the questionnaire     
If visually easy to read     
If visually easy to comprehend     
If instructions at the beginning of the 
questionnaire are clear and easy to understand 







THANK YOU VERY MUCH 
ADAPTED FROM U KYRIACOS, PhD (2011), with permission. 
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APPENDIX 4: Sample of permission requesting letter  










REQUEST FOR PERMISSION TO CONDUCT RESEARCH IN DIALYSIS CENTRE 
RESEARCH TOPIC:  
A descriptive survey of renal unit practitioners' knowledge, attitude and practice 
relative to use and effects of unfractionated heparin in selected adult chronic 
haemodialysis centres in the Cape Town Metropole 
 
I, Debra Jacqueline Ockhuis am presently studying for the Masters in Nursing Degree at the 
University of Cape Town. Your written approval is requested to conduct research at the 
_____________dialysis centre. Approval has being granted by University of Cape Town Faculty of 
Health Sciences Human Research Ethics Committee. My ethical clearance number is: 
__________________. Included, please find a copy of my research proposal. The aim of my study 
is to describe the knowledge, attitude and practice of renal unit practitioners relative to the use 
and effects of unfractionated heparin in selected adult chronic haemodialysis dialysis centres in 
the Cape Town Metropole.  
Study results may inform the design of in-service training courses to improve renal unit 
practitioners’ standards of practice for safe quality renal care.  
If permission is granted, I will ensure that all information regarding renal unit practitioners and 
their dialysis centre will be treated confidentially. Anonymity will be ensured by not disclosing 
names of dialysis centres or of respondents. This is not a comparison analysis between private 
and public dialysis centre. As the employing body, I will ensure that you will receive a copy of the 
Executive Summary of the completed research. I will comply with legal requirements regarding 









Mrs Debra Ockhuis 













APPENDIX 6: Raw data: personal and professional demographics 












002               
citizen 
003                        
prof cate 
004              
qualification 
005                      exp 006                         
orientation 
mentor 007                                          
duration of 
orientation 008                                
In-
service 
009            
1 44 2 1 1 7 52 2 3 2 
2 39 2 1 1 3 72 2 3 2 
3 48 2 1 3 7 108 1 1 1 
4 49 2 1 1 7 168 1 2 2 
5 52 2 1 1 1; 3 264 1 1 2 
6 46 2 1 1 3; 7 60 2 2 2 
7 60 2 1 1 1; 3; 7 240 2 2 2 
8 23 1 1 2 5 2 ? 1 1 2 
9 26 1 1 2 5; 6 38 1 1 1 
10 23 1 1 2 5 13 1 3 1 
11 33 2 1 2 6 108 1 2 1 
12 24 2 1 2 5; 7 2 mths 1 1 2 
13 26 2 1 2 6 64 1 2 2 
14 28 1 1 2 6 72 1 3 1 
15 43 2 1 1 3 48 1 1 2 
16 40 2 1 1 7 60 1 3 2 
17 49 2 1 3 1001 96 1 1 1 
18 1001 2 1 1 7 360 1 2 2 
19 23 2 1 2 5 40 1 2 2 
20 46 2 1 3 1001 120 2 1 1 
21 50 2 1 1 1 60 2 1 2 
22 55 2 1 1 7 336 2 3 2 
23 50 2 1 1 3 192 2 3 2 
24 44 2 1 1 7 228 1 2 1 
25 31 1 1 1 3; 7 60 1 1 1 
26 49 2 1 1 3 312 1 1 1 
27 43 2 1 1 7 156 1 1 1 
28 47 1 1 1 3 172 1 2 1 
29 38 2 1 1 3 20 1 2 1 
30 41 2 1 1 3 19 1 2 2 
31 51 2 1 1 1001 240 1 2 1 
32 35 2 1 2 6 168 1 1 2 
33 44 1 1 2 6 300 1 1 1 
34 23 1 1 2 5 24 1 1 1 
35 41 2 1 2 5 276 1 3 2 
36 55 2 1 1 1 312 2 3 2 
37 40 1 1 2 5 180 2 3 2 
38 30 1 1 2 5 96 2 3 2 
39 55 1 1 2 5 408 2 3 2 
40 31 1 1 2 5 96 1 2 1 
41 58 2 2 1 3; 7 60 1 1 2 
42 1001 2 1 1 7 144 2 3 2 
43 38 2 1 1 7 18 1 1 2 
44 51 2 1 1 7 5 mths 1 2 2 
45 49 2 1 1 1; 3 36 1 2 1 
46 35 2 1 3 7 53 2 1 1 
47 39 1 1 1 1 76 1 2 1001 
48 33 1 1 1 7 36 1 1 2 
49 54 2 1 1 7 45 1 1 2 
50 33 2 1 1 1 16 1 3 2 
51 32 1 1 2 6 96 1 2 1 
52 28 2 1 2 6 60 2 4 1 
53 42 2 1 1 1 16 2 2 2 
54 46 2 1 1 1 36 2 3 1 
55 31 2 1 1 1001 2 weeks 1 5 2 
56 51 2 1 1 3; 7 6 mths 1 2 2 
57 30 2 1 1 7 36 1 1 2 
58 25 1 1 2 6 36 1 2 1 





60 50 2 1 1 7 20 1 1 2 
61 1001 1 1 1 7 15 2 2 2 
62 38 2 1 2 5 180 1 2 1 
63 46 2 1 1 1 132 2 3 1 
64 30 2 1 1 7 2 mths 1 3 2 
65 41 2 1 1 7 9 mths 1 2 2 
66 32 1 2 2 5 48 1 2 2 
67 46 2 1 1 7 4 ? 2 3 2 
68 24 1 1001 1 1001 4 mths 1 1 1 
69 51 2 1 1 7 6 mths 1 2 2 
70 52 2 1 1 7 96 1 1 2 
71 59 2 1 1 3; 7 360 2 3 1 
72 64 2 1 1 7 444 1 2 2 
73 48 2 1 1 3 60 1 2 2 
74 29 2 2 1 1001 0 ? 1 2 2 
75 30 2 1 1 1 24 2 2 2 
76 44 2 1 3 7 36 1001 1 1 




APPENDIX 7: Captured raw data of respondents’ knowledge 










































































































































































































1 <25 °C hyperkalemia 2000 / 20000 x 100 /1 = 10 
2 1 2 4 2 2 1 not effective high urea levels 
increase bleeding 
tendency 
intravenous 1 below 25 °C inhibits secretion 
of aldosterone 
which may cause 
hyperkalaemia 
dose required / dose on 
hand x volume / 1                                                                  
2000 / 20 000 x 100 mls / 1 = 
10mls 
3 1 2 1 1 2 2 iv to prevent circuit 
from clotting 






5000u stat via 
heparin line or 
5000u stat then 
1000u every hr 




below 25 °C- 
do not freeze 
nil 2000 / 20000 x 100 /1 = 10 
4 1 1 4 2 2 1 it cannot be 
absorbed orally 
so that you can 
decide on the 
correct dose 
intravenously 1 21 °C no effect dose required / amount in 
stock x volume / 1                                                                  
2000 / 20 000 x 100 mls / 1 = 
10mls 
5 1 2 3 2 2 2 only for 
intravenous use 
an increase in urea 
values predispose 
patient to bleed 
intravenously 1 below 25 °C causes 
hyperkalemia 
dose required /dosage in 
stock x ml / 1                                                                                                     





6 1 1 4 2 2 1 metabolised via 
liver, excreted via 
kidneys 
risk of bleeding intravenously 1001 1001 I don't know 2000 / 20 000 x 100 / 1 = 10 
mls 
7 1 2 1 2 2 1 it is not absorbed 
by the gut 
high urea levels 
cause bleeding 
intravenously 1 below 25°C  increase levels dose required / dose in 
stock x volume                                                                                 
2000 / 20 000 x100 =10mls 
8 1 2 1 2 2 2 it can affect the 
internal organs 
1001 iv through the 
machine blood 
lines 
2 less than 
24°C  
not sure 2000 =?                                                                                                                                                           
20 000 = 100ml                                                                                                                         
=10ml 
9 1 2 3 3 2 4 can cause 
gastrointestinal 
bleeding 
high levels of urea 





4 less than 3°C  1001 1ml (solution) = 2 00 00 / 
100                                                                                                                       
=200IU  200 x 10 =2000IU       
10ml =2000IU 
10 1 2 1 2 2 2 to anticoagulate 
the extracorporeal 
circuit and not 
cause internal 
bleeding 
high urea values 





port with a 
needle and 
syringe 
4 32 °C 1001 20 000IU/ml / 100ml sodIUm 
chloride = 2000IU heparin 
/ml 
11 1 1 1 2 3 1 it will take long to 
be dialysed into 
body 
to check after how 
long pt will clot 
ACT 
heparin line of 
blood lines 
1001 less than 25 
°C 
hyperkalaemia 1001 





















20000 / 2000 x 100 /1 = 
10mls = 100 
13 1 2 4 2 2 2 can cause internal 
bleeding 
higher urea levels , 
higher the bleeding 
IV  1 < 25 °C hyperkalaemia 2000 / 20 000 x 100 / 1 =  20 / 





14 1 2 1 2 2 2 because it can 
cause internal 
bleeding 
1001 through the 
extra coporeal 
circuit 
4 23 °C increase K+ 
levels 
1001 
15 1 1 4 2 2 1 because orally the 
absorption take 
much longer 
the higher the urea 
levels the prone 
the patient is prone 
to bleeding 




because it stops 
the production of 
aldosterone 
2000 / 20 000 x 100 /10 = 20 
/2 =10mls 
16 1 2 1 2 3 2 oral not 
available/also it is 
for the dialysis 
pt can bleed ivi via dialysis 
lines 




DB / DV X Vol /1  =10ml 






18 1 1001 1 2 1 1 iv or subcut use 
only 
increase urea level 
can cause bleeding 
gastritis 
intravenous 1 <25 °C nil dose required / dose in 
stock x volume                                                                                 
2000 / 20 000 x100 /1 =10 
19 1001 2 1001 2 2 2 cause 
unfractionated 
heparin can cause 
internal bleeding 
high urea levels 
increse bleeding 
iv 4 <25 °C hyperkalaemia 2000/ 20 000 x 100 / 1 = 20/ 2 
= 10mls 







21 1 1 4 2 2 3 the absorption is 
not effective 
1001 intravenous 1 below 35 °C 1001 2000 / 20 000 x 100ml N 
Saline = 200 / 20 = 10ml 
22 1 1 3 2 2 4 for use to prevent 
arterial and ven 
trombos 
urea levels very 
high - patient can 
bleed 
give a start dose 
of +/- 2000 units 
and then hourly 
500u or 1000u 
for the following 
2 hours through 



















SB /SV x 100/ 1                                                                                                                                       






23 1 2 3 2 2 1 only available 
intravenously 
can instigate 








2000 / 20 000 x 100 / 1                                                                                                                                       
01 ml 
24 1 1 3 2 1001 4 it is an ivi therapy to prevent 
uncontrolled 
bleeding 
ivi 3 room 
temperature 
non 2000 / 20 000 x 1 / 100 = 100 
25 1 2 4 2 2 2 it is widely used as 
an injectable 
anticoagulant 
high urea levels 












stock needed / stock 
available x volume / 1                                                                                                                
= 2000 / 20 000 x 100 / 1                                                                                                                     
= 10ml 
26 1 2 4 2 2 2 it is an injectable 
anticoagulant 







hyperkalaemia stock needed / stock 
available x volume / 1                                                                                                                
= 2000 / 20 000 x 100 / 1                                                                                                                                        
= 10ml 
27 1 2 4 2 2 2 because it can 
used as a 
injectable 
anticoagulant 










stock needed / stock 
available x volume / 1                                                                                                                
= 2000 / 20 000 x 100 / 1  = 
10ml 
28 1 1 1 2 2 2 it is not effective 
after oral 
administration 
if urea is high and 
you give heparin it 
can cause bleeding 
intravenously 1 store below 
25°C Do not 
freeze 
it can cause 
hyperkalaemia 
20 000 x 100 ml = 20 000u / 
2000                                                                                                                                               
= 1000u 
29 1 1 4 2 2 2 it is an iv drug hyperuremia can 
also increase 
bleeding risk and 
bleeding time 





,not to be 
freezed 
none dose required / dose 
available x volume in wich 
diluted / 1                                                                   
= 2000 u/ 20 000 u x 100  ml/ 
1                                                                                                                                             
= 10ml                                                                                                                                               
10ml = 2000u heparin                                                                                                                          
30 1 1 3 2 2 4 it comes in 
intravenous 
injection only 









none 20 000IU 100m of Na CL 
0.9% . Therefore in 1 ml 
20000 / 100  therefore 200 I 
u per ml. You give 2000 / 
200 = 10 ml                                                                                             





31 1 1 1 2 1001 3 it is evenly 
distributed 
between cells and 




1 below 25°C  hyperkalaemia 
may occur 
2000 / 20 000 x 100 / 1                                                                                                                                       
10ml 
32 1 2 1 2 2 1 it is not absorbed 
by gut 
urea levels too 
high there will be 
high risk of 
bleeding 
via the heparin 
line on the 
arterial blood 
line 
1 below 25°C  may cause 
hyperkalaemia  
20 000IU/ml /100ml NaCl = 
200 IU/ml                                                            
2000IU /200IU/ml = 10 ml 
therefore 10 ml of 
heparinised (20 000IU) 
100ml/0.9%Na Cl = 2000IU 
33 1 2 4 2 2 1 heparin is not 
absorbed from the 
gut 




via arterial line 
of extra 
corporeal circuit 




10ml                                                                                                                                              
20 000IU/ 100ml NaCl = 2000 
IU/ml       2000IU/200IU/ml = 
10ml 
34 1 2 4 2 2 4 will be destroyed 
by stomach acid 
↑urea level 
increase chance of 
bleeding 
via heparin line 
on extra 
corporeal circuit 
2 > 20°C 1001 total 10millileters given 
35 1 3 4 2 2 4 1001 ↑urea ↑ bleeding iv 4 ↓25°C unsure 10ml                                                                                                                                               




1 below 25°C  nil 2000 / 20 000 x 100 / 1 
=10ml 
37 1 2 1 2 3 4 ivi ? Unsure ivi  1 25 none unsure 
38 1 2 1 2 3 3 unsure ureamia causes 
bleeding 
continuous 1  - 25°C  unsure 2000 / 20 000 x 100 / 1 = 
10ml 
39 1 1 1 1 1001 4 not manufactured 
as such 
to determine post 
dialysis bleeding 
200u as loading 
1000u / hr to end 
of dialysis 
2 room temp 
22°C  
unsure 10ml 
40 2 1 1 2 2 4 it is only indicated 
for iv use 
high urea - 
bleeding tendency 
because of toxins 
intravenous 4 room 
temperature 
( 5 - 25 °C) 
but away 
from direct 
not sure 20 000 u/ 100ml = 2000u / x                                                                                           
100ml x 2000 = 20000x                                                                                                        
2 00 000 / 20 000 = 20000x / 
x                                                                                                  






41 1 2 1 2 2 1 the body digest it 
before it can be 
used 
with high ureas 
patients bleed 
more 
5000 heparin in 
20mls subfluid 
(25mls) bolus 5 
mls iv 




can increase it 2000 / 20 000 x 100 / 1  = 
1000u 
42 1 2 1 1 2 3 Haven’t ever heard 
of oral heparin 
1001 iv 1 below 25°C  1001 2000 / 20 000  x 100 / 1 = 
10ml 
43 1 2 4 3 3 1 only indicated for 
iv, cannot be 





iv 1 5-25 °C increased 
potassium levels 
20 000 = 2000                                                                                                                         
100ml = xml                                                                                                                  
100 x2000 / 20 000n= 
20000/20000 = 10mls 
44 1 1 1 2 2 1 it gets digested 
before being used 
for its purpose 
high urea values 
make patients 
bleed more 




( 2 - 8 °C 
increases  
potassium levels 
2000 / 20 000  x 100 / 1 = 
1000u 
45 1 2 4 2 2 3 heparin contains 
sodIUm  iv therapy 
urea tendencies for 
bleeding 
intravenously 1  -   25 °C hyperkalemia due 
to aldosterone 
suppression 
2000 /  20000 x 100 / 1 = 
10mls 
46 1 2 1 2 2 1 absorbed faster 
intravenously 
increase urea ; 
increase bleeding 




2000 / 20 000 x 100 / 1 
47 1 1 1 2 2 2 1001 1001 iv 2 <25>0 1001 2000 / 20 000 x 100 / 1 = 
100ml of prepared solution                                                             
dose needed / dose in stock 
x volume for preparation / 1 
48 1 1 4 2 2 3 because it is short 
acting 
1001 ivi 4 room temp 
21°C 
don’t know 2000 / 100 x 1 / 1                                                                                                                                           
200 units / 1 ml                                                                                                                           





49 1 1 4 2 2 3 does not get 
absorbed by gut 
system 
1001 iv in 30ml 
syringe in driver 
of 5008 
Bodene below 25°C raises it 1ml = 20 000 units                                                                                                                                          
+ 99mls Na Cl0.9% + 1ml 
Heparin = 100ml Na Cl 0.9% 
+ 20 000 units Heparin 
therefore 10ml NaCL 0.9% 
with 2000u heparin 
therefore give pt 10ml for 
2000 units 
50 1 1 1 2 1 1 1001 1001 ivi 4 room temp  1001 dose req / dose stock x vol / 
1                                                                                                   
2000 / 20 000 x 1 /1 = 0.1 x 
100ml NaCl = 10 ml heparin 
mixed with Na Cl 
51 1 1 4 2 2 2 it is not absorbed 
in the GIT 
high urea levels 
can lead to 
bleeding 
iv 2 36°C -38°C increase K+ draw 1 ml out of 100 ml 
saline. Insert 1ml 20 000 
hep                                                                                                
100 ml = 20 0000 units                                                                                                                                                  
10ml = 2000 units 
52 1 2 4 2 2 2 works primarily in 
blood clotting 
cascade and could 
be aangeraise in 
the digestive 
system 
will cause thinning 








before going to 
the patient 
1 25°C could increase 
serum levels 
20 000u                                                                                                                               
100ml / 200u /ml                                                                                                                    
2000 / 200 = 10ml                                                                                       






iv 2 room 
temperature 
35°C 
not sure DR / DS X ML /1                                                                                                                                                   
=2000 / 20 000 X 1 / 1                                                                                                                                           
=10ml 
54 1 2 3 2 2 1 wont be absorbed 
in the gut 
unsure intravenously 2 1001 nil 2000 / 20 000 x 100 / 1 = 
10mls = 2000IU 
55 1 1 1 2 1 4 cannot be 
absorbed by gastro 
intestinal tract 
unsure iv unsure 21 - 25°C 1001 dosage required / dosage in 
stock x volume / 1                                                                                       
2000 / 20 000 x 100 ml / 1                                                                                                





56 1 2 1 1 1 1 company issued it 
as used per 
injection only, it 
also needs to be 
absorbed stat 
elevated urea can 
already lead to 
bleeding itself 
prescribed 
dosage mixed in 
Na Cl 0.9 % 
connected to 
prescribed port , 
which leads to 
red (arterial) 
side , = pre filter 
1 room 
temperature 
=/- 18 - 20°C 
may elevate 
potassium levels 
 dosage needed / dosage in 
stock x volume / 1                                                                                                  
2000 / 20 000 x 100ml / 1 = 
10 000IU 
57 1 2 1 2 2 1 it is not absorbed 
by the gut 
1001 intravenous 2 1001 it increase the 
potassium level 
20 000 / 100 = 200 / ml  
2000/200 = 10mls  
58 1 2 4 2 2 2 glycosaminoglycan 
molecule that is 
digested by 
enzyme and HCL 
urea affects 
clotting time (↑  
urea = ↑ clotting 
time) 






25° or less ) 
1001 20000/10ml=200u/ml=10ml 
of 200u/ml heparin 
59 1 2 3 2 2 2 can cause local 
bleeding 
high urea levels 
has a bleeding 
tendency 
via heparin line 
on A- line of 
dialysis 
1 below 25°C inhibits the 
secretion of 
aldosterone 
which may cause 
hyperkalemia 
2000 / 20000 x 100/1                                                                                                                            
200 / 2000                                                                                                                          
10ml needed from 100ml 
dilution 
60 1 1 1 2 2 1 not oral 
preparation - 
gastric bleeding 
unsure ivi 4 room temp 
23° 
unsure only use 1000  in 1ml or 
5000u in 1ml                                                                                              
20 000 / 100                                                                                                                          
20 000 in 100ml - 200u in 
1ml use 10ml for 2000 u 
61 1 2 1 3 2 1 not absorbed via 
GI Tract 
excessive bleeding 
as a result of 
elevated urea 
intravenous 2 21 - 25°C 1001 volume required / volume in 
stock = dose required / 
dose in stock                                                                             
volume req = dose req / 
dose in stock x vol in stock                                                             
2000 / 20000 x100 = 10ml 
62 1 2 1 1001 1001 1001 1001 1001 1001 2 store below 
25 °C but do 
not freeze 
can increase K+ 20 000 / 100 200 X 10 / 1 X10 
= 2000 / 10                                                                                        





63 1 2 3 2 2 1 it does not get 
digested by GIT. It 
should be 
administered ivi to 
do its work 
a high urea value 
cause bleeding 
tendency 
ivi via dialysis 
line pre dialyser 
1 under 25°C it increases it 
slightly  
2000 / 20000 x 100 /1 = 10ml 
64 1 2 1001 2 2 3 it will not have any 
effect, it will not be 
absorbed 
↑urea will already 
affect clotting 
actively 
intravenous 4 room 
temperature 
25°C 
unsure dose required / dose in 
stock x volume / 1                                                                                              
2000 / 20 000 x 100 / 1                                                                                                                                                                          
200 / 20                                                                                                                                                    
10ml 
65 1 1 1 3 3 1 unsure to check platelet 
count 
intravenously 1 room 
temperature 
not sure dose required / dose in 
stock  x v /1                                                                                                              
2ml 
66 1 2 1 2 2 1 would be broken 
down 
1001 iv 2 20 - 25 1001 20 - 100ml                     2x 
100 / 20 = 10mls 
67 1 2 1 2 2 4 no absorption lead to increase 





1,2  below 25°C hyperkalemia 20 000 heparin in 100ml 
saline                                                                                                              
200 u / ml                                                                                                                                    
10ml 
68 1 1 1 2 2 4 because it works 
on the blood 
Unsure ivi 4 1001 unsure 1001 








required amount / amount 
in stock x volume                                                                         
=2000 / 20 000 x 100                                                                                                               
= 10u 
71 1 1 3 2 2 1 designed for iv prevent bleeding iv 1001 below 25°C 1001 strength required / strength 
in stock x volume 





73 1 1 3 2 2 1 you don’t get oral 
heparin 
prevent bleeding ivi 2 21°C room 
temperature 
unknown dose required / dose in 
stock x volume / 1                                                                                              
2000  x 10 / 20 000                                                                                                                                                      
=1 ml                                                                                                
74 1 2 1 3 2 2 because it is not to 
be absorbed in the 
gut 
it is because 
heparin increases 
the level of urea 
iv 2 1001 1001 dose required in units x 
available drug dose in mls / 
available dose in units                       
= 2000 x 101 / 20 000                                                                                                                           
=202 000 / 20000                                                                                                                  
=10.1mls 
75 1 1 1 2 2 1 because of time it 
would take to be 





ivi 3 - 
mucosal 
1001 increases levels 1001 
76 1 3 1001 1001 1001 1001 1001 1001 via machine in 
30ml syringe 
1001 1001 1001 1001 
77 1 2 4 2 2 1 1001 high urea - cause 
blood to be thin 
and can lead to 
bleeding 
ivi 4 36.5°C 1001 dose required / dose in 
stock x vol / 1                                                                                                            
2000 / 20 000 x 100 / 1 = 10 
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APPENDIX 8: Captured raw data of respondents’ attitude 

































































































































































































































1 5 5 3 1 5 3 5 3 3 
2 4 5 1 1 5 4 1 2 1 
3 2 5 1 1 2 2 1 1 2 
4 1001 5 4 1 5 5 1 2 1 
5 5 4 4 1 4 4 1 2 2 
6 3 5 4 1 5 5 1 3 2 
7 4 5 1001 1 4 4 1 2 2 
8 5 5 3 3 2 5 3 2 2 
9 1 5 3 1 4 4 1 2 2 
10 5 5 3 1 2 5 1 1 1 
11 1001 4 1 1 4 5 4 2 1 
12 2 4 3 2 4 3 1 2 2 
13 5 5 5 1 5 5 1 2 2 
14 5 5 3 2 5 5 4 2 2 
15 3 5 4 2 5 5 3 1 1 
16 4 4 5 1 3 3 3 2 1 
17 1001 5 4 5 3 5 3 1 1 
18 5 5 1 1 5 5 1001 2 1 
19 5 5 3 1 5 3 3 2 2 
20 3 5 4 3 5 4 3 1 1 
21 5 5 1 1 5 5 1 2 2 
22 4 5 1 4 5 5 1 1 1 
23 3 5 1 3 4 4 4 2 2 





25 3 5 1 1 5 4 5 1 1 
26 3 5 1 1 5 5 5 1 1 
27 3 5 1 1 5 5 5 1 1 
28 4 5 1 1 5 5 5 1 1 
29 5 5 
1 - if she 
didn’t mixed 
in front of 
me 
5 5 5 1 1 1 
30 3 5 1 1 5 5 1 2 1 
31 5 5 4 3 5 5 1 2 1 
32 3 4 3 2 3 4 2 2 2 
33 4 5 1 3 4 4 2 3 2 
34 4 4 3 3 2 3 3 2 2 
35 1001 5 2 2 4 4 1 2 2 
36 5 5 1 1 5 4 3 3 2 
37 5 5 1 2 5 3 1 1 1 
38 4 5 1 3 5 3 1 2 3 
39 3 4 4 4 2 3 2 2 2 
40 3 4 1 3 4 4 3 2 2 
41 4 5 4 1 5 5 1 2 2 
42 5 5 4 1 3 5 5 2 2 
43 2 5 2 1 1 1 1 3 3 
44 4 5 1 5 5 5 1 2 2 
45 5 1001 1001 1001 1001 1001 1001 1001 1 
46 5 5 1 1 5 5 1 1 1 
47 4 5 3 1 5 4 1 2 1 
48 3 5 1 2 1 5 1 2 3 
49 1001 5 2 3 4 4 3 2 2 
50 3 5 3 2 4 3 4 2 2 
51 3 5 4 3 3 4 2 2 2 
52 4 5 3 1 3 2 3 2 3 
53 5 5 1 1 5 4 5 2 3 
54 4 5 1 2 4 3 5 2 2 
55 1001 5 1 1 1001 5 1 2 1001 
56 2 5 1 4 5 5 1 1 1 
57 5 5 3 1 3 4 1 2 2 
58 4 5 1 2 4 4 2 2 2 
59 3 5 1 1 4 5 1001 2 2 
60 3 5 4 1 4 3 1 2 2 
61 4 5 1 2 2 2 1 3 3 
62 2 3 3 2 3 3 1 2 2 





64 5 5 1 4 3 1 5 3 2 
65 3 5 2 3 5 5 5 2 2 
66 3 5 2 2 3 3 2 2 2 
67 2 5 1 1 5 5 1 2 2 
68 4 1001 1001 1001 1001 1001 1001 1001 1001 
69 4 5 1 1 3 4 1 2 2 
70 5 5 1 1 3 3 2 2 3 
71 3 5 1 1 5 5 1 1 1 
72 3 5 5 3 5 5 5 2 2 
73 3 5 1 2 5 5 5 1 2 
74 4 5 1 3 3 5 1 2 2 
75 1001 1001 1001 1001 1001 1001 1001 1001 1001 
76 1001 5 1 1001 1001 4 5 1001 1 
77 4 5 2 1 4 2 2 2 2 
170 
APPENDIX 9: Captured raw data of respondents’ practice 
































































































































































































































































































































































1 2 4 2 4 2 1 3 2,1,4,3 1 1 1 2 2 2 
2 2 3 6- when necessary 
i.e. if pt has 
prolonged bleeding 
times or 
symptomatic c/o hair 
loss, 
haematuria,petechia 
or if going for 
surgery 
2 4 1 and 4 -inform 
dr concerned 
1 1,2,4,3 3 4 1 1 4 4 
3 1 3 2 3 3 1 1 doctors 3 3 3 4 4 4 










2 3 2 1 3 1 3 2,1,3,4 3 2 3 2 4 4 
6 
1 4 2 4 3 1 3 pharmacist 4 4 4 4 4 3 
7 
1 3 6 - when necessary 4 3   2 3,1,4,2 3 3 4 3 4 4 
8 1 2 2 3 2 1 
5 - I seldom 
experience 
it 
3,4,3,3 4 3 3 4 4 4 
9 1 2 2 4 3   1 1,2 2 2 1 2 2 3 
10 4 2 4 2 2   3 3,2,4,1 3 4 4 4 4 4 
11 1 2 1 3 3 1 3 doctors 2 4 1 2 4 2 
12 1 1001 2 1 1001 1001 2 4,3,3 3 2 3 4 1001 1001 
13 1 1 6 - 3 monthly 3 3   1 4,1,2,3 4 3 4 4 4 4 
14 1 2 2 2 3 1 3 3,2,1,4 3 4 3 4 4 4 
15 2 3 2 4 3 1 1 4,2,1,3 3 4 3 3 4 4 
16 3 1 2 4 3 1 
don’t 
remember 
doctors 4 3 3 4 4 4 





18 2 3 2 3 3 1 3 4,1,2,3 3 3 3 4 4 4 





2   1001 2,3,4,1 3 1 1 3 4 4 
20 1 1001 
6- on request /every 
3 months 
3 2   3 4,2,1,3 4 4 4 4 4 4 
21 1 1 2 2 2 1 3 3,1,2,4 4 4 4 4 4 4 
22 1 1 
1 and 6 - after post 
op checked results 
before start dialysis 
3 3   4 doctors 4 4 4 4 4 4 
23 3 3 6 3 3 1 3 doctors 3 4 4 3 4 3 
24 1 3 
1 and 6 - when 
dosages change 
5 3 1 5 4-doctors 4 4 4 4 4 4 
25 1 1 
6 - only when 
patients are on 
warfarin 3 3 1 4 2,4,1,3 4 4 4 4 4 4 
26 1 1 
6 - only when 
patients are on 
warfarin 3 3 1 4 3,1,2,4 4 4 4 4 4 4 
27 1 1 
6 - only when 
patients are on 
warfarin 3 3 1 4 3,1,2,4 4 4 4 4 4 4 





29 1 1 
1 patients on 
warfarin and 6 - 
when patients have 
bleeding/ infection 
3 2   3 
formulary 
book 4 4 4 4 4 4 
30 4 4 
6 - just when they on 
warfarin or going to 
theatre 
3 4 1 












bleeding 4,2,1,3 1 4 1 4 4 4 
31 1 3 1 3 2 2 3 doctors 3 4 3 4 4 4 
32 2 4  6 When necessary 3 4 1 4 1,2,4,3 3 3 1 4 4 4 
33 2 2 1 3 4 1 2 3,1,2,4 3 3 1 4 4 3 
34 2 3 1 3 4 1 3 1,2,3,4 3 4 3 3 4 3 
35 4 4 6 not sure 5 2,3 1 4 1001 3 3 3 3 4 4 





37 2 3 2 4 3 1 5 3,1,2,4 3 2 4 4 2 4 
38 1 3 2 4 3 1 5 4,1,2,3 3 3 4 4 4 4 
39 1 4 6 - warfarin 5 2 1 4 nurses 3 3 4 4 4 4 
40 1 1 1 4 2 3 3 3,1,2,4 1 2 2 3 4 4 
41 2 2 
6 - only when 
indicated with the 
co-morbidities e.g 
warfarin 
1 2 1 4 2,1,2,2 4 4 4 3 4 4 
42 2 2 6 - 3 monthly 3 2 1 2 2,1,4,3 4 4 4 3 4 4 




heparin 4,1,2,3 2 2 2 3 1 1 
44 2 3 
6- when indicated 
with other  co-
morbidity 
3 2   4 1,3,4,2 4 1 4 2 4 4 
45 2 2 1 1 3 
1 and 4 on pts 
on plavix 
1 doctors 4 4 4 3 4 4 
46 1 3 6 4 3 
4- not to be 
adjusted 
5 pharmacists 4 4 4 4 4 4 





48 1 2 1 4 1 1 4 4,2,3,1 3 4 3 4 4 4 
49 2 4 5 1 3   3 pharmacists 4 4 4 4 4 4 
50 2 3 4 3 2   5 3,1,4,2 3 4 4 2 2 4 
51 3 3 2 3 2 1 3 2,1,3,4 3 4 4 4 3 4 
52 1 3 5 3 3 1 2 4,2,1,4 
3 -new 
patients 4 3 3 4 4 




that I saw in 
the unit 
4,2,3,1 4 3 4 4 4 4 
54 1 4 
6 - depends on 
whether they are 
using warfarin or 
other types of 
anticoagulants 
3 3   2 4,1,2,3 3 4 2 2 2 2 
55 1 unsure 6 - don’t know 
5 - never 
used it 
3   
5 -new in 
unit 4,3,2,1 1001 1001 1001 1001 1001 1001 
56 1 3 
6 - only if the patient 
is using warfarin for 
? Atrial fibrillation or 
due to DVT 
4 2 and 3 1 2 4,3,1,2 4 4 4 4 4 4 





58 1 4 6 - if requested 3 3   3 4,1,2,3 3 4 3 3 4 4 
59 1 3 
6 - when bleeding 
problems 
5 4 1 5 4,1,2,3 3 4 4 3 4 4 
60 1 4 6 - unsure 4 2   3 1,2,3,4 3 2 3 3 2 4 
61 1 3 5 2 2 1 
5 - I have 
not 
witnessed it 
yet 2,1,4,3 3 4 1 2 1001 1001 












4,3,1,2 3 4 3 4 4 4 
63 1 3 
6 - only when 
needed if there is a 
bleeding tendency.   
We evaluate the 
patients fisically 
4 2,3,4 1 3 4,2,3,1 3 4 1 4 4 4 
64 2 1 6 - unsure 2 2   2 2,3,4,1 1 1 1 2 1 2 
65 1 3 1 1001 2 1 3 1001 4 3 4 4 3 1001 
66 1 3 5 3 2   
3 - profuse 





67 1 3 6 - if asked by Dr 4 2   
5 - quality 
care 4,2,1,3 4 4 3 3 4 4 




4 3 3 3 2 3 
69 2 1 2 4 2 1 4 1,4,4,1 2 2 3 2 4 4 
70 3 3 1 5 3 
(4) write 
ordered dose, 
then doctor to 
sign 
3 2,3,4,1 3 1 1 3 4 3 
71 4 3 2 3 3 
(4)consult 
before adjust 
1 4,3,1,2 4 4 4 4 4 4 
72 1 4 5 4 3 1 4 4,3,1,2 4 4 4 4 4 4 
73 1 4 5 4 3 1 4 4,3,1,2 4 4 4 4 4 4 
74 1 4 5 1 1001 1001 1001 pharmacist 2 2 3 4 3 4 




4- for 1st 
time 
4 for 1st 
session 
4 for 1st 
session 
4 for 1st 
session 4 
4 – and 
inform the 
doctor 
76 1 1 1 1001 3 1 1001 doctors 4 4 4 4 4 4 




APPENDIX 10: Pilot study data - answer sheet for questionnaire  
Recoding (reversal of mark allocation per response) of questionnaire and answer sheet 
SECTION C: KNOWLEDGE REGARDING THE USE AND EFFECTS OF 
UNFRACTIONATED HEPARIN 
        Choose ONE response for each item by placing X in the relevant box 
010 Patients should always be asked about bleeding tendencies before 







011 Does unfractionated heparin break down blood clots? 
[0] Yes 
[1] No 
[0] Unsure  




012 A patient has an activated Partial Thromboplastin Time of less than 50 
seconds. 5000 international units of unfractionated heparin is administered 
during the haemodialysis session. Which of the following effects could 
unfractionated heparin cause? 
[3] Bleeding 
[2] Unscheduled Hospitalisation 
[1] No ill effects 









013 A patient arrives for the appointed haemodialysis session. Pre-dialysis the 
patient is normally mildly hypertensive, with a blood pressure of 
140mmHg/95mmHg. Today, the pre dialysis blood pressure systolic reading 
is 240mmHg and diastolic is 140mmHg. 












(Lankshear et al., 2010:49) 
014 Which of the following platelet counts would you not administer 
unfractionated heparin? 
[0] 420-450 x 10
9/1
 
[1] 50 -80 x 10
9/1
 
[0] 150-180 x 10
9/1 




015 A patient has completed a haemodialysis session and supposedly received 
the prescribed 5000 International Unit of unfractionated heparin during 
haemodialysis. Twenty minutes later the patient’s arterio-venous fistula is 
still actively bleeding. 
Select ONE of the following options below to arrest the bleeding. 
[1] Protamine sulphate 1 milligram per 100 international unit of 
     unfractionated heparin 
[0] Protamine sulphate 2 milligrams per 1000 international unit of 
     unfractionated heparin  
[0] Vitamin K 1milligram 
[0] Unsure 
(European Best Practice Guidelines Expert Group on Haemodialysis 






 Complete the following questions below in your own words.  
016 Why is unfractionated heparin not administered orally? 
[1] Destroyed by stomach acids  
[0] All other answers  
(Lee et al., 2001:3116) 
 
1 
017 Why is it important to have the patients' baseline urea values before 
administering the first dose of unfractionated heparin? 
[1] Bleeding risk  








018 State the route of administration of unfractionated heparin in your dialysis 
centre. 
[1] Bolus dose  
[2] IVI  
[3] continuous via dialysis machine 
All above acceptable, but [3] preferred 





 Complete the following questions below in your own words  
019 What type of unfractionated heparin is used in your dialysis unit? 
[1] Porcine 
[0] Bovine 
[0] Other __________________________________ 
[0] Unsure 
 (Shen et al.,2012:474) 
 
1 
020 At what temperature should unfractionated heparin be stored? Write the 
temperature value in degrees Celsius. 
[1] < 25 degrees celsius 





021 What effect does unfractionated heparin have on potassium levels? 
[1] Inhibits the secretion of aldosterone - hyperkalaemia 
[1] Hyperkalaemia 
[0] All other answers 
(Lankshear et al., 2010:51; AHRQ, 2011:5) 
 
1 
022 A patient needs to receive 2 000 International Units of unfractionated 
heparin. Unfractionated heparin in stock is 20 000 International Units per 
1ml. The 20 000 International Units of unfractionated heparin is added to 
100 millilitres of sodium chlorine 0.9%. 
Calculate the dose of unfractionated heparin for this patient showing the 
formula you used. 











[0] All other answers 
(Researcher designed) 










Patients on haemodialysis receiving unfractionated heparin may experience 
adverse effects. On a scale of 5 to 1 make a mark to show how would you 
rank your concerns about these adverse effects for patients receiving 








1                     2                        3                         4                           5 
Least                                                                                  Great                                                                                          
Concern                                                                                            Concern 
(Wimberley et al., 2004:46) 
024 Choose one response for each item by placing X in the relevant box  


















drug to patients 
(ISMP, 2007:2)  
5 4 3 2 1 5 




by another staff 
member 
(Chevalier et al., 
2011:344) 









heparin will result 
in punishment  
(Niccolai et al., 
2004:150S; 
Brady, Malone & 
Fleming, 
2009:693) 
1 2 3 4 5 5 
 d Adverse effects of 
unfractionated 
heparin, are 




5 4 3 2 1 5 
 e Patients are 
closely monitored 




5 4 3 2 1 5 









1 2 3 4 5 
 
5 





















SECTION E: PRACTICE REGARDING THE USE AND EFFECTS OF 
UNFRACTIONATED HEPARIN 
Choose one response for each item by placing X in the relevant box 










028 How often is a new dialysis patient’s laboratory coagulation results checked 
























030 When did you last refer to published literature on unfractionated heparin? 










031 When I am concerned about the prescribed dose of unfractionated heparin 
for a patient I … 
[0] Continue to administer the prescribed dose 
[0] Verbalise concerns to the Unit Manager 
[1] Contact the prescribing Doctor 
[0] Adjust the dosage…If you gave this response go to Question 







032 If I adjust the unfractionated heparin dose, I then ... 
[1] Document the adjusted dose I administered on patient's records  
[0] Document only what was prescribed 
[0] Do not record adjusted dose on patient record 





033 How long ago did you witness an adverse effect of unfractionated heparin? 











[1] Never, state reason 
(Researcher designed) 
034 In order of preference, indicate which of the following you will consult for 
information about unfractionated heparin or other medication used in your 
adult chronic haemodialysis unit. For example, 4=most preferred; 1=least 
preferred  










035 Choose one response for each item by placing an x in the relevant box   
 Item Statement Always  Sometimes  Usually  Never   
 a I ask patients about 
bleeding tendencies 




4 3 2 1 4 
 b I monitor patients for 
anaphylactic shock. 
(Schull, 2006:523) 
4 3 2 1 4 
 c I verify any allergy with 




4 3 2 1 4 
 d I confirm the 
unfractionated heparin 
dose with another 
qualified renal unit 
practitioner before I 
administer it. 
(ISMP, 2007:17) 
4 3 2 1 4 
 e I document adverse 
effects of unfractionated 
heparin. 
(ISMP, 2007:25) 
4 3 2 1 4 
 f I inform the Unit 
Manager of patient's 
adverse effects to 
unfractionated heparin. 
(Researcher designed) 





APPENDIX 11: Decoding section C knowledge questions 
Decoding of Section C (Appendix 1) Knowledge open questions 016;017;018;020;021;022 
Question 
No. No. Allocated Description No. Allocated Further Decoding 
16 1 not effective 1 effectiveness 
  2 prevent circuit clotting 2 effects 
  3 not absorbed orally 3 pharmacokinetics 
  4 iv use only 2 effects 
  5 affects internal organs 3 pharmacokinetics 
  6 
metabolised by liver excreted via 
kidney 3 pharmacokinetics 
  7 GIT bleeding 2 effects 
  8 take long to be dialysed by body 2 effects 
  9 not absorbed by gut 4 
destroyed by stomach 
acids 
  10 cause internal bleeding 2 effects 
  11 oral not available 3 pharmacokinetics 
  12 
prevent arterial and venous 
thrombosis 2 effects 
  13 destroyed by stomach acids 4 
destroyed by stomach 
acids 
  14 short acting 2 effects 
  15 
evenly distributed between cells and 
plasma and is not well absorbed 
3 
pharmacokinetics 
  16 cause local bleeding 2 effects 
  17 unsure 5 unsure 
          
17 1 bleeding 1 bleeding risk 
  2 ureamic- dialyse heparin free 2 increase urea levels 
  3 dosage 5 dosage 
  4 check clotting profile 3 risk for complication 
  5 interfere with heparin side effects 3 risk for complication 
  6 heparin increases levels of urea 2 increase urea levels 
  7 ensure complications 3 risk for complication 
  8 good to know value 6 information 
  9 unsure 4 unsure 
  10 affects clotting time 3 risk for complication 
  11 post dialysis bleeding 1 bleeding 
          
18 1 intravenous     
  2 via machine dialysis lines     
  3 dosage - bolus 3     
          
20 1 patient temp 1 patient temp 
  2 <3 2 2--8 
  3 21 4 21-25 
  4 23 4 21-25 




  6 <24 4 21-25 
  7 <25 4 21-25 
  8 <28 5 26-30 
  9 <32 6 31-35 
  10 <35 6 31-35 
  11 36-38 7 36-40 
  12 40 7 36-40 
  13 2 --8 2 2--8 
  14 5 --25 8 5--25 
  15 20 3 18 -20 
  16 22 4 21-25 
  17 18 - 20 3 18 -20 
          
21 1 hyperkalemia     
  2 nil     
  3 don’t know     
  4 inhibits secretion of aldosterone     
          
22 1 10mls 1 10mls 
  2 2000IU 2 2000IU 
  3 10mls= 100 3 10mls= 100 
  4 5mls 4 01--5 
  5 100 5 10 --100 
  6 01ml 4 01--5mls 
  7 10IU 5 10 --100 
  8 calculation; no answer 8 calculation; no answer 
  9 1ml 4 01--5 
  10 10.1ml 1 10mls 
  11 10 5 10 --100 
  12 1000IU 6 1000IU 
  14 2mls 4 01--5 






APPENDIX 12A: SPSS example of descriptive statistics 
Statistics 
 age 001 
gender 002              
M=1                       
F=2 
citizen 003                       
SA =1                                         
OTHER =2 
N Valid 74 77 100 
Missing 26 23 0 
Mean 41.054 1.753  
Median 41.500 2.000  
Std. Deviation 10.8184 .4339  
Range 41.0 1.0  
Minimum 23.0 1.0  




age001   
 N Mean 
Std. 
Deviation Std. Error 
95% Confidence 






RN 48 44.92 9.562 1.380 42.14 47.69 24 64 
CT 21 31.43 8.376 1.828 27.62 35.24 23 55 
EN 5 44.40 5.595 2.502 37.45 51.35 35 49 




age001   
 Sum of Squares df Mean Square F Sig. 
Between Groups 2717.774 2 1358.887 16.560 .000 
Within Groups 5826.010 71 82.056   
Total 8543.784 73    
 
Post Hoc Tests 
Multiple Comparisons 
Dependent Variable: age001 
Scheffe   
(I) Category (J) Category 
Mean 
Difference 
(I-J) Std. Error Sig. 







 2.370 .000 7.56 19.41 
EN .517 4.257 .993 -10.13 11.16 
CT RN -13.488
*
 2.370 .000 -19.41 -7.56 
EN -12.971
*
 4.508 .020 -24.24 -1.70 
EN RN -.517 4.257 .993 -11.16 10.13 
CT 12.971
*
 4.508 .020 1.70 24.24 






APPENDIX 12B: SPSS sample of crosstabulation result  
Crosstabulation result between profcate004 * poor knowledge 
Crosstab 







Count 42 9 51 
% within profcate004 82.4% 17.6% 100.0% 
% within poor knowledge 72.4% 47.4% 66.2% 
CT 
Count 15 6 21 
% within profcate004 71.4% 28.6% 100.0% 
% within poor knowledge 25.9% 31.6% 27.3% 
EN 
Count 1 4 5 
% within profcate004 20.0% 80.0% 100.0% 
% within poor knowledge 1.7% 21.1% 6.5% 
Total 
Count 58 19 77 
% within profcate004 75.3% 24.7% 100.0% 
% within poor knowledge 100.0% 100.0% 100.0% 
Chi-Square Tests 
 Value df Asymp. Sig. (2-sided) Exact Sig. (2-sided) Exact Sig. (1-sided) 
Pearson Chi-Square 9.761
a
 2 .008 .008  
Likelihood Ratio 8.383 2 .015 .013  
Fisher's Exact Test 8.291   .011  
Linear-by-Linear Association 7.510
b
 1 .006 .009 .007 
N of Valid Cases 77     
Chi-Square Tests 
 Point Probability 
Pearson Chi-Square  
Likelihood Ratio  




N of Valid Cases  





APPENDIX 12C: SPSS logistic regression: knowledge and professional category 
Logistic Regression knowledge result 
 
Block 1: Method = Enter 
Omnibus Tests of Model Coefficients 
 Chi-square df Sig. 
Step 1 
Step 8.383 2 .015 
Block 8.383 2 .015 
Model 8.383 2 .015 
Model Summary 






 .103 .153 
 
a. Estimation terminated at iteration number 4 because parameter estimates 




 Observed Predicted 




0 57 1 98.3 
1 15 4 21.1 
Overall Percentage   79.2 
 
a. The cut value is .500  
Variables in the Equation  










profcate4   6.509 2 .039    
profcate4(1) .624 .607 1.058 1 .304 1.867 .568 6.132 
profcate4(2) 2.927 1.177 6.185 1 .013 18.667 1.859 187.406 
Constant -1.540 .367 17.588 1 .000 .214   
 
a. Variable(s) entered on step 1: profcate4. 
 
 
 
